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Preface 
This thesis encompasses the work I produced from 2010 to 2014 while 
integrated in Prof. Elsa Anes’ group and in collaboration with my colleagues at 
Unidade de Retrovírus e Infecções Associadas of Faculdade de Farmácia da 
Universidade de Lisboa. A portion of the results were produced in collaboration 
with three other research groups: Prof. Olivier Neyrolles group from the Institute 
of Pharmacology and Structural Biology of Université Paul Sabatier at 
Toulouse, France; Prof. Miguel Viveiros’ group from Instituto de Higiene e 
Medicina Tropical of Universidade Nova de Lisboa, Portugal; Prof. Michael 
Niederweis’ group from the Department of Microbiology of The University of 
Alabama at Birmingham, USA. This thesis is the culmination of several different 
projects and collaborations that were brought together by their common goal to 
unravel the underlying mechanisms involved in the ability of the etiologic agent 
of tuberculosis, Mycobacterium tuberculosis, to persist in the human host by 
sustaining or manipulating the intracellular bactericidal response of 
macrophages and dendritic cells. 
I begin this thesis by introducing the disease and the complex steps that occur 
throughout the endocytic pathways, spanning from: recognition and uptake of 
the pathogen; response produced; regulatory events and the physiology of the 
intervening cells. All these processes are deeply interconnected, and while 
complex I felt the need to provide the readers with a broad review, touching all 
of them, even if, in some cases, only lightly. 
The 4 chapters that follow the introduction represent original scientific studies 
that are already under review for publishing or will be submitted. Chapters 2 and 
3 focus on the function and regulation of cathepsins. Chapter 3 centers on the 
use of pharmacologic compounds to manipulate the endocytic pathways in 
favor of the host. Chapter 4 focuses on the membrane of mycobacteria as a 
barrier against the aggressions of the host or pharmacological therapy. 
I end the thesis with a brief conclusion that covers and interconnects the several 
chapters and employed strategies. 
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Abstract 
Tuberculosis is a worldwide health concern, caused by the bacterium 
Mycobacterium tuberculosis (MTB) that causes the death of approximately 1.3 
million people per year making it the deadliest bacterial infection for human 
beings. Although antibiotic treatment exists, its severity and long duration 
hampers the implementation and compliance, leading to the generation of multi-
resistant strains. This thesis proposes that by enhancing the cellular immunity 
against the bacteria we can improve the therapeutic and reduce the emergence 
of resistant strains. In order to test this hypothesis, we first explored the 
regulation of lysosomal cathepsins caused by MTB to identify key molecules 
being subverted by the pathogen. Cathepsins are major proteolytic enzymes 
active in the endocytic pathways and thus, are interesting targets to study in the 
context of an intracellular pathogen such as MTB. Then, it is revealed that MTB 
regulates one of these cathepsins, cathepsin S, by manipulating the expression 
of the micro-RNA, miR-106b-5p. This identified one potential target to counter 
MTB-mediated manipulation of the host cells. Furthermore, it is shown that 
pharmacologic drugs already approved for other pathologies can be used to 
alter the phagosomal environment and improve macrophage-mediated killing of 
MTB. Finally it is shown that restriction of outer-membrane transport is a 
resistance factor of MTB and a novel outer-membrane channel is an entry 
pathway for drugs and host microbicidal molecules that may be exploited in the 
future. Altogether, we show that we can improve host cell-mediated 
antimycobacterial mechanisms and we propose several molecules that may be 
targeted for this purpose. 
 
Keywords 
Tuberculosis, Mycobacterium tuberculosis, macrophage, dendritic cell, 
cathepsins, micro-RNAs, ion channel blockers, outer-membrane channel, drug-
resistance. 
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Resumo* 
A tuberculose é um flagelo à escala mundial causando a morte de mais de 1 
milhão de pessoas anualmente e possuindo uma prevalência registada em 
cerca de 12 milhões de pessoas em 2012. A doença é causada por bactérias 
do complexo Mycobacterium tuberculosis que compreende um conjunto de 
espécies do género Mycobacterium com elevada proximidade filogenética e 
que têm em comum serem agentes causadores de tuberculose, apesar 
apresentarem tropismo para hospedeiros distintos. A espécie Mycobacterium 
tuberculosis (MTB) é a principal responsável para tuberculose humana. Estas 
bactérias são aeróbicas, com forma bacilar e com um longo tempo de geração 
entre 12 a 24 h. Uma das suas características estruturais mais distintas é a sua 
parede e membrana externa. Estas constituem uma forte barreira contra 
compostos tóxicos, quer de origem farmacológica ou provenientes do sistema 
imunitário do hospedeiro. É compreendida por uma parede de peptidoglicano e 
arabinogalactano localizada no espaço periplasmático, ligada aos ácidos 
micólicos do folheto interno da membrana externa que também compreende no 
seu folheto externo um conjunto de glicolípidos. É também na membrana de 
MTB que se localizam vários factores de virulência e resistência, tal como os 
sistemas de secreção tipo VII, que provocam a necrose das células dos 
hospedeiro, bombas de efluxo que permitem a extravasão de compostos 
microbicidas ou de fármacos e canais selectivos ou em número reduzido que 
restringem a entrada destes mesmos compostos e fármacos. 
A patogénese da tuberculose normalmente inicia-se com a inalação dos bacilos 
para os pulmões e a consequente fagocitose por células residentes nos 
alvéolos como os macrófagos alveolares. A infecção leva à libertação de 
citocinas pró-inflamatórias, quimiocinas e factores de adesão celulares que 
resultam na migração de outras células imunitárias para o local de infecção, tal 
como células dendríticas em circulação no sangue. Apesar da incerteza quanto 
à classificação dos vários tipos de células intervenientes na imunidade celular 
contra bactérias, vários estudos sugerem um papel local para os macrófagos, 
                                            
* extended thesis abstract in Portuguese 
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fagocitando os invasores e participando na sua destruição através dos 
mecanismos degradativos das vias endocíticas como a libertação de espécies 
reactivas oxidativas, acidificação do fagossoma e fusão com lisossomas para a 
entrega de protéases e lípases que irão degradar e processar antigénios da 
bactéria. No tecido infectado os macrófagos irão apresentar estes antigénios a 
linfócitos T, estimulando a resposta imune adaptativa. No entanto, são as 
células dendríticas que se pensam serem as principais iniciadoras da 
imunidade adaptativa. Ao fagocitarem a bactéria, migram para os nódulos 
linfáticos sofrendo um processo de maturação ao longo da migração. Este 
processo resultará no aumento da expressão de moléculas apresentadoras de 
antigénios HLA classe II que irão estimular células T específicas para os 
antigénios da bactéria. No tecido infectado, o conjunto de macrófagos, células 
dendríticas e linfócitos dará origem à estrutura mais evidente da tuberculose, o 
granuloma. Aqui, a infecção está contida, existindo um equilíbrio entre o 
crescimento da população de bacilos e a sua destruição pelas células do 
hospedeiro. Desequilíbrios causados por supressão da imunidade são a 
principal causa para a rotura do granuloma e consequente libertação de bacilos 
nos pulmões que serão expelidos pelas vias respiratórias infectando novos 
indivíduos. 
Uma das características mais estudadas do bacilo da tuberculose é a sua 
capacidade para persistir nas células do hospedeiro, resistindo e subvertendo 
os mecanismos degradativos intracelulares dos fagócitos, mencionados 
anteriormente. MTB inibe a maturação do fagossoma e fusão com os 
lisossomas evitando a acidificação e activação de enzimas proteolíticas como 
as catepsinas. As catepsinas são hidrólases lisossomais que na maioria dos 
casos necessitam de um ambiente acídico para manterem uma estrutura 
estável e serem activadas. A regulação das catepsinas também é feita por 
inibidores endógenos, as cistatinas, que bloqueiam de forma reversível a sua 
zona catalítica. As catepsinas intervêm em vários processos de homeostasia 
celular, participando na degradação de componentes membranares e 
organelos a serem reciclados; no processamento de receptores e outras 
enzimas de forma a adquirirem uma estrutura funcional; na desencadear de 
processos de morte celular; no processamento de péptidos para apresentação 
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a células T ou no processamento da própria maquinaria apresentadora de 
antigénios. 
As várias características que permitem a MTB sobreviver e ocupar nichos nas 
células do hospedeiro e no granuloma e resistir a fármacos antibióticos 
resultam no facto de o tratamento da tuberculose ser moroso e agressivo para 
o hospedeiro, com uma terapêutica que dura em média 6 meses. Isto leva a 
uma grande dificuldade por parte dos sistemas de saúde em acompanhar o 
tratamento dos doentes e garantir uma correcta posologia. Estas dificuldades 
resultaram na emergência de várias estirpes resistentes e multi-resistentes que 
dificultam o tratamento, aumentam a mortalidade e podem eventualmente 
tornar-se extremamente resistentes ou totalmente resistentes, deixando 
portanto de existir terapêutica adequada para estes últimos. Perante este 
problema surge a necessidade de novas propostas e estratégias que evitem o 
surgimento de resistências ao abordar o problema por múltiplas vias. Nesta 
tese, proponho que através da identificação dos factores do hospedeiro que 
estão a ser manipulados pela bactéria e da identificação dos seus próprios 
factores de resistência podemos desenhar estratégias que visem aumentar a 
capacidade das células do hospedeiro em eliminar os bacilos. Esta estratégia 
pode ser empregada sinergisticamente com a terapêutica antibiótica 
aumentando significativamente a probabilidade de sucesso e limitando a 
emergência de resistências. 
O problema foi abordado numa primeira fase através da descrição da 
modulação das catepsinas do hospedeiro por MTB em macrófagos e células 
dendríticas. Demonstra-se que no geral, a infecção por MTB resulta na sub-
regulação ou inibição da sobre-regulação que é desencadeada durante 
infecção por micobactérias não patogénicas. É também evidenciado que esta 
inibição da expressão das catepsinas é favorável ao crescimento intracelular da 
bactéria e que curiosamente resulta também num aumento da expressão de 
moléculas apresentadoras de antigénios HLA classe II. 
A abordagem seguinte passou por identificar mecanismos de regulação das 
catepsinas ou do ambiente fagossomal em geral, de forma a encontrar alvos ou 
estratégias que permitam reverter a modulação causada por MTB. O primeiro 
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mecanismo encontrado foi a regulação da catepsina S por um micro-RNA do 
hospedeiro, miR-106b-5p. Os micro-RNAs são pequenos RNAs que com 
conjunto com um complexo de silenciamento inibem a tradução de mRNAs 
específicos, silenciando a expressão desses genes. Neste caso, a catepsina S 
foi uma das catepsinas identificadas como importantes no controlo da infecção 
e na apresentação de antigénios. Ao identificar-se este micro-RNA como uma 
molécula manipulada por MTB para controlar a expressão da catepsinas S 
encontramos uma via potencial para reverter esta regulação e fortalecer a 
resposta do hospedeiro. O segundo mecanismo encontrado foi a manipulação 
do ambiente fagossomal através do uso de fármacos aprovados para 
patologias distintas da tuberculose que possuem actividade bloqueadora de 
bombas de efluxo. Foi evidenciado que estas moléculas actuavam na bactéria 
inibindo os seus sistemas de efluxo e portanto restringindo esta via de 
resistência a antibióticos, mas também alterando inespecificamente as 
vesículas endocíticas do hospedeiro resultando na sua acidificação. 
Demonstra-se também que essa acidificação resulta no aumento da actividade 
da catepsina B, sugerindo que neste ambiente as catepsinas que possuem 
maior actividade em ambientes acídicos estão mais activas. No seu todo, esta 
estratégia permite melhorar o tratamento antibiótico contra estirpes de MTB 
susceptíveis e resistentes, sendo um forte indicador de uma potencial via 
alternativa de terapêutica contra a emergência de estirpes multi-resistente de 
MTB. 
Finalmente, é colocado o foco na bactéria e nos seus factores de resistência, 
especificamente no transporte de pequenas moléculas por canais na 
membrana externa. É revelado que a um canal formado pela proteína CpnT, 
recentemente descrito, é uma via de susceptibilidade ao constituir uma porta de 
entrada para fármacos e moléculas bactericidas do hospedeiro, tal como o 
óxido nítrico. MTB restringe esta via de entrada exprimindo poucos canais na 
membrana externa, no entanto estes são necessários para a o influxo de 
nutrientes e por isso podem ser potencialmente explorados no desenvolvimento 
no novas terapêuticas. 
Concluindo, nesta tese: (1) identifico moléculas do hospedeiro manipuladas por 
MTB, as catepsinas; (2) Identifico vias de regulação destas moléculas que 
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podem ser usadas para fortalecer o hospedeiro, os micro-RNAs e 
bloqueadores de bombas de efluxo; (3) identifico uma via de susceptibilidade 
na bactéria, a proteína canal CpnT. 
Palavras-chave 
Tuberculose, Mycobacterium tuberculosis, macrófagos, células dendríticas, 
catepsinas, micro-RNAs, bloqueadores de canais iónicos, canais da membrana 
externa, resistência a antibióticos. 
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On the 24th of March of 1882, Robert Koch presented his work to the 
Physiological Society of Berlin (Koch, 1882), a presentation that made a deep 
impact in the scientific field of infection - which was just starting to emerge. 
During that exposition, Koch presented the evidence for the isolation of a living 
rod-shaped organism causing the disease, tuberculosis:  
“On the basis of my extensive observations, I consider it as proven that in all 
tuberculous conditions of man and animals there exists a characteristic 
bacterium which I have designated as the tubercle bacillus, which has specific 
properties which allow it to be distinguished from all other microorganisms.” 
Moreover, he was able to show that not only could he identify the bacillus and 
stain infected tissues; he could also recover and cultivate it in the laboratory and 
use it to cause the disease in healthy animals: 
“In order to prove that tuberculosis is brought about through the penetration of 
the bacilli, and is a definite parasitic disease brought about by the growth and 
reproduction of these same bacilli, the bacilli must be isolated from the body, 
and cultured so long in pure culture, that they are freed from any diseased 
production of the animal organism which may still be adhering to the bacilli. 
After this, the isolated bacilli must bring about the transfer of the disease to 
other animals, and cause the same disease picture which can be brought about 
through the inoculation of healthy animals with naturally developing tubercle 
materials.” 
The identification of a microorganism causing a disease opened an array of 
possibilities for medical research. Causative agents could now be isolated and 
tested in order to develop treatment. More than that, a specific set of criteria 
had been drawn by Koch’s postulates (Koch, 1884) creating a well-defined 
method for the validation of infectious microorganism. These achievements 
were, by themselves, worthy of scientific praise, yet the fact that they were 
performed on the world’s greatest killer at that time (Barnes, 2000), were all the 
more significant. In 1905, Robert Koch was awarded the Nobel Prize for 
Physiology or Medicine, adding to several other awards and distinctions 
received during his lifetime. 
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1.1.   Tuberculosis 
Tuberculosis is the disease caused by bacteria of the Mycobacterium 
tuberculosis Complex (MTC), a group comprising the closely related species M. 
tuberculosis, M. bovis, M. africanum, M. pinnipedii, M. microti, M. caprae and M. 
canettii (Coscolla et al., 2013; Wirth et al., 2008). This disease affects humans 
and other mammals although host tropism varies within the MTC. The majority 
of infected individuals develop the disease in the lungs (pulmonary TB) although 
the disease may occur in any other organ (extrapulmonary TB) (ECDC and 
WHO, 2014). The spread of the bacilli is most effective when the disease 
affects the lungs, since it uses the respiratory system to escape the host 
through coughing and then to infect other individuals (Sepkowitz, 1996). The 
main symptoms of the disease are a long-lasting cough (3 weeks or longer), 
pain in the chest, hemoptysis or expectoration, fatigue, weight loss, anorexia, 
chills, fever and nocturnal hyperhidrosis (CDC, 2013).  
The main method of diagnosing the disease has remained almost unmodified in 
the last 100 years, relying on microscopic observation of sputum smear 
samples to identify the presence of the bacilli and then cultivation of the sample 
which takes several weeks to yield results and depends on developed 
laboratory infrastructure and trained personal. New molecular methods, such as 
Xpert MTB/RIF, have recently been applied to the diagnosis allowing much 
faster detection rates. The World Health Organization’s (WHO) current effort to 
increase the widespread use of Xpert MTB/RIF has enabled rapid diagnosis of 
pulmonary tuberculosis and detection of resistance to rifampicin, the most 
powerful drug used for treatment, by targeting the rpoB gene (Raizada et al., 
2014; Zar et al., 2013). 
Tuberculosis is a fatal disease when untreated, with estimates of 70% mortality 
for smear-positive and 20% for culture-positive smear-negative untreated 
tuberculosis patients (Tiemersma et al., 2011). The causes of death often 
involve severe necrosis of the infected tissues resulting in chronic respiratory 
failure and hemoptysis (Davis et al., 1985; Tomono, 1998). However, the 
majority of current deaths related to TB could be prevented using the standard 
antibiotic therapy. The first line therapy involves the use of an antibiotic cocktail 
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consisting of rifampicin, isoniazid, ethambutol and pyrazinamide during 6 
months. This regimen is reported to yield 85% chance of a successful treatment 
(WHO, 2013a). Tuberculosis caused by multi-drug resistant strains (MDR-TB), 
however, has a severe impact in treatment success rates, lowering them to 
below 50%, on the global scale. MDR-TB is caused by bacilli resistant to the 
two most effective drugs, rifampicin and isoniazid, and occurs in 3.6% of new 
TB cases and 20% in previously TB-treated cases (WHO, 2013a). Treatment of 
MDR-TB involves a longer therapy of 20 months, as recommended by the 
WHO, using more toxic and expensive second line drugs. The high incidence of 
MDR-TB in recurring TB cases is an indication that a significant part of the 
occurrences could be prevented by focusing on treatment monitoring and 
compliance. Amongst TB cases caused by bacilli resistant to treatment, 
extreme cases are classified as extremely drug-resistant TB (XDR-TB), when 
the bacteria are resistant to rifampicin, isoniazid, any fluoroquinolone and to at 
least one of the second line injectable drugs: kanamycin, capreomycin or 
amikacin. In these extreme cases, successful treatment rates may drop to 20%.  
Concerning vaccination, although new candidates and strategies are being put 
to trial, none so far was proved to induce protective immunity in the host 
(Kaufmann, 2014). The only vaccine still administered in numerous regions of 
the world is the famous Bacille Calmette-Guérin (BCG) vaccine. BCG is an 
attenuated strain from over a hundred years ago, derived from continuous 
culture of M. bovis for over a decade. This led to the loss of several virulence 
associated regions of the genome with the resulting consequence of also 
loosing important antigenic regions (Zhang et al., 2013b), especially the RD1 
region which encodes several virulence factors. The vaccine is able to induce a 
strong immunological response in the host but ineffectively protects against 
adult pulmonary TB (Fine, 1995) and is mostly used to prevent severe forms of 
TB in children. However, new guidelines recommend avoiding treatment of HIV-
infected children following studies indicating that immune-compromised children 
may suffer disseminated BCG disease (Hesseling et al., 2007). 
Mycobacterium tuberculosis is estimated to infect one third of the human 
population although the estimates vary depending on the region, for example, in 
the United States of America, only 5% of individuals are expected to be infected 
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(CDC, 2013). Still, only a small fraction, ranging from 5% to 10% of infected 
individuals, will develop disease, which in 2012 resulted in 8.6 million new 
cases. Tuberculosis prevalence is unevenly distributed, with regions such as 
southwest Asia and western pacific accounting for more than half of total cases 
and Africa accounting for one-quarter of cases (WHO, 2013a). Worldwide, 
approximately 12 million individuals suffer from TB. The probability of 
developing the disease is much higher in HIV-infected individuals with a 12% 
prevalence of HIV in TB incident cases worldwide, rising to 36.6% in Africa and 
decreasing in Europe to 5.26% in 2012 (WHO, 2013a). TB is also more 
prevalent in males than females, with more incidence in adults in economically 
productive age groups which is thought to be a consequence of male 
overrepresentation in risk groups such as homeless, prisoners, seasonal 
migrant workers and people living with HIV among male homosexuals (ECDC 
and WHO, 2014). In the European Union/European Economic Area (EU/EEA) 
26.8% of new cases are from foreign origin, ranging from 85% in Norway and 
Sweden to 15.6% in Portugal and 0.2% in Bulgaria and Romania (ECDC and 
WHO, 2014). 
 
Figure 1.1. Estimated incidence rates of tuberculosis in 2012.  
Values per 100,000 individuals per year (WHO, 2012). 
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1.2.   Mycobacterium tuberculosis 
The genus Mycobacteria has recently been assigned to the new order of 
Corynebacteriales (Goodfellow, 2012). The majority of the 150 species that 
comprise this genus are non-pathogenic environmental bacteria that possess 
striking similarities with other bacteria of the phylum Actinobacteria such as 
Streptomyces (Scherr and Nguyen, 2009). Evolution within this genus has 
originated a few successful and widespread host-adapted pathogens such has 
Mycobacterium leprea, M avium, and particularly those included in the 
Mycobacterium tuberculosis complex (MTC), the etiologic agents of TB. The 
species comprising this group share as high as 99.9% nucleotide similarity and 
identical 16S rRNA sequences (Böddinghaus et al., 1990; Sreevatsan et al., 
1997) yet full sequencing of the ≈4Mbps genome of M. tuberculosis (Cole et al., 
1998) revealed several variable regions of differentiation enabling the distinction 
of the various species (Gordon et al., 1999). Mycobacterium tuberculosis 
(MTB), the major etiologic agent of human tuberculosis, has no known 
environmental reservoir and is now thought to have originated in Africa and co-
evolved with its human host for more than 70,000 years (Comas et al., 2013). 
This indicates a very stable relationship between humans and these bacteria. In 
fact, some hypotheses suggest that early linages of MTBC were highly 
prevalent in the human population suggesting that the infection would not be 
very detrimental (Comas et al., 2013), perhaps due to a lower virulence of those 
linages, as can be observed today by studying differences in disease 
progression in different strains of MTB (de Jong et al., 2008). Recent evidence 
has shown that in some cases bacterial infection may induce protection against 
other microorganisms (Perry et al., 2010; Selbach et al., 2008); if so, it may 
represent an increase in evolutionary fitness in specific conditions such as 
those that occurred during the migration of humans out of Africa and 
consequent encounter of new pathogens. Moreover, when considering the co-
evolution between MTB and humans we must not discard the impact that this 
microorganism might have had in the generation of adaptive changes in human 
genome (Barnes et al., 2011). 
 Mycobacterium tuberculosis are rod-shaped, non-spore-forming, aerobic 
bacteria typically measuring approximately 0.5 µm in diameter and 3 µm in 
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length, this last varying according with period of culture (Cook et al., 2009). 
They are slow growing bacteria with a doubling time of 12-24h under optimal 
conditions and are classified as acid-fast bacilli due to a unique cell wall 
structure (Knechel, 2009). The MTB peculiar cell wall is in fact one of its major 
features, providing a strong impermeable barrier to toxic compounds, whether 
being drugs or molecules released by the host immune system (Delogu et al., 
2013). The mycobacterial cell membrane is constituted by an asymmetrical lipid 
bilayer and a periplasmic region of arabinogalactan-peptidoglycan polymer 
which constitutes the cell wall (Hoffmann et al., 2008; Zuber et al., 2008). The 
outer-membrane of mycobacteria is one of the thickest (≈10nm) reported in 
bacteria (Brennan and Nikaido, 1995; Engelhardt et al., 2002), representing one 
of the greatest obstacles to TB therapy. It is comprised of long fatty acids, 
designated mycolic acids in the inner leaflet and of glycolipids and waxy 
components on the outer layer. In the innermost side of the periplasmic space 
there is a thin layer of peptidoglycan covalently linked to arabinagalactan and 
lipoarabinomannan which in turn are bound to the mycolic acids on the outer-
membrane (Figure 1.2). Interestingly, when Hoffman and colleagues (2008) 
engineered a mycolic acid-deficient Corynebacterium glutamicum, the bacteria 
were unable to produce an outer-membrane. They used C. glutamicum as a 
model since they are closely related to mycobacteria yet able to survive without 
the mycolic acids while such mutations are lethal in mycobacteria (Portevin et 
al., 2004). Overall, the mycobacterial membrane has a high hydrophobic nature, 
keeping hydrophilic compounds from entering the cytoplasm whereas the 
thickness of the membrane makes diffusion of hydrophobic compounds a slow 
and difficult process (Brennan and Nikaido, 1995). Furthermore, the membrane 
has a very low fluidity with a melting temperature above 70 ºC (Liu et al., 1996). 
Other surface structures that constitute major virulence factors in mycobacteria 
are secretion systems. So far, five type VII secretions systems have been 
described in mycobacteria (ESX1-5) (Abdallah et al., 2007), among which only 
three, ESX-1, ESX-3 and ESX-5 have known substrates and are classified as 
being virulence factors (Houben et al., 2014) These systems use the hydrolysis 
of ATP to drive the secretion of proteins and protein complexes across the 
membrane and cell wall of mycobacteria. ESX-1 is the most studied of these 
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secretion systems and its absence was identified as one major reason why the 
vaccine strain M. bovis BCG classified as attenuated (Lewis et al., 2003; Pym et 
al., 2002a). Amongst several substrates, the ESX-1 secretes two major culture 
filtrate proteins, ESAT-6 and CFP-10 (Stanley et al., 2003), now designated 
EsxA and EsxB. These two small proteins are highly immunogenic and are the 
basis of the Interferon-γ release assay (IGRA) (Diel et al., 2011; Mishra et al., 
2010) which allows the distinction of MTB-infected individuals from those 
previously immunized with BCG, since the latter lacks ESX-1, EsxA and EsxB. 
For this reason the IGRA test is much more informative than the Mantoux 
intradermal injection test of purified protein derivate (PPD) of M. tuberculosis 
(Nayak and Acharjya, 2012).  
ESX-3 is involved in zinc and iron homeostasis and is required for siderophore-
mediated iron acquisition and growth of MTB in culture (Serafini et al., 2009, 
2013; Siegrist et al., 2009, 2014). ESX-5 is also an essential virulence factor 
mediating the secretion of EsxN, and members of the PPE and PE_PGRS 
protein family (Bottai et al., 2012; Houben et al., 2012; Di Luca et al., 2012), 
which have been recently shown to trigger a range of innate immune 
responses, being also targets of the adaptive immune system (Balaji et al., 
2007; Bansal et al., 2010; Ramakrishnan, 2000; Sampson, 2011). ESX-5 
disruption has also been shown to lead to decreased cell wall integrity and 
increased susceptibility to detergents and hydrophilic antibiotics (Bottai et al., 
2012). 
A significant portion of the studies cited throughout this thesis, as well as in the 
work I present, involve the use of a model species of mycobacteria, 
M. smegmatis that is neither part of the MTC nor an intracellular pathogen. This 
bacterium is a saprophytic environmental microorganism which may cause 
opportunistic disease though most of the time easily controlled by the immune 
system. Many studies use these bacteria as models of MTB since there is 
significant genome conservation within the mycobacteria genus. Manipulation of 
MTB requires biosafety-level 3 facilities, highly trained personnel and carries a 
risk of accidental exposure. Moreover, being a fastidious microorganism, the 
long generation time of MTB makes experiments very time consuming. 
M. smegmatis is a BSL-1 microorganism with a generation time of 3 h. By using 
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this bacterium it is possible to draw significant insights about its physiology, 
metabolism, membrane composition and transport and also genetic engineering 
and expression of MTB proteins. In fact, many studies on the ESX secretion 
systems were performed in M. smegmatis prior to MTB (Coros et al., 2008; 
Siegrist et al., 2009). Also, dormancy genes regulated by the highly conserved 
Dos regulon were found to be present in both MTB and M. smegmatis (Lin et 
al., 2009), Concerning host response to infection, M. smegmatis are readily 
killed by macrophages and are susceptible to the microbicidal mechanisms of 
the host, such as nitric oxide release and phagosome acidification (Anes et al., 
2006). 
In this thesis, the use of M. smegmatis has served a differed purpose. Being 
part of the same genus as MTB but devoid of a clear pathogenic life cycle, 
M. smegmatis are perfect bacteria to compare with MTB at the level of immune 
response generated by the host and putative pathogen-dependent immune-
modulatory mechanisms. While the same purpose could be achieved using 
other bacteria such as Escherichia coli, the greater phylogenetic distance could 
confuse interpretation of the result. For example, the presence of the pathogen 
associated molecular pattern (PAMP) LPS in E. coli, which is absent in 
mycobacteria, would be difficult to compare with MTB and to elucidate details of 
its virulence factors. When comparing MTB and M. smegmatis PAMPs, we can 
associate different phenotypes with subtle differences in PAMP molecular 
structure. Such is the case of the abundant MTB-cell wall lypoglycan, ManLam, 
which differs from that of M. smegmatis in the simple fact that this last isn’t 
capped by mannose (Briken et al., 2004). So this comparison between MTB 
and M. smegmatis will ease our task of revealing MTB-specific virulence and 
resistance factors and pathogenic mechanisms. 
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Figure 1.2. Model of the mycobacterial plasma membrane.  
Summarized representation of the several layers that comprise the mycobacterial 
plasma membrane as well as ESX-1 as an example of a transportation system. 
Interrogation point refers to the unknown intermediate channel protein in ESX other 
membrane transport. 
 
 
1.3.   Pathogenesis of tuberculosis 
In most cases, the first infection with the bacilli occurs in the lungs (Figure 1.3) 
and may then expand to other organs. Mycobacteria enter the lung parenchyma 
and invade alveolar resident macrophages, dendritic cells, neutrophils and 
monocytes (Kang et al., 2011; Wallgren, 1948; Wolf et al., 2007). Recognition of 
MTB PAMPs through membrane and cytosolic receptors (see “MTB recognition 
by TLRs and NLRs”) will result in the expression of pro-inflammatory cytokines, 
chemokines and cellular adhesion receptors (Cooper, 2009; Cooper et al., 
2011; Means et al., 1999). The signals initiated at this stage will result in 
activation and migration of innate immune cells such as monocyte-derived 
macrophages and dendritic cells (DCs) from the blood stream to the site of 
infection in the lung. Usually this recruitment results in the containment of the 
infection but in the case of MTB infection this might actually benefit the bacteria 
in the early stage of infection by providing additional cellular niches for the 
bacteria to invade and expand (Davis and Ramakrishnan, 2009). Nonetheless, 
this recruitment will also provide the basis for the initiation of adaptive immune 
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response by inducing the recruitment and maturation of DCs (Cooper, 2009). 
DCs that engulf bacteria maturate and migrate to the lymph nodes (Bodnar and 
Serbina, 2001; Henderson et al., 1997; Hertz et al., 2001) where they will prime 
CD4 and CD8 T cells against mycobacterial antigens. There, DCs express on 
their surface MTB-derived peptides bound to HLA class I and II molecules. HLA 
class II molecules bind MTB exogenous peptides from the endosomal pathway 
(e.g. from the MTB containing phagosome). In contrast the HLA class I 
molecules that bind endogenous or foreign peptides from the cytosol (e.g. from 
cytosolic bacteria or viruses) followed by transport into the ER and then to the 
plasma membrane. Presentation through these two different classes of 
molecules will result in clonal expansion of different subsets of antigen-specific 
T cells. HLA class II-presented antigens will prime CD4 T cells whereas HLA 
class I-presented antigens will prime CD8 T cells (Parham, 2005). These 
primed T cells expand and migrate back to the focus of infection in the lungs. 
Cellular immunity is crucial at this stage of infection and CD4 T cell Th1 
immunity at the site of infection is especially critical for MTB control (Ernst, 
2012; Flynn, 2004). The Th1 cytokines interferon-γ (IFN-γ) and tumor necrosis 
factor-α (TNF-α) are required for control of bacterial growth in both animals and 
humans. Mice deficient in these cytokines are unable to control MTB infection 
(Flynn et al., 1993; Mogues et al., 2001) and individuals with defects in the IFN-
γ receptor were also shown to be highly susceptible to mycobacterial infections 
(Jouanguy et al., 1999). These cytokines promote the control of bacterial growth 
in the macrophage by activating intracellular killing mechanisms and partially 
overcoming MTB-induced phagosome maturation arrest (Jordao et al., 2008) 
(further described below in “Macrophages and Dendritic cells” and 
“Manipulation of host endocytic pathways by MTB”). 
One of MTB’s intriguing characteristics is its ability to attenuate those cellular 
responses mediated by CD4 and CD8 T cells, allowing an increase of the initial 
bacterial load in the lungs. One particular mechanism was proposed, involving 
the induction of massive proliferation of regulatory T cells upon direct 
presentation of MTB antigens by DCs (Shafiani et al., 2010) in the lung-draining 
lymph nodes, early after MTB infection. Regulatory T cells were shown to 
accumulate at sites of infection in both mice and humans (Kursar et al., 2007; 
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Scott-Browne et al., 2007) leading to a delayed entry of effector T cells into the 
lung (Shafiani et al., 2010). It is also interesting to note that during MTB 
infection there is a delay on the generation of antigen-specific immune 
response. Adaptive immune response is only measurable in humans after 
42 days of exposure (Poulsen, 1950; Wallgren, 1948) and after 11-14 days in 
mice (Chackerian et al., 2002; Reiley et al., 2008; Wolf et al., 2008). In mice, the 
activation of MTB antigen-specific CD4 T cells first occurs in the lymph nodes 
draining the lungs and requires the transport there of live bacteria by DCs 
(Chackerian et al., 2002; Reiley et al., 2008). Interestingly this process takes 8 
to 10 days during MTB infection of humans while during influenza virus infection 
it only takes 20 h (Ho et al., 2011). The reason for this delay is not yet clear. 
There is evidence that MTB inhibits the migration of DCs to the lymph nodes 
(Blomgran and Ernst, 2011).  
Ultimately, equilibrium will be achieved between bacterial expansion and 
cellular immunity culminating in the formation of a granuloma – the hallmark of 
TB – and a state of latency. Granulomas formation is a chronic inflammatory 
response. Granulomas are formed at an early stage by a mass of macrophages 
and DCs and at the latter stage are joined by B and T cells. This standoff is 
probably the result of several described factors such as impaired MHC class II-
mediated antigen presentation (Pancholi et al., 1993), down regulation of 
mycobacterial antigen expression (Bold et al., 2011; Egen et al., 2011), 
induction of regulatory T-cells (Scott-Browne et al., 2007) and resistance to IFN-
γ-induced macrophage activation (Fortune et al., 2004; Ting et al., 1999). 
Remarkably, studies show that although there is stabilization in bacterial 
numbers during this chronic silent stage of infection, a subpopulation of bacteria 
remains actively replicating. Instead of a stasis, it may be that there is a 
dynamic immunologic equilibrium, demonstrated by evidence of bacteria 
replication in mice (Gill et al., 2009) and accumulation of mutations in non-
human primates (Ford et al., 2011) during latency. Nevertheless bacterial gene 
regulation during latency has been described with particular emphasis on the 
bacterial regulon controlled by the two-component signal transduction system of 
mycobacteria, the DosR-DosS which is induced during hypoxia (Park et al., 
2003), as well as by nitric oxide (Voskuil et al., 2003) and carbon monoxide 
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(Kumar et al., 2008). This system controls the expression of genes which allow 
the use of alternative energy sources (Muñoz-Elías and McKinney, 2005). 
Working against this system are “resuscitation proteins”, resembling the 
resuscitation-promoting factor (Rpf) of Microccocus luteus, a secreted protein 
which enables bacteria to leave the nutrient-starved state (Chao and Rubin, 
2010). 
As previously referred, 5% to 10% of latently infected individuals will develop 
TB. This reactivation mostly occurs due to immune depression of the infected 
individual. HIV infection and consequent depletion of CD4 T cells is one the 
greatest causes of TB reactivation. Therapeutic inactivation of TNF-α is another 
major described cause of TB possibly due to a decrease in antimicrobial activity 
in macrophages (Clay et al., 2008). Another interesting possibility is a 
destabilization of the equilibrium inside the granuloma due to alterations in cell 
trafficking. Considering that this equilibrium is maintained by constant migration 
of fresh phagocytes and T cells to the granuloma, when chemokine deletion 
mutant mice were engineered, these showed a decreased ability to control the 
infection (Scott and Flynn, 2002). The result of reactivation will be the 
propagation of bacteria and extrusion from the granuloma. In the most 
infectious cases, individuals suffer extensive lung-tissue damage, thereby 
generating large open spaces filled with bacilli, a condition termed cavitary TB 
(Kaplan et al., 2003; Rodrigo et al., 1997). Curiously, individuals infected with 
HIV and with depleted CD4 T cells experience this phenomenon less frequently 
comparatively with individuals with a regular T cell population (Kwan and Ernst, 
2011). In cavitary TB, the large cavities, connected to the airways provide an 
efficient pathway for bacteria expectoration and transmission. 
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Figure 1.3. The pathogenesis of tuberculosis.  
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews Microbiology 
(Nunes-Alves et al., 2014), copyright 2014. 
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1.4.   Macrophages and Dendritic cells  
Macrophages and DCs function as effector cells in the cellular immune 
response against TB forming large networks able to recognize the molecular 
patterns of invaders. Macrophages are professional phagocytes, a relatively 
straightforward definition, first given by Rabinovitch (Rabinovitch, 1967). Classic 
dendritic cells as first defined by Steinman and Cohn were clearly distinct from 
macrophages since they had little phagocytic ability and corresponded to the 
cells present in T cell areas in lymphoid organs and migratory cells in afferent 
lymph. Since then, this definition broadened to include phagocytic DCs and 
resulted in a division in numerous functional subsets of cross-presenting, 
migratory, myeloid, lymphoid, tolerogenic, and inflammatory or TipDCs. DCs are 
considered the antigen presenting cells par excellence, yet macrophages are 
also described to possess this ability leading to a division between those that 
include all these cells in the macrophage group or the DC group (Geissmann et 
al., 2010; Jenkins and Hume, 2014). A plethora of subpopulations of 
macrophages and DCs have been described, that are related to functional 
differences, as well as to their location in the body. In the lung, resident 
dendritic cells and alveolar macrophages are some of the first cells to respond 
to an invasion by foreign microorganisms. Infection will also lead to the 
recruitment of another population of monocyte-derived dendritic cells. The 
distinctions between these cells are less perceivable in vivo than those found in 
purified laboratory cultures. Although several markers have been proposed to 
distinct subsets of lung DCs and macrophages, the large overlap between these 
markers and different cell lineages as well as often subtle differences in their 
increased or decreased expression lead to an often mis-characterization of 
these populations and a misconception of their exact role during infection 
(Guilliams et al., 2013).  
The populations of primary human cells analyzed in the following chapters of 
this thesis correspond to macrophages and DCs derived from a common 
circulating precursor, CD14 monocytes, and differentiated in vitro. For the 
purposes of this thesis I will apply a broad definition of macrophage and 
dendritic cell assuming that both cell types possess an inherent ability to 
phagocytize and to present antigens to T cells.  
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Macrophages play a crucial role in the inflammatory response and account for 
approximately 10% of the total cells of any organ (Hume, 2006). After reaching 
the infection site, they rapidly internalize the invading organism and kill it 
through a variety of processes that occur within the endocytic pathway such as 
the release of toxic nitrogen and oxygen species, acidification and lysosomal-
mediated killing dependent on acidification of the phagosomal lumen and 
activation of lysosomal enzymes (Hope et al., 2004) (see “Cathepsins in the 
intracellular response against M. tuberculosis”). This antimicrobial activity is 
necessary not only to control the infection by killing the invading organism but 
also to process and present its antigens to T lymphocytes (see “Regulation of 
antigen presentation in MTB-infected cells”) in the context of major 
histocompatibility complex (MHC) molecules, as seen in mice (Hope et al., 
2004) or their human counterpart, the human leukocyte antigens (HLA).  
Macrophages have been classified as classically (M1) and alternatively (M2) 
activated macrophages. Prototypical M1 activation is mediated by IFN-γ and 
lipopolysaccharide (LPS). These macrophages mediate defense against 
bacteria, viruses and parasites with potent antimicrobial response and induction 
of IL-12-mediated Th1 response and secretion of pro-inflammatory cytokines, 
TNF-α, IL-1β, and IL-6 (Guirado et al., 2013). As previously mentioned, IFN-γ-
activated macrophages induce a potent release of reactive oxygen or nitrogen 
species that are able to destroy the bacterial invaders. Curiously this release 
will affect the phagosomal environment by increasing the pH and resulting in a 
lowered activity of low pH-dependent proteolytic enzymes. The consequence of 
these events will be partial proteolysis of the pathogen, with preservation of 
antigenic peptides to be presented to lymphocytes (Russell et al., 2009; Yates 
et al., 2007). This is the opposite of what occurs when no inflammatory stimulus 
is produced and macrophages silently eliminate the phagolysosomal contents 
due to high proteolytic activity and destruction of antigenic peptides (Russell et 
al., 2009).  
M2 macrophages can be activated by stimuli with different cytokines, including 
IL-4 or IL-13 and have an anti-inflammatory role with induction of Th2 
responses with secretion of IL-10 and TGF-β as well as reduced 
responsiveness to IFN-γ and decreased iNOS expression (Guirado et al., 2013; 
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Martinez et al., 2008). M2 macrophages participate in wound healing and 
resolution of inflammatory process. They rapidly clear phagocytized molecules 
and recent studies suggest they preserve much of the features of resting 
macrophages (M0), with rapid progression of phagosome maturation and 
lysosome fusion and highly acidic and proteolytic response (Balce et al., 2011; 
Canton et al., 2014). However, the M1 and M2 classification might be an 
oversimplification since these cells have been shown to retain the ability to 
switch from one state to another in response to changes in the environment 
(Mylonas et al., 2009; Stout et al., 2005). Moreover, often we can find features 
of both types of macrophages in alveolar macrophages. These have been 
shown to participate in pathogen clearance (M1) yet they do not trigger an 
exacerbated inflammatory response and actively suppress the production of 
pro-inflammatory cytokines (M2) (Martinez et al., 1997). 
 
 
Figure 1.4. Macrophage polarization and its relevance for the endocytic/antigen 
presentation pathways 
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Dendritic cells are a minor population in most tissues, in contrast to the much 
more abundant resident macrophages. However, DCs are capable of forming 
large networks that spread to various parts of the body, such as the skin, 
intestine and the lungs (Hope et al., 2004). Their main purpose is to gather 
antigens that will be processed and presented to lymphocytes following 
migration of DCs into the lymphoid organs (Cella et al., 1997a). While 
performing their role in monitoring exposure of body surfaces to antigens, these 
cells are considered immature DCs (imDCs), that express low levels of MHC 
and co-stimulatory molecules but with a high capacity to phagocytose invading 
organisms as determined in mice models (Puré et al., 1990; Reis e Sousa et al., 
1993). In the presence of tissue injury, inflammation or infection, imDCs are 
stimulated to migrate towards lymph nodes (Dudziak et al., 2007). There they 
maturate and acquire the capacity to stimulate naïve T lymphocytes while at the 
same time losing their active phagocytic and endocytic functions (Banchereau 
et al., 2000). Indeed, DCs have developed specific control of endocytic 
functions in order to allow efficient antigen presentation (Mellman and 
Steinman, 2001). These cells contain lower levels of active lysosomal proteases 
and lysosome acidification is inefficient in the immature stage due to the limited 
recruitment of the proton pumping vATPase to endosomes and lysosomes, 
relative to macrophages (Delamarre et al., 2005; Russell, 2007; Trombetta et 
al., 2003). The mild pH of the endocytic pathway of DCs assures an efficient 
processing of pathogen antigens (Savina et al., 2006), in which cysteine 
cathepsins and their natural inhibitors cystatins play a crucial role (Kopitar-
Jerala, 2006; Zavasnik-Bergant et al., 2005, 2006) (see "Regulation of antigen 
presentation in MTB-infected cells”). Since one of the most direct ways to 
control protease activity is by pH this can constitute an adaptation of these cells, 
but it also can favor bacterial persistence in a less degradative environment. 
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Figure 1.5. Dendritic cells maturation its relevance for the endocytic and antigen 
presentation pathways 
 
1.5.   MTB uptake by Macrophages and DCs 
The first step in the phagocytic process is the internalization of the foreign body 
or pathogen. Several surface molecules of MTB have been implied in receptor-
mediated uptake of the bacteria by phagocytes and most evidences come from 
studies in macrophages (Schäfer et al., 2009). As mentioned before in this 
thesis, the ability of MTB to infect phagocytes appears to be important for its 
dissemination so it is not hard to imagine the variety of intermediates that have 
evolved for this process. However, this multitude of molecules involved creates 
a challenge for researchers studying the contributions of single molecules on 
MTB uptake; in the end we must keep in mind that all these processes are 
occurring together and that in the same cell the bacteria might face different 
fates which will in some occasions lead to its survival, others to its death but all 
contributing to the global pathogenesis of TB. 
Bacteria are recognized by opsonic and non-opsonic receptors. In the former, 
bacteria are coated with various host proteins such as antibodies, complement 
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proteins, lectins or surfactants; all these molecules serve to target the bacteria 
for recognition by macrophage receptors of host proteins. In contrast, pattern 
recognition receptors (PRRs) directly recognize bacterial ligands on their 
surface. In the initial stages of infection, non-opsonic binding or surfactant-
mediated opsonic binding is thought to occur more prominently since there is 
limited serum and complement proteins in the alveoli (Schluger, 2001; Torrelles 
et al., 2008). In the latter stages of infection, with the buildup of adaptive 
immunity, the contribution of opsonic receptors might help to contain the 
infection (Stokes et al., 1993, 1998).  
Regarding uptake, the non-opsonic receptors described include c-type lectins, 
integrins and scavenger receptors. C-type lectins play an important role in 
mycobacterial binding and in generation of inflammatory responses due to the 
presence of carbohydrate rich molecules in the mycobacterial surface (Schäfer 
et al., 2009). This group includes the macrophage mannose receptor (MMR), 
DC-specific intracellular adhesion molecule 3–grabbing non-integrin (DC-SIGN 
or CD209), and Dectin-1. The MMR is the predominant C-type lectin expressed 
on non-activated human macrophages and is expressed in alveolar 
macrophages (McGreal et al., 2005), monocyte-derived macrophages and 
dendritic cells (Stahl and Ezekowitz, 1998), but not on monocytes (Stahl, 1992). 
MMR was the first C-type lectin to be associated with recognition of MTB, 
binding to its mannosylated surface structures (Torrelles and Schlesinger, 
2010). It also has high avidity and affinity for endogenous mannans serving to 
maintain homeostasis of the host (Lee et al., 2002). DC-SIGN also recognizes 
mannosylated cell wall components and is present on immature and mature 
DCs and small sets of macrophages (Bleijs et al., 2001; McGreal et al., 2005). 
Although it is not expressed on non-activated human macrophages, its 
expression can be up-regulated upon MTB infection (Tailleux et al., 2005). DC-
SIGN mediates the internalization and uptake of bound particles and directs 
them to mature phagolysosomes  (Philips and Ernst, 2012). Both MMR and DC-
SIGN bind to the abundant MTB lipoglycan ManLAM. ManLAM is mannosylated 
in pathogenic mycobacteria whereas it binds to the arabinose capped- or 
inositol phosphate capped-LAM of environmental mycobacteria such as (Briken 
et al., 2004). ManLAM has been investigated as a potential virulence factor and 
 
Chapter 1:   Introduction 
51 
was shown to inhibit the TLR-2-mediated inflammatory effects of LPS, LPS-
induced TNF-α secretion and IL-12 p40 mRNA synthesis probably through 
ligation to mannose receptors (Knutson et al., 1998) of macrophages. In DCs, 
DC-SIGN binding by LAM was shown to partially inhibit LPS-induced DC 
maturation and induce IL-10 secretion (Geijtenbeek et al., 2003). However, 
mice lacking the MMR are equivalent to wild- type controls in terms of their 
ability to control MTB (Court et al., 2010).  
Concerning DC-SIGN, inhibition studies revealed that DC-SIGN is the major 
mycobacterial receptor in human DCs (Tailleux et al., 2002). Studying DC-SIGN 
in mice has been proven difficult due to the existence of 7 paralogs of DC-SIGN 
in mice (Ehlers, 2010). Nonetheless, engineering of BCG and M. marinum 
mutants that do not add mannose caps to LAM showed that the absence of 
ManLAM does not lead to attenuation of infection in macrophages or in mice 
(Appelmelk et al., 2008). DC-SIGN also recognizes other mannosylated 
components such as hexamannosylated phosphatidylinositol mannan (PIM6). 
Nevertheless, mutants defective in both ManLAM and PIM6 showed no 
observable phenotype (Driessen et al., 2009), suggesting that other ligands in 
the mycobacterial cell wall may engage DC-SIGN and other receptors.  
Dectin-1 is expressed by macrophages, DCs, monocytes, and a subset of T 
cells (Taylor et al., 2002). It binds to mycobacteria and β-glucan (absent in 
MTB), but its MTB ligand is still unknown. However, functional studies show that 
Dectin-1 ligation triggers phagocytosis and intracellular signaling cascades, 
including synergistic interactions with the TLRs, leading to a pro-inflammatory 
response (Lee and Kim, 2007) and oxidative burst (Zhang et al., 2000). 
The complement C3 receptors (CR1, CR3 and CR4) play an important role in 
both opsonic and non-opsonic phagocytosis of MTB by macrophages 
(Ferguson et al., 2004; Schlesinger, 1993; Schlesinger et al., 1990). They 
interact with surface polysaccharides (Cywes et al., 1996), PIMs and 
glycopeptidolipids (Villeneuve et al., 2005). CR3 (also named integrin αMβ2 or 
CD11b/CD18 or Mac-1) mediates MTB phagocytosis yet uptake via this 
receptor leads to unclear host responses. Although bacterial uptake is 
decreased, the intracellular bacterial growth is kept unchanged (Melo et al., 
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2000). It was also shown that CR3-mediated phagocytosis does not induce the 
release of reactive oxygen species (Le Cabec et al., 2000). However, CR3-
knockout mice failed to reduce bacterial burden or lessen pathological lesions 
when MTB was injected intravenously (Hu et al., 2000). 
Opsonic Fcγ receptors are also important receptors in macrophages and 
monocytes and are relatively high expressed in alveolar macrophages. 
However, since these receptors require an opsonizing antibody for their activity 
they do not play a role in the initial phagocytosis of MTB (Schlesinger et al., 
1990) However, when the bacteria are opsonized with MTB-specific antibodies 
and activate these receptors, there is enhanced phagosome–lysosome fusion 
(Armstrong and Hart, 1975), facilitating an increased host macrophage 
protective response. 
Pulmonary collectins (soluble C-type lectins) play an important role in MTB 
interaction with alveolar macrophages (Beharka et al., 2002; Crowther et al., 
2004; Henning et al., 2008; Kuronuma et al., 2004). Upon entry into the alveoli, 
MTB encounters surfactant, and two surfactant-associated collectins, surfactant 
protein A (SP-A) and surfactant protein D (SP-D). SP-A has been shown to 
enhance PRR activity, increase phagocytosis, alter production of pro-
inflammatory cytokines, and decrease reactive nitrogen and oxygen species in 
response to stimuli (Crowther et al., 2004; Wright, 2005). In contrast, SP-D 
decreases phagocytosis of MTB by binding to the mannose caps of ManLAM 
and inhibiting the interaction with the MMR (Ferguson et al., 2006) whereas SP-
D-opsonized MTB display reduced intracellular growth in macrophages due in 
part to increased phagosome–lysosome fusion (Ferguson et al., 1999, 2006). 
 
1.6.   MTB recognition by TLRs and NLRs 
The understanding of the mechanisms of innate immune recognition was 
greatly enhanced by the findings of Medzhitov and Janeway  more than 15 
years ago (Medzhitov and Janeway, 1998), when they proposed a key role for 
the Toll protein as regulators of immune signaling.  Since then, mammalian toll-
like receptors (TLRs) have been shown to sense various PAMPs at the cell 
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surface or within phagosomes (Lee and Kim, 2007). Therefore, TLRs recognize 
extracellular or membrane encased foreign organisms. More recently, another 
family of PRRs was described, the NOD (nucleotide binding and oligomerization 
domain)-like receptors (NLRs) (Inohara et al., 2005; Meylan and Tschopp, 
2006; Meylan et al., 2006). These differ from TLRs by being soluble proteins 
that survey the cytoplasm. Moreover, some members of the NLR protein family 
have been shown to form cytosolic complexes with pro-caspase-1 leading to its 
activation and consequent processing of pro-IL-1β and thereby revealing yet 
another route for the engagement of the inflammatory process. These 
complexes were termed “inflammasomes” (Martinon et al., 2002) and since then 
many different studies have identified different types of inflammasomes that 
assemble in response to different stimuli. These findings gave new perspectives 
on the study of intracellular pathogens and raised new questions about the 
possible interplays between the membrane-attached TLRs and this cytosolic 
family of receptors. In fact, many reports show synergistic crosstalk between 
TLR agonists and NOD2 agonists in pro- and anti-inflammatory cytokine release 
(van Heel et al., 2005; Netea et al., 2005; Uehara et al., 2005; Watanabe et al., 
2004, 2006), adding to the difficulty in discriminating their role in innate 
immunity. 
TLRs are a highly conserved family of trans-membrane receptors comprised by 
12 members in mammals and responding to a variety of ligands (Akira et al., 
2006; Brightbill et al., 1999; Medzhitov et al., 1997; Rock et al., 1998; Trinchieri 
and Sher, 2007). They are expressed in a multitude of cells, including 
macrophages, neutrophils, lymphocytes, and DCs, as well as by alveolar 
epithelial cells (Armstrong et al., 2004; Dasari et al., 2005; Hayashi et al., 2003; 
Kadowaki et al., 2001; Krutzik and Modlin, 2004). They possess an extracellular 
amino-terminal leucine-rich repeat (LRR) domain that recognizes PAMPs and 
an intracellular carboxy-terminal tail that is homologous to the interleukin 1 
receptor (IL-1R) (Basu and Fenton, 2004). The receptor contains a Toll-IL-1R 
(TIR) domain that forms a scaffold for the assembly of signaling intermediates. 
TLRs are either expressed on the cell surface such as TLR2 and TLR4, or 
intracellularly such as TLR8 and TLR9. MTB and its cell wall components are 
recognized by several TLRs, including TLR1, TLR2, TLR4, TLR6, and TLR9 (Jo 
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et al., 2007). Mycobacterial cell wall PIMs, lipomannan (LM) and the 19-kDa 
lipoprotein have been shown to interact with TLR2 (Dao et al., 2004; López et 
al., 2003; Vergne et al., 2004). After specific ligand binding, TLRs such as TLR2 
and TLR4 initiate an intracellular signaling cascade, which generally leads to 
differential activation of NF-κB and an inflammatory response (Akira et al., 
2006; Malhotra et al., 1990; Poltorak et al., 1998). TLRs can be regulated by the 
pulmonary surfactant by means of increasing the expression of a negative 
regulator, interleukin-1 receptor-associated kinase M (IRAK-M) and IL-10 
production in macrophages (Nguyen et al., 2012). SP-A also up-regulates the 
surface expression of TLR2 on human macrophages, while inhibiting the 
intracellular signaling of TLR2 and TLR4, which results in a dampened pro-
inflammatory response (Henning et al., 2008). Moreover, TLRs have also been 
increasingly found to interact with other surface receptors leading to a 
modulation of the inflammatory response (Cambi et al., 2005; Kawai and Akira, 
2011). 
NLR family members also play a major role in innate immunity, being a second 
line of recognition molecules inside macrophages and mediating cell death 
pathways (Inohara et al., 2005). NLRs are mainly expressed in antigen 
presenting cells, including macrophages, DCs and epithelial cells. NOD1 and 
NOD2 are part of the NLR family (Ting et al., 2008). NOD1 is found in multiple 
cell types, whereas NOD2 protein expression is abundant in human 
macrophages (Brooks et al., 2011; Ogura et al., 2001). NOD1 and NOD2 
recognize specific muropeptides found in the peptidoglycan layer of Gram-
positive and Gram-negative bacteria (Inohara et al., 2003). NOD2 recognizes 
an N-glycolylated form of muramyl dipeptide (GMDP) found in MTB and controls 
the nature of the inflammatory response and subsequent fate of MTB and M. 
bovis BCG in human macrophages (Brooks et al., 2011). Upon ligation, NODs 
indirectly induce NF-kB and AP-1 activation by signaling trough mitogen-
associated protein kinase (MAPK), ultimately leading to the production of pro-
inflammatory cytokines (Chen et al., 2004). NOD2 can also directly bind and 
activate caspase-1 and interact with the NLRP1/NLRP3 inflammasomes (Hsu et 
al., 2008). Mice studies have revealed that although NOD2 does not appear to 
have a significant role in the control of early MTB infection, it may be important 
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at latter stages (Divangahi et al., 2008; Gandotra et al., 2007). Furthermore, in 
those studies MTB infection was shown to induce a decrease in pro-inflamatory 
cytokine production in NOD2-knockout macrophages but without affecting 
intracellular growth of the bacteria.  
As mentioned before, inflammasomes are multiprotein complexes. They share 
caspase-1 as a terminal effector that cleaves pro-IL-1β (Schroder and Tschopp, 
2010) yet they are part of different NLR subfamilies with different sensor 
domains. NLRP3 mediates activation of caspase-1 in response to MTB (Mishra 
et al., 2010) yet NLRP3-deficient mice display no increased susceptibility to M. 
tuberculosis infection (Schroder and Tschopp, 2010). In contrast, mice lacking 
the adaptor protein PYCARD/ASC, which links several distinct NLRs to 
inflammasome activation, are highly susceptible to MTB infection and exhibit 
early mortality, high bacterial burdens, and poorly formed granulomas (Schroder 
and Tschopp, 2010).  
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Figure 1.6 Immune recognition of MTB during phagocytosis.  
This figure by Hindawi Publishing Corporation: BioMed Research International 
(Hossain and Norazmi, 2013) is licensed under CC0 1.0. 
 
1.7.   Manipulation of host endocytic pathways by MTB 
There is now considerable evidence supporting the thesis that MTB subverts 
intracellular immune mechanisms by modulating cellular trafficking and 
phagosomal maturation, consequently avoiding lysosomal-mediated killing, to 
generate a favorable niche for its growth (Blomgran et al., 2012; Chackerian et 
al., 2002; Khader et al., 2006). Then, MTB induces its release from the host cell 
through virulence factors such as ESX-1, inducing necrotic cell death and 
promoting the recruitment of fresh phagocytes to be infected and thus allow the 
growth and expansion of MTB population (Davis and Ramakrishnan, 2009). Yet, 
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so far I have presented several studies that show different outcomes and 
responses to MTB infection related to the type of cell, its activation and also the 
receptors triggered. It is reasonable to assume that in the midst of all this 
immunomodulation MTB is likely to occupy different intracellular niches 
throughout the endocytic/phagocytic pathways (Figure 1.8), which may lead to 
phagosomal arrested maturation or to phagolysosome fusion; to the initiation of 
the autophagic process, or the cell death by necrosis or apoptosis. The different 
outcomes of these pathways will dictate the survivability of the bacilli and also 
the availability of its antigens to be presented by the antigen presentation 
machinery. I will now address these pathways, how they are exploited by MTB 
and how the host cell responds. 
Although the intracellular pathways of mycobacterial survival are well 
characterized in macrophages, less information is available on the intracellular 
fate of MTB in other host cells, especially in myeloid DCs, which harbor MTB in 
humans and mice (Wolf et al., 2007). The transcriptional profile of MTB is 
significantly different when the bacteria are inside DCs as compared with 
macrophages (Tailleux et al., 2008), which indicates that comparative studies of 
the intracellular trafficking and fate of MTB in macrophages and DCs are likely 
to yield valuable information about the life cycle of the pathogen. 
The regular phagocytic process involves the engulfment of the bacteria through 
actin-mediated membrane movements with the sequential recruitment of Rab 
GTPases to the phagosomal membrane, which will then recruit vacuolar 
ATPases, leading to the acidification of the phagosomal lumen. The mature 
acidic phagosome will then fuse with a lysosome and merge their contents, 
leading to the acquisition and activation of acidic hydrolases (Guirado et al., 
2013). Bacteria enclosed in the phagosomal compartment must suffer attrition 
in an iron-limiting, carbon-poor, hypoxic, nitrosative and oxidative environment 
(Schnappinger et al., 2003). MTB is able to resist this bactericidal response by 
synthesizing antioxidants, repairing DNA and proteins, maintaining intracellular 
pH and also cell wall integrity (Boshoff et al., 2003; Buchmeier et al., 2000; 
Colangeli et al., 2009; Darwin and Nathan, 2005; Master et al., 2002; Vandal et 
al., 2008, 2009). Furthermore, as previously mentioned, MTB may alternate its 
metabolism by activating the dormancy regulon thus enabling its survival in an 
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hypoxic and growth-limiting environment (Griffin et al., 2011; Leistikow et al., 
2010; Marrero et al., 2010; Ryndak et al., 2010). 
The best documented and repeatedly mentioned feature of MTB-infected 
phagocytes is the alteration of phagosomal trafficking and phagosomal 
maturation arrest. The first report of these events comes from the observation 
that MTB does not colocalize with ferritin-labeled lysosomes (Armstrong and 
Hart, 1971). Since then, this arrested phagosome has been characterized by a 
variety of molecular markers. The MTB-phagosome is an early endosome-like 
compartment, retaining early endosomal markers that are usually cleared from 
maturing phagosomes (Ferrari et al., 1999; Kyei et al., 2006; Roberts et al., 
2006) It remains in communication with early recycling endosomes, thereby 
acquiring iron from the transferrin/transferrin receptor system (Clemens and 
Horwitz, 1996; Sturgill-Koszycki et al., 1996); and also acquiring host 
cholesterol and fatty acids to be used as sources of carbon. There is a failure to 
replace the loss of the early marker Rab5 with late marker Rab7 on the 
mycobacterial phagosome (Sun et al., 2007; Via et al., 1997), and numerous 
late endosomal or lysosomal markers are diminished or absent, including the 
vacuolar ATPase (vATPase), that results in a failure to fully acidify (Russell, 
2001). MTB resides in a unique phagosome with an abnormally high pH of 
approximately 6.2 and with limited fusion with lysosomes (Deretic et al., 2006; 
Russell, 2001) favoring its survival and growth. Nonetheless, even when MTB is 
coated with immune serum, resulting in uptake via Fc receptors and delivery to 
lysosomes, the bacteria are able to resist the acidic environment and grow 
(Armstrong and Hart, 1975). 
 
1.7.1.   MTB lipids and proteins in phagosomal maturation arrest 
Compared with phagosomes containing latex beads or heat-killed pathogenic 
mycobacteria, phagosomes containing live pathogenic mycobacteria exhibit 
diminished phosphatidylinositol-3- phosphate (PI3P) (Chua and Deretic, 2004; 
Purdy et al., 2005; Vergne et al., 2005). PI3P is a critical lipid intermediate in the 
recruitment of the vacuolar GTPases to the phagosome (Kaufmann and Britton, 
2008) and is generated by a class III phosphatidylinositol 3-kinase (PI3K). The 
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exact mechanism by which MTB impairs PI3P generation is not fully clear. 
Reports claim that ManLAM can inhibit normal calcium increase in the cytosol, 
causing a disruption in calmodulin complex formation with the PI3K (Chua et al., 
2004; Deretic et al., 2006; Fratti et al., 2003) and thereby prevent the 
recruitment of PI3P to the phagosomal membrane (Vergne et al., 2003). MTB 
can also inhibit calcium signaling by inhibiting sphingosine kinase (Malik et al., 
2003). Yet another mechanism proposed for PI3P degradation occurs by a PI3P 
phosphatase secreted by MTB, SapM, which was shown to block phagosome 
fusion with late endosomes (Vergne et al., 2005). However, a BCG mutant 
lacking SapM displayed no defect in its ability to arrest phagosome maturation 
(Festjens et al., 2011). Due to the lack of PI3P in the phagosomal membrane, 
PIP3 effectors, such as early endosomal autoantigen 1 (EEA1) (Fratti et al., 
2001; Schlesinger et al., 2008) and hepatocyte growth factor-regulated tyrosine 
kinase substrate (Hrs), are diminished on phagosomal membranes (Connolly 
and Kusner, 2007; Kusner, 2005; Russell, 2001). Lack of PI3P and Hrs may 
interfere with recruitment of the endosomal sorting complex required for 
transport (ESCRT) that restricts the intracellular growth of mycobacteria (Philips 
et al., 2008). Also, EEA1 and Syntaxin-6 are required for the delivery of 
lysosomal hydrolases, cathepsins, and vATPases (Guirado et al., 2013). 
Another important lipid in MTB-mediated modulation of the endocytic pathways 
is trehalose dimycolate (TDM). Extraction of MTB surface lipids results in 
increased localization of MTB in more acidified compartments and diminished 
intracellular survival, a phenotype which can be partially reversed by purified 
TDM (Indrigo et al., 2003). Consistent with these results is the evidence that 
mutants defective in TDM generation depict altered phagosome maturation 
(Katti et al., 2008) and latex beads coated with TDM exhibit delayed 
phagosome maturation (Axelrod et al., 2008; Indrigo et al., 2003). 
Besides the previously mention SapM, other MTB proteins play a role in 
phagosome maturation arrest, such as PtpA (tyrosine phosphatase), PknG 
(serine/threonine kinase), LpdC (lipoamide dehydrogenase), Zmp1 (Zn2+ 
metalloprotease) and GAP (GTPase-activating protein) (Philips, 2008).  
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PtpA is required to arrest phagosome maturation and enhances MTB survival in 
human macrophages (Bach et al., 2008) probably acting together with other 
bacterial effectors to prevent acquisition of activated Rab7 on the phagosome. 
Latex beads coated with PtpA reduce phagolysosomal fusion. The mechanism 
proposed for PtpA involves its cytosolic substrate Vps33B, which is part of a 
family of proteins that aid SNARE assembly (soluble N-ethylmaleimide-sensitive 
fusion protein attachment receptors) to promote vesicle docking and fusion. 
Consistently, Vps33B depletion by RNAi dampens the delivery of lysosomes to 
latex bead-containing phagosomes (Bach et al., 2008). 
PknG is also required for phagosome maturation arrest, and M. smegmatis 
expressing it are able to prevent phagosome-lysosome fusion (Walburger et al., 
2004), although the mechanism is still unknown. 
LpdC role in phagosome maturation was discovered because LpdC from MTB 
and BCG, but not M. smegmatis, exhibits a cholesterol-dependent interaction 
with coronin 1 in infected macrophages. Coronin 1 is recruited and retained at 
the phagosomal membrane, where it activates calcium–calcineurin signaling. 
Activated calcineurin blocks the delivery of MTB to lysosomes, probably by 
dephosphorylating an unknown host cell substrate (Pieters et al., 2013). This 
facilitates the long-term survival of MTB within phagosomes. When M. 
smegmatis are made to express the MTB LpdC, the resulting phagosome 
retains coronin 1 with enhanced bacterial survival (Deghmane et al., 2007). 
ESX-1 secretion appears to be important for phagosomal arrest in both MTB 
and M. marinum, since mutants defective in the ESX-1 secretion system exhibit 
reduced arresting of phagosome maturation (MacGurn and Cox, 2007; Tan et 
al., 2006). However this secretion system is absent in the BCG genome and yet 
this species is still capable of mediating phagosome-lysosome fusion arrest. In 
MTB, known substrates of the ESX-1 system (EsxA, EsxB and EspA) appeared 
dispensable, suggesting an unidentified effector (MacGurn and Cox, 2007). 
Interestingly, the ESX-1 machinery could lead to the exact opposite effect since 
it was shown that this system is an important inflammasome activator (Koo et 
al., 2008; Master et al., 2008; Mishra et al., 2010). The mechanism by which the 
inflammasome enhances phagosome maturation is unknown, but Zmp1, a zinc-
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dependent metalloprotease of MTB, antagonizes its activity, thereby inhibiting 
phagosome maturation (Master et al., 2008). 
The ESX-1 secretion system of pathogenic mycobacteria has been implicated in 
phagosomal membrane damage leading to the leakage of bacterial antigens or 
even whole bacterial escape to the cytosol. This phenomenon was especially 
known to occur in M. marinum (Gao et al., 2004; Smith et al., 2008) yet In 
human macrophages and DCs, ESX-1 also appears to promote the escape of 
MTB from the phagosome (van der Wel et al., 2007). The two secreted effectors 
of ESX-1, EsxA (ESAT-6) and EsxB (CFP-10) were implicated in membrane 
damage yet EsxA alone appears to be sufficient to mediate the process (Hsu et 
al., 2003; de Jonge et al., 2007a; Smith et al., 2008). Also, damage to the 
phagosome may activate autophagic clearance of the bacteria although no 
direct evidence has been reported. An interesting consequence of membrane 
damage and leakage would be the increased accessibility of bacterial antigens 
to the class I antigen presentation machinery and also of MTB PAMPs to 
cytoplasmic receptors. In fact, cell wall N-glycolyl-muramyl dipeptide is only able 
to stimulate NOD2 in bacteria carrying an effective ESX-1 system (Coulombe et 
al., 2009; Pandey et al., 2009; Stanley et al., 2007). Similarly, as previously 
mention, ESX-1 is required for the bacteria to activate the inflammasome in the 
host cytoplasm (Koo et al., 2008; Mishra et al., 2010). In addition to facilitate 
access of antigenic peptides the ESX-1 is also directly involved in generation of 
adaptive immunity since both EsxA and EsxB are prominent antigens 
recognized by both CD4 and CD8 T cells (Brodin et al., 2004).  
 
1.7.2.   The role of Autophagy in MTB-infected cells 
Autophagy is an essential cellular homeostasis mechanism through which 
protein aggregates, damaged organelles or also intracellular microbes are 
encased in double membrane vacuoles termed autophagosomes which 
undergo maturation and fusion with lysosomes (Levine et al., 2011; Shintani 
and Klionsky, 2004). The complex membrane dynamics of autophagosome 
formation are not completely understood. Autophagy is induced by nutrient 
starvation, stress inputs, and immune mediators through the inhibition of 
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mammalian target of rapamycin (mTOR) leading to the recruitment of PI3K and 
consequentially to the generation of PI3P (see “MTB lipids and proteins in 
phagosomal maturation arrest”) (Levine et al., 2011). Autophagosome formation 
depends upon two protein-protein and protein-lipid conjugation systems 
(Atg5/Atg12 and Atg8/LC3). This process is not only responsible for removing in 
excess or damaged organelles but also to provide means of cell survival during 
starvation through turnover of macromolecules  (Shintani and Klionsky, 2004). 
Autophagy sequesters bacteria that access the host cell cytosol, which can 
promote both bacterial eradication and antigen presentation. The cytosolic 
bacteria are coated with ubiquitin, recognized by adaptor proteins and targeted 
to the autophagic machinery to be enclosed in a double-membrane 
compartment that matures to an autolysosome. It’s noteworthy that bacteria 
adapted to the cytosol such as Listeria and Shigella inhibit autophagy. When M. 
marinum escapes the phagosome it becomes ubiquitinated and is sequestered 
into structures resembling autophagosomes. Still this process appears not to 
require LC3 or Atg5, so it might be an independent pathway (Collins et al., 
2009). As previously mentioned, MTB also appears to escape to the cytosol yet 
since most autophagy studies were performed with BCG (which lacks ESX-1), it 
is still unclear if MTB is attacked by autophagy, or whether it inhibits it, or if it is 
sequestered in an independent pathway such as what occurs with M. marinum. 
Still, it is worth mentioning that an RNAi screen in human monocytic cell line 
THP-1 revealed that endogenous negative regulators of autophagy are required 
for MTB growth (Kumar et al., 2010). 
Basal autophagy does not appear to make a major contribution to bacterial 
clearance, but autophagy is bactericidal when activated by multiple stimuli, 
including starvation, rapamycin, IFN-γ, vitamin D, TLR4/TLR7 (Delgado et al., 
2008; Gutierrez et al., 2004; Harris et al., 2007; Xu et al., 2007; Yuk et al., 
2009). When autolysosomes fuse with MTB-containing phagosomes they 
deliver peptide-ubiquitin conjugates with anti-mycobacterial activity (Alonso et 
al., 2007; Ponpuak et al., 2010). Of great interest was the fact that this process 
was shown to overcome MTB inhibition of PI3P and to decrease bacillary 
viability by reinstating phagosomal maturation (Gutierrez et al., 2004). Indeed 
the stimulation of autophagy increased phagosomal co-localization with Beclin-
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1, a subunit of the PI3K complex, as well as with LC3. The finding that 
autophagy can be a means to improve bacterial killing and surpass MTB 
phagosomal maturation arrest opened the door for a mechanism to improve the 
presentation of MTB antigens. Making use of rapamycin as an autophagy 
inducer, another group showed that by increasing autophagic activity, both 
macrophages and DCs exhibited an increase in presentation of antigen 85 
(Jagannath et al., 2009). Mice immunized with rapamycin-treated DCs infected 
with BCG showed enhanced Th1 CD4 cell–mediated protection when 
challenged with MTB. 
 
1.7.3.   Necrosis vs Apoptosis in MTB persistence in host cells 
Cell death is a host defensive mechanism in response to many stimuli, including 
microbial infection. However, intracellular pathogens often manipulate the cell 
death pathways, inhibiting them in order to persist and replicate in the host and 
then induce them latter to enhance their dissemination. So far, a plethora of cell 
death types have been described, including apoptosis, autophagy, mitoptosis, 
necrosis, necroptosis, netosis, oncosis, pyroptosis, and pyronecrosis 
(Parandhaman and Narayanan, 2014). Concerning TB, there is increasing 
evidence associating the virulence of specific strains with their ability to inhibit 
apoptosis and ultimately direct the host cell towards a necrotic cell death (Behar 
et al., 2010). Apoptosis is a process mediated by a caspase cascade that 
results in the formation of apoptotic vesicles. These vesicles are then degraded 
by adjacent macrophages in an anti-inflammatory fashion (Harris and Keane, 
2010) although there is evidence that apoptosis may also lead to a pro-
inflammatory response dependent on MTB-infected apoptotic neutrophils 
(Persson et al., 2008). Apoptosis also promotes antigen presentation trough 
cross-presentation of MTB antigens to CD8 T cells leading to the development 
of an adaptive immune response (Behar et al., 2011; Schaible et al., 2003; 
Winau et al., 2006) (see “Cross-presentation in the generation of MTB-specific 
immunity”). Unlike apoptosis, necrosis leads to a pro-inflammatory response 
due to the permeabilization of the cellular membrane and leakage of the cell 
contents. Inside the granuloma, the characteristic caseous area is caused by 
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necrotic cell death of macrophages infected with a high burden of bacteria and 
the release of inflammatory cytokines by infected macrophages and uninfected 
leukocytes that surround the granuloma (Repasy et al., 2013). In vitro studies in 
macrophages have also shown that apoptotic cells release fewer bacteria 
compared to necrotic cells (Molloy et al., 1994). Several MTB mutants that 
promote macrophage apoptosis were shown to be attenuated in vivo (Hinchey 
et al., 2007; Velmurugan et al., 2007). The avirulent strain of MTB, H37Ra, for 
example, stimulates the production of the pro-apoptotic prostaglandin E2 
(PGE2) while the virulent strain H37Rv induces the production of lipoxin A4 
(LXA4) which induces macrophage apoptosis (Chen et al., 2008). Mice lacking 
an upstream gene, 5-lipoxygenase, required to produce LXA4 are also more 
resistant to the infection (Divangahi et al., 2010). Two other types of cell death, 
pyroptosis and pyronecrosis may also occur during MTB infection, through the 
activation of the inflammasome. As previously mentioned, MTB activates the 
inflammasome in an EsxA (ESAT-6) dependent fashion (Mishra et al., 2010) but 
there is no direct evidence that it induces pyroptosis and pyronecrosis. 
 
1.7.4.   Activators of the mycobactericidal mechanisms of macrophages 
I previous mentioned that activation by specific cytokine mediated stimulus 
induces changes in the macrophage intracellular response to foreign bodies 
(see “Macrophages and Dendritic cells”). While MTB is able to survive and 
replicate in resting macrophages, MTB killing activity is enhanced when a 
stimulus is provided by other macrophages or T cells, with the release of IFN-γ, 
TNF-α and vitamin D. IFN-γ was shown to be essential for MTB control in 
humans and mice (Chan et al., 1992; Jouanguy et al., 1999). Primed T cells 
release IFN- γ and activate macrophage killing mechanisms by increasing the 
expression of nitric oxide synthase 2 (NOS2) and production of reactive 
nitrogen species (RNS) (Chan et al., 1992). Nonetheless, there is still much 
debate on the actual contribution of RNS to MTB killing in human macrophages. 
As mentioned above, IFN-γ also stimulates autophagy-dependent delivery of 
lysosomes to the MTB-containing phagosome. The curious finding is that IFN-γ 
impairs the rate of phagosome-lysosome fusion in latex bead-containing 
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phagosomes, causing diminished hydrolytic and proteolytic activity in the 
phagosome (Trost et al., 2009; Yates et al., 2007). Although it is still unknown if 
this delay also occurs in pathogen-associated phagocytosis, it might be 
beneficial to the host, by preserving intact peptides to be presented to T cells by 
HLA class II molecules. 
TNF-α is also essential for control of MTB in humans and in animals (Solovic et 
al., 2010) by activating macrophages for killing intracellular MTB and to 
modulate apoptosis of infected cells (Balcewicz-Sablinska et al., 1998; Clay et 
al., 2008). TNF-α can also act with IFN-γ to activate macrophages for the 
control of MTB growth. Nevertheless, excessive TNF-α response contributes to 
the immunopathology of TB (Bekker et al., 2000; Tobin et al., 2010), resulting in 
tissue damage. MTB has developed mechanisms to modulate TNF-α production 
through the secretion of a bacterial adenylate cyclase (Agarwal et al., 2009), 
thereby enhancing virulence and lung inflammation in mice. 
Another relevant mechanism that has been studied with interest is vitamin D-
induced killing of MTB. The expression of the vitamin D receptor is dependent 
on vitamin D active form, 1,25- dihydroxyvitamin D3 (calcitriol). This receptor 
mediates the transcription of the gene encoding cathelicidin, the precursor of 
LL-37, which was shown to kill MTB and other bacteria (Liu et al., 2007; 
Martineau et al., 2007). TLR2-mediated activation of human macrophages was 
also shown to increase the expression of the vitamin D receptor and cathelicidin 
(Liu et al., 2006) in the presence of calcitriol. Similarly to IFN-γ, calcitriol may 
activate autophagy since calcitriol-dependent expression of cathelicidin elicits 
the transcription of autophagy-related genes. Moreover, LL-37 is also recruited 
to the autophagosome (Yuk et al., 2009). Recent reports also implicate vitamin 
D in alterations in MTB lipid metabolism due to down-regulation of the proa-
dipogenic peroxisome proliferator-activated receptor γ (PPARγ) in infected 
macrophages (Salamon et al., 2014). 
Besides these inducers of macrophage bactericidal response, some focus has 
been given to lipid-mediated inhibition of MTB growth. A study reported that 
inhibition of mycobacterial growth in macrophages could be observed after 
addition of several bioactive lipids such as arachidonic acid, sphingomyelin, 
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sphingosine, or ceramide (Anes et al., 2003). These effects were proposed to 
occur via enhanced actin nucleation on the phagosomal membrane. While it is 
not proven that these events are actin-dependent, previous studies have shown 
that MTB may modify the cytoskeleton of infected macrophages, modify actin 
filament network and inhibit the movements of lysosomes in the vicinity of newly 
formed phagosomes (Guérin and de Chastellier, 2000; Hart et al., 1987). This 
was shown to inhibit proper localization of the inducible nitric oxide synthase 
(iNOS), the enzyme responsible of nitric oxide synthesis, in the vicinity of the 
MTB-phagosome in mice (Miller et al., 2004). Purified phagosomes containing 
latex beads or non-pathogenic mycobacteria promote actin nucleation in vitro 
while phagosomes containing pathogenic mycobacteria were shown to inhibit 
this process (Anes et al., 2003). Stimulation of actin-dependent mechanisms, as 
was shown by addition of lipids such as arachidonic acid (Anes et al., 2003), 
might prove to be a pathway for improving MTB clearance in humans. 
 
1.7.5.   Regulation of antigen presentation in MTB-infected cells 
In order to mount an effective immune response against MTB, the 
immunologically naïve cell populations that mediate adaptive immunity, such as 
T cells, need to be primed by cells carrying MTB antigens. This will lead to an 
antigen specific reaction that will target MTB and MTB-infected cells that display 
bacterial antigens. Foreign pathogen-derived peptides are expressed at the 
surface of APCs, like dendritic cells and macrophages, through binding to HLA 
class I and HLA class II molecules. HLA class II molecules bind exogenous 
peptides from the endosomal pathway (e.g. from the MTB containing 
phagosome) contrary to HLA class I molecules that bind peptides from the 
cytosol (e.g. from cytosolic bacteria or virus) upon transport to the ER. 
Presentation through these two different molecules will result in clonal 
expansion of different subsets of antigen specific T cells. HLA class II-presented 
antigens will prime CD4 T cells whereas HLA class I-presented antigens will 
prime CD8 T cells. 
For the presentation of MTB antigens to occur, bacterial peptides must be 
produced by proteolysis and then bound to HLA class II molecules. HLA class II 
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molecules are assembled in the endoplasmic reticulum where they are also 
associated with a invariant chain (li) molecule to prevent premature peptide 
loading prior to delivery to the phagolysosome. In the phagolysosome, the 
invariant chain is degraded by proteases, particularly cathepsin S, leaving the 
class II-associated li peptide (CLIP) in the peptide-binding groove. Only then 
HLA-DM will catalyse the dissociation of CLIP and exchange with the 
phagolysosomal peptides (self or foreign). The peptide-HLA class II complex is 
then transported to the plasma membrane where it will interact with CD4 T cells 
(Wearsch and Cresswell, 2009). HLA class II-mediated antigen presentation 
can be negatively regulated by another HLA molecule, HLA-DO which binds to 
HLA-DM and inhibits its function, preventing CLIP dissociation (Wearsch and 
Cresswell, 2009). Another described mechanism occurs through transcriptional 
control of HLA-class II by the class II transactivator (CIITA) (Boss and Jensen, 
2003; Harton and Ting, 2000; Masternak et al., 2000; Reith and Boss, 2008; 
Reith and Mach, 2001; Steimle et al., 1993, 1994). CIITA interacts in the 
assembly and action of several transcription factors, resulting in the induction of 
HLA class II transcription and also regulation of the invariant chain and HLA-DM 
(Boss and Jensen, 2003; Chang and Flavell, 1995; Chang et al., 1996). Control 
of CIITA expression is performed by different promoters in macrophages and 
DCs (Muhlethaler-Mottet et al., 1997). In macrophages the majority of these 
promoters are responsive to IFN-γ, leading to the induction of CIITA and HLA 
class II genes, while in immature DCs, the promoter was shown to induce CIITA 
independently of IFN-γ (Pai et al., 2002). 
So far, there is considerable evidence that MTB interferes with the synthesis 
and expression of HLA class II molecules (Harding and Boom, 2010). Some 
studies propose that this regulation occurs directly in HLA class II gene 
promoters (Wang et al., 2005) while others propose that this regulation is 
mediated by the inhibition of CIITA (Kincaid and Ernst, 2003; Pai et al., 2003; 
Pennini et al., 2006, 2007; Wojciechowski et al., 1999). MTB-infected 
macrophages exhibit an inhibition of HLA class II molecules following 
approximately 15-24 hours after infection (Noss et al., 2000, 2001; Pai et al., 
2003). A proposed model (Harding and Boom, 2010) implies TLR signaling in 
the decreased expression of HLA class II molecules via mitogen-activated 
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protein kinase (MAPK) activation, nitric oxide and the induction of inhibitory 
transcription factors that will lead to decreased expression of CIITA. The 
consequent decay of MHC class II molecules transiting through the ER and 
Golgi and delivery to the phagolysosome would take several hours, possibly 
explaining the delay in HLA class II inhibition mentioned above (Harding and 
Boom, 2010). 
Assessing inhibition of HLA class II antigen presentation beyond the regulation 
of gene expression presents a more difficult challenge since it requires a 
functional analysis rather than a simple measure of expression. MTB was 
shown to inhibit the expression of several genes involve in antigen processing 
and presentation in macrophages via its 19 kDa lipoprotein, after prolonged 
TLR signaling (Pai et al., 2004). Mice studies revealed that high-frequency MTB 
infection of lung DCs resulted in a decreased ability to prime CD4 T cells 
without altering the surface expression of HLA class II molecules (Wolf et al., 
2007). MTB was also shown to inhibit surface expression of HLA class II 
molecules though intracellular sequestration of these molecules (Hmama et al., 
1998). Phagosome maturation arrest might also impact antigen presentation, 
although several studies indicate that this does not impair the processing of 
MTB antigens (Majlessi et al., 2007; Ramachandra et al., 2001, 2005). An 
interesting theory relates the impairment of HLA class II-mediated antigen 
presentation in macrophages to the need to reduce the pro-inflammatory 
response elicited by CD4 T cells in the infected tissues. Since macrophages 
mostly present antigens in the locus of infection, this mechanism would prevent 
tissue damage after prolonged exposure of macrophage receptors, such as 
TLRs, to MTB PAMPs. Meanwhile, DCs would require an enhanced activation 
by those receptors to increase the expression of HLA class II molecules while 
travelling to the lymphoid organs to prime CD4 T cells (Harding and Boom, 
2010). 
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Figure 1.7. The different antigen presentation responses of macrophages and dendritic 
cells to Toll-like receptor signaling. 
 (a) In DCs, TLR signaling induces maturation, which involves increased expression of 
peptide–MHC class II molecule complexes and co-stimulatory molecules. DC 
maturation also involves migration to lymph nodes, where DCs present antigen to naive 
T cells, priming the T cell response to pathogens. (b) By contrast, macrophages initially 
show little decrease in MHC class II antigen presentation and then, after prolonged 
stimulation (approximately 24 hours or more), show inhibition of antigen presentation 
with decreased expression of MHC class II molecules. This contrast in MHC class II 
levels results from regulation of the post-translational stability of MHC class II 
molecules, which is greatly enhanced during DC maturation but is not increased in 
macrophages upon TLR stimulation. Accordingly, TLR stimulation of DCs by 
microorganisms results in a final burst of antigen processing and the accumulation of a 
kinetic cohort of peptide–MHC class II molecule complexes that include microbial 
peptides; this cohort is expressed for a prolonged period and provides effective 
stimulation of naive T cells. Reprinted by permission from Macmillan Publishers Ltd: 
Nature Reviews Microbiology (Harding and Boom, 2010), copyright 2010. 
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1.7.6.   Cross-presentation in the generation of MTB-specific immunity 
In spite of being encased by the phagosomal vacuole, MTB-infected cells are 
able to prime CD8 T cell trough the HLA class I machinery. Accessibility of MTB 
antigens to the HLA class I machinery is thought to occur via cross-presentation 
(Guermonprez et al., 2002; Heath et al., 2004). Cross-presentation refers to the 
activation of CD8 T cells by APCs that obtained those antigens from a donor 
cell. This process involves an antigenic transfer between the cell initially 
infected and the antigen-presenting cell (Winau et al., 2005). For example, the 
antigenic content of apoptotic vesicles from macrophages are able to prime 
APCs for cross-presentation (Winau et al., 2005). Another type of cross-
presentation was also found to take place through a direct pathway, which does 
not need an intermediary cell. There is no consensus about how this occurs, yet 
a proposed explanation states that antigens phagocytised by DCs and some 
macrophages are only partially degraded in the phagosome. Then they are 
transported into the cytosol where they are further broken down (Watts, 2006). 
Finally, upon being taken by the ER, they are loaded onto MHC class I 
molecules to be presented at cell surface to CD8 T cells.  
In fact, as previously mentioned there are reports proposing that MTB is 
capable of escaping the phagosome and/or compromise its structural integrity 
through the Esx-1 secretion system. This event would permit the leakage of 
MTB antigens into the cytosol, thus rendering them accessible to the HLA class 
I-mediated antigen presentation pathway. So far, evidence of phagosomal 
escape has been show to occur only in late periods of infection (days) while 
HLA class I-mediated antigen presentation occurs in hours (Grotzke et al., 
2009, 2010). Studies also show that the ESX-1 machinery is not required to 
onset CD 8 T cell immunity (Woodworth et al., 2008), arguing that phagosomal 
escape might not explain cross-presentation. Still, antigen leakage into the 
cytosol remains an interesting hypothesis since proteins secreted by MTB are 
over-represented as antigens recognized by CD8 T cells (Woodworth and 
Behar, 2006). Generation of apoptotic vesicles is a pathway for cross-
presentation of MTB antigens and was found to be important to provide 
protection against MTB in mice. Researchers found that DCs had a major role 
in crosspriming by taking up MTB antigens from apoptotic vesicles and then 
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migrating into the lymph nodes to prime CD 8 T cells (Winau et al., 2006). This 
was further confirmed by abrogating the expression of MHC class I molecules 
on the surface of the apoptotic cell, indicating that an intermediary DC was 
necessary.  
Another pathway for cross-presentation might involve a non-apoptotic type of 
vesicle, the exosome. Exosomes are 50–150 nm membrane vesicles originating 
from multivesicular bodies by inward budding of endosomal membranes and 
are released via fusion of the limiting membrane of multivesicular bodies with 
the plasma membrane, resulting in release of intraluminal vesicles as exosomes 
(Schorey and Bhatnagar, 2008). Exosomes may play a role in both innate and 
adaptive immunity. They carry several MTB PAMPs, such as LAM, PIM, TDM 
and phenolic glycolipids (Beatty et al., 2000). Exosomes carrying these 
molecules can stimulate bystander cells and induce inducible nitric oxide 
synthase and secretion of pro-inflammatory cytokines such as TNF-α and 
RANTES (Bhatnagar and Schorey, 2007; Bhatnagar et al., 2007). Moreover, 
lipoprotein 19 kDa was also shown to be important for pro-inflammatory 
stimulation by exosomes (Stewart et al., 2005). Exosomes where already found 
to be successful antigen presenters in cancer immunotherapy. In the case of 
MTB, exosomes from BCG-infected macrophages were shown to stimulate CD4 
T cells and CD8 T cells in vitro and in vivo (Giri and Schorey, 2008). Exosomes 
from macrophages treated with MTB culture filtrate proteins were found to 
induce antigen-specific IFN-γ and IL-2-expressing CD4 and CD8 T cells. When 
mice were vaccinated with these exosomes they exhibited similar Th1 
response. 
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Figure 1.8. The endocytic/antigen presentation pathways during MTB infection. 
(1) MTB impairs phagosome-lysosome fusion, replicates and causes necrosis of the cell. (2) External stimuli, such as IFN-γ released from T 
cells, induces a strong oxidative burst and phagolysosome-fusion leading to the destruction of the pathogen and presentation of its antigens via 
HLA class II. (3) Apoptosis induced with budding of the membrane and release of apoptotic vesicles with MTB and/or MTB antigens. (4) 
Multivesicular body formation leads to secretion of antigen-containing exosomes. (5) Formation of autophagosomes with fusion with lysosomes 
and consequent MTB elimination and antigen presentation. DCs cross-present MTB antigens by uptake of the contents of apoptotic vesicles 
and exosomes then present them via HLA class I. 
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1.8.   Cathepsins in the intracellular response against 
M. tuberculosis 
In 1955, Christian de Duve (Novel Prize, 1974) discovered a distinct population 
of vesicles containing acidic hydrolases, among them a cathepsin protease, 
now known as aspartic cathepsin D. These vesicles were called lysosomes due 
to their abundance in hydrolytic enzymes (Christian de Duve, B.C. Pressman, 
R. Gianetto, R. Wattlaux, 1955). The finding that these hydrolases act on 
different substrates suggested that the lysosomes, also known as “suicide 
bags”, might play a role in intracellular digestion at acidic pH. Lysosomes were 
then discovered in several cell types, playing a role in intracellular acidic 
digestion and found to be involved in the degradation of extracellular material 
taken up via endocytosis and also intracellular material sequestered via 
autophagy (de Duve, 1983, 2005). For an efficient degradation of the 
internalized macromolecules, lysosomes possess a variety of hydrolytic 
enzymes including proteases, amylases, lipases and nucleases. Amongst the 
most abundant, widespread and studied proteases are aspartic, serine and 
cysteine cathepsins, as named according to the amino acid residue present at 
their catalytic site. Cathepsins include the serine proteases cathepsins A and G, 
the aspartic proteases cathepsins D and E and the cysteine proteases 
cathepsins B, C, F, H, K, L, O, S, V, X and W. Optimal activity of lysosomal 
cathepsins typically require a slightly acidic and reducing environment and most 
of them are unstable at neutral pH and suffer irreversible unfolding (Turk et al., 
1995, 1999). Cathepsin S is an exception, being stable at neutral or slightly 
alkaline pH and retaining its activity (Kirschke et al., 1989). Cathepsin L is at the 
opposite extreme, being the most unstable cathepsin at neutral pH (Turk et al., 
1993). Cathepsin B also shows irreversible loss of activity at pH accompanied 
by structural changes (Turk et al., 1994).  
Different roles of cathepsins might be attributed to their substrates but also to 
their location. Most human cathepsins, such as cathepsins B, H, L, C, X, F and 
O, are ubiquitously expressed in human cells, and are probability involved in 
normal protein turnover. Others, such as cathepsins K, S and W are restricted 
to specific tissues, indicating a more specific role. Cathepsin K is highly 
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expressed in osteoclasts (Salminen-Mankonen et al., 2007) and is essential for 
extracellular matrix degradation and bone resorption. Cathepsin W is 
predominantly expressed in CD8 T cells and natural killer (NK) cells (Linnevers 
et al., 1997; Wex et al., 2003).  
Cathepsin S is predominantly expressed in APCs, such as DCs and also in B-
cells (Hsing and Rudensky, 2005). Cathepsin V (also named L2) is highly 
homologous to cathepsin L yet is only expressed in the thymus and testis 
(Brömme et al., 1999; Santamaría et al., 1998). Cathepsins are also known to 
act in other cellular compartments outside the scope of this thesis. Nonetheless 
it is worth mentioning that several cathepsins are secreted in order to cleave 
extracellular-matrix components such as elastins, collagens and proteoglycans 
as exemplified by cathepsins K, L, S, F, H, V and B (Brömme et al., 1996; 
Fonović and Turk, 2014a; Lutgens et al., 2007; Yasuda et al., 2004). Cysteine 
cathepsins exhibit broad specificity, cleaving their substrates preferentially after 
basic or hydrophobic residues, consistent with their roles in intracellular protein 
degradation (Turk et al., 2000). Most cathepsins are endopeptidases, whereas 
cathepsins X and C are exopeptidases. In addition to their endopeptidase 
activity, cathepsins B and H also exhibit exopeptidase activity (Zavasnik-
Bergant et al., 2006).  
Cathepsins are regulated by endogenous protein inhibitors, cystatins, thyropins 
and serpins, among others. These compete for the active site of the cathepsin 
and bind in a reversible fashion, preventing substrate binding. These regulators 
act in emergency situations, when cathepsins are leaked outside of their proper 
compartments or when pathogens release their own proteases, and inactivate 
them to avoid cell damage. They also act by regulating the activity of cathepsins 
by inhibiting them in the absence of their target or modulating their activity 
according to cellular responses (Klotz et al., 2011; Turk et al., 2002). For 
example, in immature DCs, HLA class II-invariant chain complexes accumulate 
and need to be processed by cathepsin S. This event will depend on the ratio 
between cathepsin S and its inhibitor cystatin C (Pierre and Mellman, 1998). 
Upon maturation, cystatin C is down-regulated, and the activity of cathepsin S 
increases, promoting degradation of the invariant chain and allowing the export 
of peptide-loaded class II molecules to the cell surface. 
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Cathepsins have been implicated in cell death pathways. Pyronecrosis, a 
process initiated by inflammasome activation is dependent on cathepsin B and 
is observable in shigellosis (Carneiro et al., 2009; Willingham et al., 2007). In 
addition, cathepsin D activation during pneumococcal infection was shown to 
induce apoptosis of macrophages, therefore promoting the death of this 
pathogen (Bewley et al., 2011). Another study reported that an MTB protein, 
Rv3364c, binds to cathepsin G on the plasma membrane of phagocytic cells 
and inhibits caspase-1 activity and pyroptosis (Danelishvili et al., 2011). 
Several cathepsins have been found to play a role in antigen presentation. 
Cathepsins S, L, F and V were shown to degrade the invariant chain and also 
generate antigenic peptides for HLA class II-mediated antigen presentation in 
different cells types in humans and mice (Beers et al., 2005; Hsing and 
Rudensky, 2005; Shi et al., 2000; Tang et al., 2006; Villadangos and Ploegh, 
2000). Cathepsin G found in endocytic compartments of a variety of antigen 
presenting cells (but not monocyte-derived DC) has been implicated in 
processing of several foreign and self-antigens (Burster et al., 2010). 
Insights into antigen cross-presentation provided interesting conclusions that 
might be of great interest to those studying intracellular pathogens. Savina and 
colleagues (Savina et al., 2006) showed that antigen cross-presentation by 
dendritic cells is promoted by attenuation of the activity of proteases found in 
the phagosome, and by recruitment of NADPH oxidase, a known microbicidal 
enzyme of neutrophils. They revealed that dendritic cells maintained a neutral 
and even alkaline phagosomal environment, thereby contrasting to the acidic 
phagosome usually known of macrophages. This elevated pH occurs through 
recruitment of NADPH oxidase and production of reactive oxygen species 
(ROS) in the phagosomal lumen that neutralize the acidic environment. 
Production of ROS was found to be maintained for several hours, contrasting 
with macrophages where only short bursts were detected. These studies are 
revealing that attenuation of proteolysis might diminish the destruction of 
antigens needed for presentation, thus explaining why dendritic cells are more 
effective in antigen presentation to lymphocytes than macrophages.  
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One must not forget the evidence in support of the need for an acidic 
environment for the activity of several cathepsins. Cathepsin S is, until now the 
only vacuolar enzyme demonstrated to be necessary for cross-presentation 
(Shen et al., 2004). This enzyme is one of the few vacuolar cathepsins that 
remains stable and active in a neutral pH environment (Lennon-Duménil et al., 
2002), which fits the above-proposed model for presentation of antigens 
originating in a neutral pH. On the one hand, this model fits cross presentation 
through MHC class I pathway, but on the other hand, it does not explain fully 
the activity of proteolytic enzymes of the MHC class II pathway that function in 
an acidic medium. A proposed explanation is the diversity of ranges of pH 
observed inside phagosomes (Butor et al., 1995). 
In the same cell, one can observe different kinetics of PI3P accumulation 
(Henry et al., 2004). Since PI3P is required for recruitment of NADPH-oxidase 
subunits p40phox and p47phox, this suggests different activities for NADPH 
oxidase in each phagosome, thus rendering the possibility that different 
presentation pathways may occur. As previously mentioned, MTB is known to 
inhibit the activity of PI3P through the bacterial lipid ManLAM and the PI3P 
phosphatase SapM (see “MTB lipids and proteins in phagosomal maturation 
arrest”). This may prove of some interest for MTB antigen presentation by 
dendritic cells. 
The modulation of phagosomal maturation by MTB clearly affects the delivery of 
lysosomal enzymes needed for antigen presentation. Moreover, if we take into 
consideration the fact that some cathepsins might be delivered to early 
endosomes, an acidic pH would be necessary to activate those proteases. Even 
so, CD4 T cells respond to MTB antigens on an antigen specific fashion (Beatty 
et al., 2001; Ramachandra et al., 2001). We may hypothesized that to some 
extent, only a minor fraction of MTB-containing phagosomes need to be able to 
maturate and acquire lysosomal proteases for an effective antigen presentation 
to occur. 
Several studies searched for possible relations between cathepsin activity and 
mycobacteria survival. Studies on THP-1 monocytic cell line revealed that IFN-
γ-induced Cat S expression was down-regulated when those cells were infected 
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with BCG (Sendide et al., 2005). Due to that, MHC class II molecules without 
peptide antigen load accumulated in the interior as well as on the surface of the 
cells. Moreover, this phenotype was found to be linked to BCG-induced 
secretion of IL-10. This reveals an ability of BCG to inhibit peptide loading into 
class II molecules. In another study, BCG was engineered to express Cat S. 
This resulted in the recovery of normal surface expression of class II MHC 
molecules carrying BCG antigens (Soualhine et al., 2007). Remarkably, these 
bacteria were much more readily killed by THP-1 monocyte-derived 
macrophages than the wild type bacteria, and the BCG-containing vesicles co-
localized significantly with late endosomal markers. Another cathepsin, Cat G 
was shown to possess bactericidal properties. In THP-1 cells, Cat G was shown 
to be down-regulated upon MTB infection (Rivera-Marrero et al., 2004), a 
possible strategy to render MTB bacilli more viable. Still, another research 
group demonstrated in murine alveolar macrophages that down-regulation of 
Cat G only occurred at 6 and 12 hours post infection (Srivastava et al., 2007). 
After 3 and 7 days the opposite effect was observed, with high up-regulation of 
Cat G expression. 
Clear evidence for the requirement of acidification for cathepsin activation was 
depicted in a study concerning Cat D (Singh et al., 2006). The authors 
correlated the presence of active form (30-kDa) of Cat D with increased 
acquisition of the proton pump vATPase by the phagosome in macrophages 
infected with the attenuated strain H37Ra. The consequence of vATPase 
accumulation was as expected, an acidification of the phagosomal lumen. This 
study concluded that during infection with the pathogenic strain H37Rv or BCG, 
vATPase exclusion and more neutral pH phagosomal environment led to an 
increase in the levels of the Cat D inactive form (46-kDa). Increased 
phagosomal acidification and Cat D activity upon infection with H37Ra strain 
resulted in increased MHC class II antigen presentation-dependent induction of 
IL-2 in T cells. 
Cathepsins have also been shown to play a role in the initiation of innate 
responses to microbes. Cathepsin K inhibition results in attenuation of 
inflammatory autoimmune diseases, while its pharmacological or genetic 
inhibition leads to defective TRL9 (endosomal-membrane TLR) signaling in 
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DCs, without affecting antigen presentation (Asagiri et al., 2008). Similarly, 
cathepsins B, F, L, and S were shown to be required for TLR9 responses 
(Matsumoto et al., 2008) by inducing the proteolytic cleavage required for TLR 
signaling (Ewald et al., 2008; Park et al., 2008). Unprocessed TLR9 retain the 
capacity to bind their ligands, yet only the processed forms recruit the signaling 
adaptor protein MyD88. Concerning cytokine signaling, cathepsins were shown 
to activate or inhibit certain cytokines. In macrophages, a study found that 
cathepsin B was required for optimal post-translational processing and 
production of TNF-α in response to LPS (Ha et al., 2008). This suggests a role 
for intracellular cathepsin B in vesicle trafficking of TNF-α to the plasma 
membrane. 
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Table 1.1. List of cathepsins function in immunity and their inhibitors. 
Name Gene 
Catalytic 
type Distribution Function 
Inhibitor 
Cystatin 
cathepsin A CTSA Serine Ubiquitous Protective protein  
cathepsin B CTSB Cysteine Ubiquitous 
Early neutrophil, T and B cell apoptosis 
TLRs signaling and TNF-alpha production 
Processing peptide-HLA II complexes 
Cystatins A, 
B, C, E/M 
and SN 
cathepsin C CTSC Cysteine Ubiquitous Activation of granzymes A and B 
Cystatins A, 
B, C, SN 
cathepsin D CTSD Aspartic Ubiquitous 
Early neutrophil, T and B cell apoptosis 
Processing peptide-HLA II complexes 
 ECM degradation 
 
cathepsin E CTSE Aspartic 
Immune 
cells 
Processing peptide-HLA II complexes  
cathepsin F CTSF Cysteine Ubiquitous 
TLRs signaling 
Processing peptide-HLA II complexes 
 
cathepsin G CTSG Serine 
Neutophils, 
B cells 
IL-8, IL-1beta and TNF-alpha activation IL-
6 deactivation 
Destruction of the autoantigen MBP (in B 
cells) 
 
cathepsin H CTSH Cysteine Ubiquitous ECM degradation 
Cystatins A, 
B, C, D 
cathepsin K CTSK Cysteine 
DCs, 
epithelial 
cells 
TLRs signaling 
ECM degradation and bone remodeling 
 
cathepsin L CTSL1 Cysteine Ubiquitous 
TLRs signaling 
Processing peptide-HLA II complexes 
 NK T and CD4 T cells production, 
neuronal cell death and osteoclastic bone 
degradation 
Cystatins A, 
B, C, D, E/M, 
F 
cathepsin O CTSO Cysteine Ubiquitous   
cathepsin S CTSS Cysteine APCs 
TLRs signalling 
Processing peptide-HLA II complexes  
NK T cells production, ECM degradation 
Cystatins A, 
B, C, D 
cathepsin V CTSL2 Cysteine Ubiquitous 
Processing peptide-HLA II complexes 
 NK T and CD4 T cells production 
Cystatins 
E/M 
cathepsin W CTSW Cysteine 
NK and T 
cells 
Processing peptide-HLA II complexes  
cathepsin X CTSZ Cysteine Ubiquitous T cell activation  
(Rawlings et al., 2014). 
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1.9.   MicroRNA regulation in MTB-infected host cells 
Genomic studies have revealed numerous portions of the genome that do not 
encode proteins, while encoding bioactive non-coding RNA species. This 
explained why only less than 2% of the genome contains protein-coding genes 
although more advanced techniques determined that at least 90% of the 
genome was transcribed (Costa, 2010; Ponting and Grant Belgard, 2010; Stein, 
2004).  A part of this huge, non-protein coding portion of the genome was 
shown to encode RNA molecules that regulate the expression of other genes, 
similarly to another already known process called RNA interference. These 
small non-coding regulator RNAs were called microRNAs (miRNAs), 
possessing 19-22 nucleotides long and being involved in post-transcriptional 
gene expression control (Bartel, 2004) and influencing many biological systems. 
including mammalian immune systems (Williams, 2008). 
Human miRNAs have been shown to be involved in cell development, 
differentiation, proliferation, apoptosis, DNA methylation, DNA repair and 
provide anti-inflammatory or pro-inflammatory stimuli (Belver et al., 2010; Small 
and Olson, 2011). miRNAs are matured and processed in a multistep process 
involving several enzymes. The primary transcript is transcribed by RNA 
polymerase II as a several hundred nucleotides long double-stranded transcript 
called pri-miRNA (O’Connell et al., 2010a). Pri-miRNA folds into a hairpin 
structure which is poly-adenylated and capped. The RNase III-type enzyme 
Drosha converts this precursor into a double-stranded miRNA precursor of 60 to 
100 nucleotides hairpin known as pre-miRNA (Denli et al., 2004). Pre-miRNAs 
contain a local stem-loop structure that encodes miRNA sequences which are 
exported from the nucleus to cytoplasm by exportin 5 (Yi et al., 2003). Pre-
miRNAs are then processed in the cytoplasm by the RNase II Dicer in order to 
yield imperfect, approximately 22-nucleotides long double-stranded miRNA. 
This duplex is unwounded by helicases into two single strands consisting of a 
guide strand, that will become the mature miRNA, and a passenger strand 
which will be degraded (Chendrimada et al., 2005). The mature miRNA is 
incorporated into the RNA-induced silencing complex (RISC), which recognizes 
specific targets and induces posttranscriptional gene silencing thus regulating 
protein expression (Khvorova et al., 2003).  
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Another alternative biogenesis pathway for miRNAs was recently discovered in 
which following Drosha processing, the pre-miRNA directly enters RISC and 
skips further processing by Dicer (Cheloufi et al., 2010). The silencing occurs 
when miRNA-RISC complex binds the miRNA in the complementary region 
inside the 3’ untranslated region (3’ UTR) of the mRNA in order to terminate the 
translation or to lead to degradation of the mRNA (Lu et al., 2005; O’Donnell et 
al., 2005). Once the miRNA is bound to a completely complementary region the 
mRNA is degraded. However, miRNA-mediated regulation does not require a 
perfect match. Only the 7-base sequence between 2nd and 8th nucleotide is 
called the “seed region,” and a complete match of this sequence is required. It 
is thought that the strength of the inhibition varies depending on the sequence 
but the precise relevant factors are still to be determined (Singh et al., 2013a). A 
single miRNA may target hundreds of mRNAs and several miRNAs can also 
target the same mRNA and result in enhanced translational inhibition (Selbach 
et al., 2008).  
A plethora of miRNAs have been found to regulate key cells of the immune 
system. Evidences found regulation in T cell differentiation and function (Du et 
al., 2009; Ebert et al., 2009; O’Connell et al., 2010a, 2010b; Stittrich et al., 
2010) and in the innate function of macrophages, DCs and NK cells (Bezman et 
al., 2010; O’Connell et al., 2010a; Taganov et al., 2006). Moreover, miRNAs 
have not only been found in tissues but also in serum and other body fluids 
protected from RNAse activity trough a stable association with RISC and 
circulating freely or bound to exosomes. 
Pathogenic mycobacteria use the host miRNA to manipulate its response to 
infection (Table 1.2). A recent study with M. avium in human macrophages 
(Sharbati et al., 2011) revealed several miRNAs to be up-regulated or down-
regulated upon infection. Notably, let-8e and miR29a were found to respectively 
target caspases 3 and 7, major effectors of apoptose triggering (Fink, 2005), 
providing more evidence for MTB-induced inhibition of apoptosis. In contrast, in 
murine T cells infected with Listeria monocytogenes or BCG, miR-29 was found 
to be down-regulated while its target was IFN-γ mRNA (Ma et al., 2011). 
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Two miRNAs, miR-125b and miR-155, were found to be differentially regulated 
upon infection of macrophages with MTB or M. smegmatis. While miR-125b 
targets TNF-α mRNA, miR-155 is thought to indirectly enhance TNF-α 
production by increasing TNF-α mRNA half-life and translation (Tili et al., 2007). 
During infection with live MTB or simply by treatment with MTB lipomannan 
there was an induction of miR-125b and reduction of mIR-155 expression 
leading to low TNF-α production. In contrast, when macrophages were infected 
with live M. smegmatis or treated with its lipomannan, miR-155 expression was 
induced while miR-125b was reduced, leading to high TNF-α production 
(Rajaram et al., 2011). In DCs, miR-99b was also found to mediate TNF-α 
generation while its knockdown led to enhanced production of TNF-α with 
impact in MTB intracellular growth (Singh et al., 2013b). Recent work also found 
that EsxA (ESAT-6) induced the expression of miR-155, which subsequently 
repressed Bach1 and SHIP1 expression. Bach1 is a transcriptional regulator of 
heme oxygenase-1, which has been implicated in activation of MTB dormancy 
regulon (Dos), while SHIP1 inhibits the activation of a serine/threonine kinase 
AKT that is important for MTB survival. Another role for miR-155 is mediation of 
macrophage apoptosis through TLR signaling. BCG were found to trigger miR-
155 by a TLR2-dependent mechanism (Ghorpade et al., 2012). 
I previously mentioned the important role of vitamin D in enhancement of 
macrophage-mediated killing of MTB (see “Activators of the mycobactericidal 
mechanisms of macrophages”). Two vitamin D-dependent peptides, CAMP and 
DEFB4A were found to be regulated by miR-21, possibly by down-regulation of 
TLR2/1 heterodimer-induced CYP27B1. Triggering of TLR2/1 was found to 
induce IL-1β secretion, increase the expression of IL-1 receptor (IL- 1R1) and 
decrease the secretion of IL-1 receptor antagonist (Liu et al., 2009). Inhibition of 
this pathway by miR-21 thus resulted in decreased IL-1β expression and 
activity, and also indirectly  byup-regulation of IL-10 (Liu et al., 2012). 
Knockdown of miR-21 in M. leprea-infected monocytes led to restoration of 
CAMP and DEFB4A expression and TLR2/1-mediated antimicrobial activity. 
More recently, one microRNA, miR-142-3p, was found to interfere with 
macrophage phagocytosis by targeting the actin-binding protein N-WASP 
(Bettencourt et al., 2013). This microRNA was differentially regulated by MTB 
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and M. smegmatis. Comparatively with M. smegmatis, MTB induced an early 
up-regulation of miR-142-3p at 1 h in mouse macrophages and 4 h in human 
macrophages while another study revealed that miR-142-3p was down-
regulated later during the infection (24 h post-infection) in mouse macrophages 
(Martinez et al., 2013). In another study regarding miR-142-3p, the authors 
found that BCG infection induced early down-regulation of miR-142-3p and that 
this led to an increase in the expression of IRAK-1 (Xu et al., 2013), an inhibitor 
of TLR signaling (Ghorpade et al., 2013). These results indicate an increased 
recognition of BCG and generation of pro-inflammatory response, while MTB 
avoids it by up-regulating miR-142-3p during the early stages. 
Since miRNAs circulate in the body they have the potential to become 
accessible biomarkers of disease and aid in diagnostic procedures. Distinct 
miRNA levels have been found in PBMCs (Liu et al., 2011; Wu et al., 2012), 
serum (Fu et al., 2011) and sputum (Yi et al., 2012) of TB patients as compared 
with healthy control. Of the various miRNAs, miR-29a, miR-155, miR-155*, miR-
125b, miR-3179a and miR-147 may be potential biomarkers for the diagnosis of 
TB. Still, further validation is required to determine if these are indeed reliable 
targets and also how specific is their expression signature in relation to the 
disease. In a study comparing TB and sarcoidosis patients, although significant 
differences were found in miRNA expression between patients and healthy 
individuals, both TB and sarcoidosis patients revealed highly similar miRNAs 
profiles (Maertzdorf et al., 2012).  
The medical significance of miRNAs goes far beyond their potential for good 
biomarkers. miRNA regulation has received increasing interest from the 
pharmacologic perspective. miRNAs induced in disease might be targets for 
specific inhibitors while those that are being down-regulated during the disease 
could receive an exogenous boost to improve the response against the disease. 
Efforts have been made for the development of miRNA-based drugs, especially 
for cancer (Takeshita et al., 2010) and hepatitis C virus infection (Lanford et al., 
2010). The differentially expressed miRNAs found in response to MTB infection 
might reveal great potential as future therapeutics, although no clinical trials 
have been made so far (Singh et al., 2013a). 
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Although outside of the scope of this thesis, it is worth mentioning that bacteria 
and particularly mycobacteria also possess their own small RNAs (sRNAs), 
typically with 50–500 nucleotides in length, known to act as global regulators of 
cellular phenotypes (Gottesman and Storz, 2011). The first experimental 
confirmation of sRNAs in mycobacteria was published in 2009, revealing five 
trans-encoded and four cis-encoded sRNAs in M. tuberculosis H37Rv (Arnvig 
and Young, 2009). There is still a limited number of functionally characterizer 
sRNAs in mycobacteria but they might prove to be interesting medical targets to 
exploit bacterial mechanisms involved in survival (for a current review of sRNAs 
in mycobacteria see Haning et al., 2014). 
 
 
Table 1.2. MicroRNAs in mycobacterial infection 
MicroRNA Species Target Cell/tissue Function 
Let-7e M. avium CASP3 Macrophages Anti-apoptotic 
miR-125b MTB TNF-α Macrophages Regulates Th1 response 
miR-142-3p MTB, BCG 
N-WASP 
IRAK-1 
Macrophages 
Disrupts phagocytosis and 
TLR singling 
miR-144* MTB 
TNF-α 
INF-γ 
PBMCs 
T cells 
Cytokine signaling and cell 
proliferation 
miR-146a BCG 
IRAK-1 
TRAF6 
DCs 
Suppress Th1 and Th17 
response 
miR-155 MTB SHIP1 Macrophages Enhance TNF-α 
miR-181a M. leprae SHP2 Macrophages Dampens T cell activation 
miR-21 M. leprae 
CYP27B1 
IL1B 
IL-12p35 
PDCD4 
Skin lesions 
Macrophages 
Monocytes 
Inhibition of antimicrobial 
activity 
miR-29 BCG INF-γ NK and T cells Regulates Th1 response 
miR-29a M. avium CASP7 Macrophages Anti-apoptotic 
miR-99b MTB TNF-α DCs Regulates Th1 response 
(Bettencourt, 2012; Mehta and Liu, 2014). 
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1.10.   MTB membrane transport in drug resistance and 
intracellular persistence 
While MTB has evolved several mechanisms to modulate the host immune 
response it also possesses several defensive structural features that enable its 
survival in harsh environments. Mediators of membrane transport are key 
molecules in MTB survival. As previously mentioned, the MTB-membrane is a 
phenomenal barrier against diffusion of harmful molecules (see “Mycobacterium 
tuberculosis”) (Figure 1.2). However, the cytosol needs to communicate with the 
extracellular medium to allow the transport of nutrients and other growth 
requirements of the bacteria. Evolution towards survival in an intracellular niche 
likely originated specific and highly regulated transport pathways that provide 
the minimal open doors for the required molecules while restricting the passage 
of bactericidal factors or provide the bacteria with the ability to extrude harmful 
molecules and maintain their internal homeostasis. Some of these strategies 
are not only useful to protect the bacteria against the host response but also to 
limit the entry of antibiotics or to excrete them out of the cell.  
Concerning the entry of bactericidal molecules into mycobacteria, the influx of 
toxic compounds is significantly restricted by the complex cell wall and lipid 
bilayer presenting a significant barrier to the influx of antibiotics (Brennan and 
Nikaido, 1995). The reduction in membrane permeability leads to a decrease 
drug influx, thus leading to a decrease in intracellular drug accumulation 
(Niederweis, 2003; Pasca et al., 2005; Viveiros et al., 2003). Porins represent a 
fast way across the membrane of mycobacteria for the uptake of nutrients and 
other molecules (Stephan et al., 2005; Wolschendorf et al., 2007). Porins are 
multimeric non-specific channels first reported in Gram-negative bacteria but 
present as well in other bacteria, fungi, plants and mammalian cells.  
The mycobacteria water-filled channel proteins function in a similar way to the 
porins of Gram-negative bacteria. They provide passage for water, ions and 
other small molecules through passive diffusion. Nonetheless, this mechanism 
of transportation was shown to be very inefficient in mycobacteria. In 
comparison to the porin pathway of Escherichia coli, the porin pathway of 
mycobacteria is collectively about 1000-fold less efficient (Jarlier and Nikaido, 
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1990; Stahl et al., 2001). Although there are still no definite answers explaining 
the reason for this lack of efficiency, evidences point towards a significant lower 
expression of porins in mycobacteria (Niederweis, 2003). This is correlated to 
the resistance of mycobacteria to antibiotics such as penicillins, cephalosporins 
and tetracyclines (Nikaido, 2001) and also to the characteristic slow growth of 
pathogenic mycobacteria (Sharbatitehrani, 2004; Stephan et al., 2005).  
The first porin identified in mycobacteria, MspA, allows hydrophilic compounds 
to enter M. smegmatis (Niederweis et al., 1999). Studies have shown that 
deletion of the mspA gene leads to reduced membrane permeability towards 
glucose and phosphates (Stahl et al., 2001; Wolschendorf et al., 2007). M. 
smegmatis has a faster growth rate than slow growing MTB. When mspA was 
knocked down, researchers verified that the growth rate of M. smegmatis was 
reduced (Stephan et al., 2005). Not only was there less inflow of nutrients, but 
also the resistance of these bacteria to antibiotics was increased (Danilchanka 
et al., 2008a). Moreover, in another study, when slow growing mycobacteria 
such as MTB and BCG were cloned with mspA, their glucose uptake increased 
and resulted in a faster growth rate in BCG (Mailaender et al., 2004). Also, 
susceptibility of both bacteria to β-lactam antibiotics, isoniazid, ethambutol and 
streptomycin increased. MspA porin has also been implicated in increased 
susceptibility of M. smegmatis to intracellular killing by macrophages. Mutants 
without the mspA gene were more resistant to nitric oxide in vitro and also 
displayed increased survival in macrophages (Fabrino et al., 2009). 
Furthermore, these porins also facilitate antibiotic inflow into the bacteria. In 
another study, Niederweis and colleagues generated several BCG mutants 
using transposon mutagenesis and tested them for antibiotic resistance 
(Danilchanka et al., 2008a). Recently, an outer membrane protein, CpnT, was 
identified in MTB and its channel activity was demonstrated in glycerol uptake 
(Danilchanka et al., 2014). However there is still no evidence for its role in the 
transportation of other molecules or as a resistance factor. 
Concerning efflux mechanisms, efflux pumps are thought to have evolved due 
to selective pressure to protect the bacteria against intracellular toxic molecules 
and maintain cellular homeostasis and physiological balance through active 
transport of toxic metabolites to the extracellular environment (Louw et al., 
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2009). Recent evidence suggests that mycobacteria actively extrude many 
drugs (Lomovskaya and Watkins, 2001; Telenti, 1997; Victor et al., 2002) via 
active efflux systems (Marquez, 2005; Pasca et al., 2005; Sander et al., 2000). 
This broad range of efflux of toxic compounds might be a side effect of the 
transport of other substrates (Choudhuri et al., 1999, 2002; Putman et al., 2000; 
Zhang et al., 1999). Still, some efflux pumps were shown to be specific of 
certain types or classes of antibiotics while others are able to expel a variety of 
structurally different compounds (Kumar and Schweizer, 2005; Lomovskaya 
and Watkins, 2001; Marquez, 2005). Multidrug efflux pumps can be regulated 
by induction of their expression by antibiotics (Grkovic et al., 2001, 2002) or 
they can also suffer mutations in their regulatory regions leading overexpression 
(Nikaido, 2001).  
Previous studies have explored the contribution of efflux mechanisms to 
antibiotic resistance in MTB, describing several putative efflux pumps of 
different classes were shown to be involved in the transport of different 
compounds (Viveiros et al., 2012). Moreover, while these mechanisms allow the 
bacteria to survive in sub-inhibitory concentrations of antibiotics, spontaneous 
mutations emerge, leading to the emergence and selection of drug resistant 
bacteria (Machado et al., 2012). In addition to this genetic resistance, evidence 
has emerged for non-genetic or phenotypic resistance phenomenon, also 
referred to as tolerance. This phenomenon is now considered to be mainly due 
to the up-regulation of efflux pumps and it was demonstrated that this 
phenotypic resistance could be lowered when a given antibiotic is administered 
together with an efflux inhibitor. This highlights the contribution of active efflux to 
the overall resistance level of a drug resistant strain of MTB (Louw et al., 2011; 
Machado et al., 2012). Development of mechanisms targeting efflux pumps 
might be a strategy to decrease the development of drug resistance as well as 
diminish the length of treatment (Adams et al., 2011; Gupta et al., 2013; 
Machado et al., 2012; Rodrigues et al., 2012).  
Several compounds have been considered as potential efflux inhibitors through 
their ion channel blocker activity. Some of the described inhibitors are 
phenotiazines: (1) thioridazine, (2) chlorpromazine and its derivative (3) 
flupenthixol, a high-potency thioxanthene; (4) haloperidol, a butyrophenone 
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structurally and clinically related with phenothiazines, and (5) verapamil, a 
phenylalkylamine (Viveiros et al., 2012). Thioridazine and verapamil have been 
shown to have active efflux inhibition properties and to inhibit the in vitro growth 
of MTB strains alone or in combination with anti-mycobacterial drugs (Amaral et 
al., 1996, 2007; Machado et al., 2012; Silva et al., 2001). Verapamil has been 
shown to exhibit the most potent mycobacterial inhibitory activity to date, being 
able to enhance isoniazid and rifampicin killing activity in MTB clinical strains 
(Louw et al., 2011; Machado et al., 2012; Rodrigues et al., 2012). This inhibitor 
was also shown to potentiate the activity of bedaquiline (Gupta et al., 2014), a 
diarylquinoline recently approved for the treatment of MDR-TB (WHO, 2013b). It 
has also been shown that the addition of verapamil accelerates the bactericidal 
and sterilising activities of TB therapy in mice (Gupta et al., 2013). Besides the 
direct activity of efflux inhibitors on mycobacteria, reports also show that their 
activity may enhance the killing activity of macrophages and modulate their 
response to the bacteria. 
Beyond their anti-mycobacterial activity, these compounds also induce immune-
modulatory responses in MTB-infected macrophages. It was shown that 
inhibitors of calcium and potassium can enhance the killing of MTB by 
macrophages (Martins et al., 2008; Ordway et al., 2003). Also, the inhibition of 
macrophage calcium channels increases calcium influx, consequently activating 
immune responses against intracellular MTB (Gupta et al., 2009). The 
evidences revealed by these studies might constitute new strategies to 
overcome MTB-induced inhibition of calcium-dependent intracellular response 
(see “MTB lipids and proteins in phagosomal maturation arrest”). 
 
1.11.   Thesis Goals 
This thesis focuses on enlightening the mechanisms by which MTB manipulates 
macrophages and DCs to facilitate bacterial persistence and growth. 
Conversely, with this information we can consider how to manipulate the 
infected cells to overcome the disease. Ultimately, our goal is to identify 
relevant molecules for mycobacterial killing that are being suppressed by the 
infection and then develop ways to restore or enhance their activity. 
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Our strategy to address to problem began by focusing on the lysosomal killing 
mechanisms with particular attention to proteolytic cathepsins. Our main 
working hypothesis relied on the fact that cathepsins are major enzymes in cell 
homeostasis and participate in pathogen killing and antigen presentation. We 
thus proposed that due to their relevance, cathepsins would be excellent targets 
for MTB-mediated manipulation and relevant for MTB persistence in 
macrophages and dendritic cells. Indeed, our results show that macrophages 
and dendritic cells infected with MTB show a general down-regulation of 
cathepsin expression, in contrast to what occurs with M. smegmatis infected 
cells. Consequently, this enhanced the intracellular survival of MTB and also 
increased the surface expression of HLA class II molecules. 
Following these lines of evidence and considering our previous experience in 
mycobacterial manipulation of the host cells, we proposed that the mechanism 
behind cathepsin manipulation could involve the host endogenous regulators, 
miRNAs. We tested this hypothesis, revealing a yet unknown miRNA in 
regulation of MTB immunity, miR-106b-5p. We show that this miRNA is 
overexpressed in MTB-infected macrophages, relative to M. smegmatis-infected 
macrophages and that it also regulates cathepsin S expression. The outcome of 
increased miR-106-5p expression mimicked the effects observed in cathepsin 
S-depleted macrophages and DCs. 
In the third part of our approach, we decided to test pharmacologic molecules 
described as ion channel blockers to manipulate the endocytic/phagocytic 
pathways. As summarized in the introduction, these molecules enhance 
antibiotic treatment by dampening drug efflux, but there are also reports 
claiming they can act in the host cells themselves, thereby enhancing their 
bactericidal activity. We proposed that a significant part of the killing 
enhancement generated by these compounds occurs due to manipulation of the 
endocytic/phagocytic environment. Our results show that the ion channel 
blockers lead to an non-specific increase in the acidification of the endocytic 
compartments; besides the likely direct effect of low pH, the enhanced MTB 
killing was also due to increased activity of acidic proteases such as cathepsin 
B. 
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In the last set of results, we decided to put the focus on the bacteria themselves 
and their innate mechanism of resistance. In the introduction I mentioned that in 
spite of MTB-induced manipulation of the host, these bacteria possess 
mechanisms that allow their survival even when the conditions are potentially 
very detrimental, limiting the access of harmful molecules to its cytosol and 
initiating metabolic programs adapted to starvation. In this last part, we 
proposed that restricted channel activity in MTB is a resistance factor that limits 
the potential damages caused by molecules released throughout host endocytic 
pathways and that exploiting this pathway might be important to improve host-
mediated killing. We show that a novel channel protein of MTB, CpnT, is a 
candidate for drugs and host bactericidal molecules. Our results show that the 
absence of this protein increases the resistance of the bacteria even when we 
induce strong oxidative stress by IFN-γ-induced release of nitric oxide. 
Moreover, we also determined that the presence of this protein leads to 
enhanced pro-inflammatory response, arguing that it is either a recognized 
PAMP or a pathway for PAMP secretion. 
Overall, we delineated a multidisciplinary strategy to study the interaction 
between the host cells and MTB. Our results revealed (1) specific cathepsins as 
important molecules in killing and antigen presentation; (2) how MTB uses the 
host own regulatory miRNAs to reduce the activity of one specific cathepsin, 
cathepsin S; (3) a pharmacological method to improve macrophage-mediated 
MTB killing by inducing acidification of the endocytic compartiments and 
enhancing cathepsin activity; (4) an MTB-channel protein that might represent a 
pathway for diffusion of host bactericidal molecules and recognition by innate 
receptors. 
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2.1.   Abstract 
Mycobacterium tuberculosis resides within phagosomes in host macrophages 
and dendritic cells and prevent vesicle fusion with lysosomes. A consequence 
of this inhibition is reduced acidification and proteolysis resulting from less 
activity of lysosomal cathepsins. Cathepsins are proteolytic enzymes known to 
participate in the maintenance of cell homeostasis. They are of particular 
interest in the control of microorganisms through direct pathogen killing as well 
as by processing of microbial antigens and the antigen presentation machinery 
itself. In this work, we have screened cathepsin gene and proteins expression in 
primary human macrophages and dendritic cells and our results indicate that 
the infection by M. tuberculosis induces a general down-regulation of 
cathepsins expression in infected cells as well as an inhibition of IFN-γ or TNF-
α-mediated induction of cathepsin expression. We further reveal that the 
decrease in cathepsin B, S and L expression and biochemical activity favors 
bacterial survival, both in macrophages and dendritic cells. The silencing of 
cathepsins B, S or L in these cells was associated with an increase in the 
surface expression of class II antigen presentation complex HLA-DR. Overall, 
we have shown that cathepsins are important for the control of MTB infection 
and that the bacteria manipulate their expression to favor their survival. 
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2.2.   Introduction 
Tuberculosis remains a worldwide health problem with 8 million new cases 
diagnosed per year and more than 1 million deaths per year as reported by the 
World Health Organization (WHO, 2013a). The onset of antibiotic treatment led 
to a great reduction in the prevalence and incidence of the disease particularly 
in developed countries. Still, the emergence of multi- (MDR) or extremely-drug 
resistant (XDR) strains of M. tuberculosis (MTB), the etiologic agent of TB, has 
brought renewed attention to the dangers of TB spread with the reports 
estimating 450,000 new cases of MDR-TB per year (WHO, 2013a). New 
strategies that synergistically fight the disease not only through antibiotic 
treatment but also by enhancing the natural ability of the immune system to 
tackle the pathogen might be the answer to improve MTB clearance and 
thereby reduce the probability of generating resistant strains.  
One of the first encounters of the immune system with the pathogen begins in 
the lungs where macrophages and dendritic cells internalize the bacteria (Kang 
et al., 2011). These cells are usually able to destroy bacteria upon phagocytosis 
by inducing oxidative stress at an early stage and then acidifying the bacteria-
containing phagosome by fusion with late endosomes and lysosomes and 
ultimately inducing the activity of proteolytic and lipolytic enzymes (Russell et 
al., 2009). These events will lead to pathogen destruction and processing of its 
antigens to be presented to lymphocytes through the class II antigen 
presentation machinery. Pathogenic mycobacteria, however, impair these 
phenomena by blocking phagosome maturation and consequent fusion with late 
endosomes and lysosomes, avoiding contact with their degradative enzymes 
(Deretic et al., 2006; Russell, 2001). Still, there is evidence that mycobacteria 
antigens are presented to lymphocytes and that a fraction of phagosomes fully 
mature, that is they fuse with lysosomes (Cooper, 2009; Jordao et al., 2008).  
The intracellular environment of DCs was shown to be less permissive for MTB 
growth than the environment in the macrophage. DC-mediated antigen 
presentation is fundamental for the initiation of cellular immunity and stimulation 
of MTB-infected macrophages with pro-inflammatory cytokines, such as 
interferon-γ, secreted by antigen-specific T cells (Cooper et al., 2011; Flynn et 
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al., 1993; Philips and Ernst, 2012). Besides macrophage activation by pro-
inflammatory cytokines, other cellular processes, such as autophagy and 
apoptosis (Alonso et al., 2007; Behar et al., 2011; Gutierrez et al., 2004; Winau 
et al., 2006) may overcome the arrest of phagosome maturation and lead to the 
digestion of the pathogen, suggesting an important role for lysosomal effectors. 
Cathepsins are the most investigated proteases. They operate in several cell 
functions, such as protein processing, pathogen killing, antigen presentation, 
apoptosis and tissue remodeling (Conus and Simon, 2010). Some of these 
cathepsins, such as cathepsins B, D, G and S are already known to interact and 
kill invading microorganisms (Bewley et al., 2011; Hole et al., 2012; Rivera-
Marrero et al., 2004; Soualhine et al., 2007; Steinwede et al., 2012). There is 
also evidence for the role of cathepsins S, F, L and V in antigen presentation by 
processing the invariant chain linked to class II HLA molecules in several types 
of cells (Beers et al., 2005; Hsing and Rudensky, 2005; Shi et al., 2000; Tang et 
al., 2006; Villadangos and Ploegh, 2000). The type of cell infected and its 
stimulation also results in different kinetics of cathepsin activity. Resting 
macrophages are thought to be more prone to initiate a strong proteolytic 
activity upon microbial invasion, that will lead to the destruction of peptidic 
antigens. By contrast, dendritic cells rely on control of acidification and cystatin 
expression to reduce this proteolytic response in order to preserve epitopes and 
thus elicit more efficient lymphocyte priming (Pierre and Mellman, 1998; Savina 
and Amigorena, 2007; Savina et al., 2006; Yates et al., 2007). The host 
transcriptional profile induced by MTB is significantly different when the bacteria 
are inside DCs as compared with macrophages (Tailleux et al., 2008), indicating 
that comparative studies of the intracellular events and fate of MTB in 
macrophages and DCs are likely to yield valuable information. 
In this study we decided to screen for how cathepsins and their inhibitors 
cystatins are being regulated in primary human macrophages and dendritic cells 
during infection with M. tuberculosis comparatively with the non-pathogenic 
M. smegmatis. M. smegmatis is a non-pathogenic mycobacteria readily killed in 
macrophages yet sharing a significant number of orthologous genes with MTB 
(Altaf et al., 2010), making it suitable for comparing and identifying molecules 
involved in the pathogenesis of tuberculosis. We further analyzed the relevance 
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of cathepsins and their inhibitors to mycobacteria survival and processing of the 
antigen presentation machinery. Our results show that M. tuberculosis induces 
a general down-regulatory profile of cathepsins expression in both cell types. 
We show that this down-regulation leads to increased survival of the bacteria 
but also to an increase in expression of HLA-DR class II antigen presentation 
molecules. 
 
2.3.   Materials and Methods 
2.3.1.   Cell lines and culture conditions 
Human monocyte-derived macrophages were obtained from healthy blood 
donors provided by the national blood institute (Instituto Português do Sangue, 
Lisbon, Portugal). Differentiation of the monocytes into dendritic cells or 
macrophages proceeded as previously described (Wang et al., 2010). When 
required, macrophages and dendritic cells were stimulated with 100 IU/ml IFN-γ 
or 50 ng/ml of TNF-α, respectively, 24 h prior to the infections. 
 
2.3.2.   Bacterial Cultures 
The strain Mycobacterium smegmatis mc2155, containing a p19 (long lived) 
EGFP plasmid was kindly provided by Dr. Douglas Young (London School of 
Hygiene and Tropical Medicine, London, UK), and the green fluorescent protein 
(GFP)-expressing strain of M. tuberculosis (H37Rv-pEGFP) plasmid was a kind 
gift from G. R. Stewart (University of Surrey, United Kingdom). M. smegmatis 
was grown in medium containing Middlebrook's 7H9 Medium (Difco), Nutrient 
broth (Difco) supplemented with 0.5 % glucose and 0.05 % Tween 80 at 37 ºC 
on a shaker at 200 r.p.m. (Anes et al., 2003). M. tuberculosis H37Rv was grown 
in Middlebrook's 7H9 medium and supplemented with 10 % OADC Enrichment 
(Difco) (Anes et al., 2003). 
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2.3.3.   Macrophage and Dendritic Cell Infection 
Bacterial cultures on exponential grown phase were centrifuged, washed in 
phosphate-buffered saline (PBS). Bacteria were then resuspended in the 
desired culture medium without antibiotics. In order to dismantle bacterial 
clumps, the bacterial suspension was passed through a 21 G needle followed 
by 5 min ultrasonic bath. Residual clumps were removed by 1 minute 
centrifugation at 500 x g. Single-cell suspension was verified by fluorescence 
microscopy. Macrophages and dendritic cells were infected with an MOI of 1 for 
3 h at 37 ºC with 5 % CO2. Following internalization, cells were washed three 
times with PBS and re-suspended in appropriate culture medium without 
antibiotics. 
 
2.3.1.   qPCR 
Macrophages and dendritic cells were seeded in 6-well plates at a density of 2 x 
106 cells per well. RNA was isolated and purified from infected cells using Trizol 
reagent (Life Technologies) and following the manufacturer protocol. 1 µg of 
total RNA was used for cDNA synthesis (SuperscriptTM II reverse transcriptase, 
Invitrogen) according to the manufacturer protocol. qPCR was performed using 
SYBR Green PCR Master Mix (Applied Biosystems) and different sets of 
primers (Table 2.1) (Eurofins Genomics) at a final concentration of 0.5 μM. The 
PCR reaction proceeded as follows: 1 cycle of 95 ºC for 10 min, followed by 40 
cycles of 95 ºC for 15 s, 60 ºC for 30 sec and, 72 ºC for 30 sec. The mRNA 
expression profiles were normalized with respect to GAPDH (Glyceraldehyde 3-
phosphate dehydrogenase). The qPCR was performed using an ABI 7300 Real 
Time PCR System (Applied Biosystems) and data was collected with SDS v1.2 
software. The mean of two non-stimulated and uninfected donor samples was 
taken and used to produce log2 ratios with respect to the normalized data from 
stimulated and/or infected cells. 
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Table 2.1. List of qPCR primers 
Target Gene  Target sequence (5'-3') 
Cathepsin B 
Forward CCAGGGAGCAAGACAGAGAC 
Reverse GAGACTGGCGTTCTCCAAAG 
Cathepsin C 
Forward CCCCTACACAGGCACTGATT 
Reverse CAGCTCAAAGGGGTTGAAAG 
Cathepsin D 
Forward GACACAGGCACTTCCCTCAT 
Reverse CTCTGGGGACAGCTTGTAGC 
Cathepsin E 
Forward ACTTGACATCCACCCTCCAG 
Reverse GAATGCCCCAGCCTAACATA 
Cathepsin F 
Forward GCCTGTCCGTCTTTGTCAAT 
Reverse TGGCTTGCTTCATCTTGTTG 
Cathepsin G 
Forward GCCTTTCAGGAAAGATGCAG 
Reverse CACAAAGTCTTCTCGCACCA 
Cathepsin H 
Forward ACGGAGGAGTACCACCACAG 
Reverse GCAATTCTGAGGCTCTGACC 
Cathepsin K 
Forward TTCTGCTGCTACCTGTGGTG 
Reverse GCCTCAAGGTTATGGATGGA 
Cathepsin L 
Forward AGGAGAGCAGTGTGGGAGAA 
Reverse ATCTGGGGGCCTCATAAAAC 
Cathepsin O 
Forward AGTGGGACAAACTCCAGCAC 
Reverse CCTCTTTGATCCCACCTGAA 
Cathepsin S 
Forward TCTCTCAGTGCCCAGAACCT 
Reverse GCCACAGCTTCTTTCAGGAC 
Cathepsin V 
Forward TCCGTGAGCCTCTGTTTCTT 
Reverse CTAGCCATGAAGCCACCATT 
Cathepsin W 
Forward CCACCCCAAGAAGTACCAGA 
Reverse GTGGCCTTGATCACACCTTT 
Cathepsin X 
Forward GGGAGAAGATGATGGCAGAA 
Reverse ATAGGTGCTGGTCACGATCC 
Cystatin A 
Forward GAGGCTTATCTGAGGCCAAA 
Reverse TCATTTTGTCCGGGAAGACT 
Cystatin B 
Forward TGTCATTCAAGAGCCAGGTG 
Reverse AGCTCATCATGCTTGGCTTT 
Cystatin C 
Forward CCAGCAACGACATGTACCAC 
Reverse ACAGGTGGATTTCGACAAGG 
Cystatin D 
Forward GAAGTTCGGTCGAACCACAT 
Reverse CCTAGACTTTCCGGCACTTG 
GAPDH 
Forward AAGGTGAAGGTCGGAGTCAA 
Reverse AATGAAGGGGTCATTGATGG 
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2.3.2.   Western Blotting 
Macrophages and dendritic cells were seeded in 6-well plates at a density of 2 x 
106 cells per well. Total proteins were recovered with 200 µl of Laemmli buffer 
(Sigma-Aldrich). Protein extracts were subjected to electrophoresis in 12 % 
SDS-PAGE gels, transferred to a nitrocellulose membrane and blocked with 0.1 
% Tween 20, 5 % of low fat milk TBS (Tris Buffered Saline). The nitrocellulose 
membrane was then incubated with primary antibodies specific for human 
cathepsin S, cathepsins B, cathepsin L and β-tubulin (abcam), overnight at 4 
°C. All membranes were washed and incubated with secondary HRP-
conjugated antibodies. The bands were visualized with a chemiluminiscence 
reagent (Merck Millipore) and quantified using ImageJ (Schneider et al., 2012). 
 
2.3.3.   Enzymatic activity 
Macrophages and dendritic cells were seeded in 6-well plates at a density of 2 x 
106 cells per well. Macrophages and dendritic cells were recovered with a 5 mM 
EDTA/PBS solution. Cell lysis and measurement of the enzymatic activity was 
performed using an activity fluorometric assay kit specific for each cathepsin 
(Biovision) or using caspase-1/ICE fluorometric assay kit (Biovision) and 
following the manufacturer’s instructions. The fluorescence intensity was 
measured with a spectrofluorometer, Tecan M200. 
 
2.3.4.   Inhibition of cathepsin activity 
Twenty-four hours prior to infection, macrophages and dendritic cells were 
treated with 20 µM of inhibitors of cathepsin B, S, L or with cystatin C (Sigma-
Aldrich). E-64d, a general irreversible inhibitor of cathepsins (Sigma-Aldrich) 
was used at 10 µM after infection due to high cytotoxic effects. Bacteria survival 
was measured after 24 h of infection. 
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2.3.5.   RNAi silencing 
Silencing of cathepsin B, S and L gene expression was performed with Biontex 
K2® Transfection System. Macrophages were first incubated for 2 h with 4 µl/ml 
of K2 Multiplier reagent in culture medium. Then, they were incubated with the 
transfection reagent and 100nM of SMARTpool ON-TARGETplus siRNA (GE 
Dharmacon) in a ratio of 5 μlreagent:1 μgsiRNA. for 24 h in antibiotic free medium. 
Following that, transfection medium was removed and the cells were incubated 
for 3 days in fresh medium prior to any experiment in order to achieve maximum 
silencing (data not shown). The transfection efficiency achieved was 
approximately 95 %, as evaluated by flow cytometry using siGLO Green 
Transfection Indicator (GE Dharmacon). 
 
2.3.6.   Bacteria survival 
Macrophages and dendritic cells were seeded in 96-well plates at a density of 5 
x 104 cells per well. When required, infected cells were lysed in 0.05 % Igepal 
solution. Serial dilutions of the resulting bacterial suspension were plated in 
Middlebrook 7H10 with 10 % OADC (Difco) and incubated for 2-3 weeks at 37 
ºC before colonies were observable. 
 
2.3.7.   Flow Cytometry 
Macrophages and dendritic cells were seeded in 24-well plates at a density of 3 
x 105 cells per well. Macrophages and dendritic cells were recovered with a 5 
mM EDTA/PBS solution and fixed with 4 % paraformaldehyde for 30 min. 
Following that, cells were stained for 30 min with antibodies specific for human 
HLA-DR (clone L243, Biolegend) and then analysed in Guava easyCyte™ 5HT 
flow cytometer.  
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2.4.   Results 
2.4.1.   Cathepsin profile is cell type- and stimulation-specific 
In order to determine the role of cathepsins and their regulators during 
mycobacterial infection, we started by performing qRT-PCR transcriptomic 
analysis of cathepsins and cystatins expressed in macrophages and dendritic 
cells at early stages of infection. We hypothesized that if the infection translates 
into altered cathepsin expression, those alterations would be measurable as 
early as 1 day of infection since otherwise their impact in the infection would be 
less significant. In fact, in another gene expression screen, Tailleux and 
colleagues (2008) already pointed that while overall gene expression levels 
change throughout the course of infection the majority of host genes showing 
regulation induced by MTB in the first 24h remain the same at later time points 
of infection.  
In our analysis we focused on macrophages and DCs infected with 
M. tuberculosis and compared them to macrophages infected with the non-
pathogenic M. smegmatis at a resting state (M0 macrophages or immature 
DCs) or following activation with IFN-γ (M1) or TNF-α (mature DCs), 
respectively. We decided to analyze these cells at different states of 
activation/maturation since during the pathogenesis of tuberculosis the bacteria 
will encounter different populations of cells or will potentially be exposed to the 
effects induced by the cytokines secreted by bystander cells. We began by 
identifying differences in cathepsin expression between uninfected 
macrophages and dendritic cells (Figure 2.1). The analysis of immature DCs 
revealed an up-regulation of cathepsins C, E, O, W, X and cystatins B, C, D 
while cathepsins L, S and particularly cathepsin K were found to be significantly 
down-regulated relative to the levels seen in macrophages.  
In Figure 2.2 the data are presented by comparing the different conditions within 
macrophage and DCs. We can observe that stimulation with IFN-γ led to a 
clearly distinguishable cathepsin profile with up-regulation of cathepsins B, D, E, 
G, H, K, L, S, V, X and cystatins A and D. The strongest changes induced by 
TNF-α- maturation of DCs occurred in cystatins expression, with up-regulation 
of cystatins A and D and down-regulation of cystatins C. Cystatin C down-
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regulation was already proposed to be a mechanism to explain the increase of 
HLA-class II antigen presentation in mature DCs (Pierre and Mellman, 1998). 
Concerning cathepsins, DC maturation also resulted in up-regulation of 
cathepsins G and K and down-regulation of cathepsins C, L and V. 
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Figure 2.1. Gene expression of cathepsins and cystatins during infection of macrophages and DCs by MTB and M. 
smegmatis. 
 RNA from macrophages and DCs was recovered after 24 h of infection. When required, 24 h prior to infection, 
macrophages were stimulated with 100IU/ml of IFN-γ and DCs were stimulated with 50µg/ml of TNF-α. Values are 
depicted as log2 gene expression relative to uninfected macrophages. Msm, M.smegmatis. 
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Figure 2.2. Gene expression of cathepsins and cystatins during infection of 
macrophages or DCs by MTB and M. smegmatis.  
RNA from macrophages and DCs was recovered after 24 h of infection. When 
required, 24 h prior to infection, macrophages were stimulated with 100IU/ml of IFN-γ 
and DCs were stimulated with 50µg/ml of TNF-α. Values are depicted as log2 gene 
expression relative to uninfected macrophages or uninfected DCs. Msm, 
M.smegmatis. 
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2.4.2.   M. tuberculosis induces a specific and cell type-dependent 
cathepsin expression profile 
Next we infected macrophages and DCs with MTB and compared them with 
M. smegmatis infection to highlight the different regulatory phenotypes that they 
induce and potentially correlate them with MTB pathogenicity or discard them 
as general phagocytosis phenomena. We determined that infection of 
macrophages and DCs with MTB or M. smegmatis results in different profiles of 
cathepsins expression, specific of each species (Figure 2.2). MTB infection of 
macrophages results in the most prominent regulation, leading to a down-
regulation of the majority of analyzed cathepsins and cystatins with the 
exception of cathepsin G, whose expression remained unaltered, and the up-
regulated cathepsins H, L and cystatin A. M. smegmatis infection also resulted 
in the down-regulation of several genes though to a lesser extent than MTB 
when compared to uninfected control cells. The expression levels of cathepsins 
B, C, D, K, S and X are the most differentially regulated between the two 
mycobacteria. When macrophages were stimulated with IFN-γ prior to the 
infection, the expression levels of cathepsins and cystatins were higher than 
those of non-stimulated cells. The exceptions were cathepsins C, O and W and 
cystatins B and C, which remained unaltered. Cathepsin F was the only one 
found to be down-regulated after stimulation. Although IFN-γ increased the 
expression of most cathepsins, when those cells were infected with MTB, an 
overall down-regulatory profile was observed. When comparing uninfected and 
MTB-infected IFN-γ-macrophages, cathepsins B, C, D, K, S, V and cystatin C 
were the most differentially expressed. Curiously, cathepsin L again showed the 
opposite effect, being up-regulated upon infection with MTB, similarly to what 
occurred in non-stimulated macrophages. 
In DCs, the infection also resulted in distinguishable patterns of expression 
(Figure 2.2). M. smegmatis-infected DCs showed a general up-regulation of all 
cathepsins and cystatins with the exception of cathepsin E and cystatins D 
which were down-regulated. On the contrary, MTB-infected DCs displayed 
lower levels of cathepsin expression then M. smegmatis-infected DCs. Among 
these, the most differentially expressed between the two bacteria were 
cathepsins B, C, D, L, S and cystatin C while cathepsins A and D were more 
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expressed during infection with MTB. When we infected mature DCs (mDCs) 
with M. smegmatis few differences were observed in comparison to infected 
immature DCs. The exceptions were cathepsin C and cystatin C, which were 
more expressed in immature DCs, and cystatin D, whose expression was 
increased in the M. smegmatis-infected mDCs. Conversely MTB-infected mDCs 
revealed several differences in comparison with MTB-infected immature DCs, 
the majority of which correspond to down-regulation. It is noteworthy that when 
comparing uninfected mDCs with MTB-infected mDCs, we could only observe 
differences in the expression of cathepsins K and X. Otherwise the infection 
appears to be silent concerning cathepsin and cystatin expression. 
 
2.4.3.   M. tuberculosis inhibits cathepsins B, S and L expression and 
activity 
Cathepsins (Cat) B, S and L are some of the most highly expressed cathepsins 
in the lysosomes of antigen-presenting cells, and are described as participating 
in diverse cell functions, such as antigen processing, TLR signaling and 
cytokine production (Conus and Simon, 2010); these features should render 
them as obvious candidates to participate in MTB killing and antigen 
presentation. Our initial screen revealed that these three cathepsins are down-
regulated in macrophages and DCs during MTB infection, relative to M. 
smegmatis infection. Accordingly we decided to deepen our analysis of these 
three cathepsins. In order to understand their relevance in infection we 
addressed their expression at the level of mRNA, protein and enzyme activity. 
We began by analyzing the mRNA expression of these cathepsins at 3, 24 and 
48 h post infection (Figure 2.3). In macrophages, we observed that for Cat S 
and Cat L the differences in gene expression increased throughout the infection 
while for Cat B, the major difference occurred at 24 h. In DCs we could observe 
similar results with MTB infection inducing a lower expression of these 
cathepsins when compared with M. smegmatis infected cells at 24 h post-
infection. We proceeded by asking whether this down-regulation had any impact 
on the protein quantity or the activity of these cathepsins (Figure 2.4). Our 
results show that for all three cathepsins, expression was lowered during 
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infection with MTB, in comparison with M. smegmatis, regardless of the type of 
cell analyzed. Cathepsin activity also followed this trend (Figure 2.5). For Cat S 
each species induced an opposite effect, with M. smegmatis inducing an 
increase in activity whereas MTB induced a decrease. For Cat B both species 
led to reduced activity while MTB had a slightly lower activity than M. 
smegmatis. The activity of Cat L remained constant in macrophages, 
irrespective of the infection, while in DCs M. smegmatis induced a lower activity, 
and MTB an even more pronounced reduction in Cat L activity. 
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Figure 2.3. Gene expression of cathepsin B, S and L in macrophages and DCs 
infected with MTB or M. smegmatis.  
Values are depicted relative to uninfected control. (*p<0.05 and **p<0.01 relative to 
uninfected control). 
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Figure 2.4. Protein expression of cathepsin B, S and L in macrophages and DCs 
infected with MTB or M. smegmatis for 24 h.  
Bar plots represent protein expression relative to uninfected control and were obtain 
by densitometry analysis of the western blots. 
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Figure 2.5. Enzymatic activity of cathepsin B, S and L in macrophages and DCs 
infected with MTB or M. smegmatis for 24 h.  
Cathepsin activity was measured with a fluorimetric substrate that is activated by 
cleavage of a cathepsin-specific sequence. Values are depicted relative to uninfected 
control (*p<0.05 and **p<0.01 relative to uninfected control). 
 
 
Chapter 2:   Mycobacterium tuberculosis manipulation of host cathepsins 
137 
2.4.4.   MTB impairs cathepsin B, S and L up-regulation in activated 
macrophages and mature DCs.  
Macrophage activation with IFN-γ had a different impact on the kinetics of 
cathepsins expression (Figure 2.6). For Cat B and Cat S, IFN-γ stimulation of 
macrophages induced an increase in expression at all time points, while 
M. smegmatis expression peaked early during infection, at 3h for Cat B and 24 
h for Cat S and then decreased afterwards. For both cathepsins, MTB infection 
resulted in inhibition of IFN-γ-mediated up-regulation. Concerning Cat L, its 
expression did not respond to IFN-γ stimulus in uninfected macrophages, yet 
both bacteria resulted in its up-regulation, with M. smegmatis being significantly 
more expressed than MTB which peaked at 24 h, thereafter showing decrease 
in Cat L expression. 
When TNF-α was used to induce mature dendritic cells, maturation alone 
resulted in up-regulation of Cat S and Cat L throughout the experiment while 
Cat B did not display any changes. Infection of these cells with M. smegmatis 
resulted in a peak expression of Cat S and Cat L at 24h with subsequent 
decrease at 48 h while for Cat B the expression remained the same as that of 
uninfected cells, dropping afterwards. Once again, MTB infection inhibited these 
peaks in cathepsin expression and resulted in a down-regulation for the three 
cathepsins.  
Cathepsin protein expression analysis of stimulated macrophages (Figure 2.7) 
revealed minor changes in uninfected macrophages while cathepsin activity 
(Figure 2.8) responded to the stimulus with a severe increase of Cat S activity 
and a slight decrease on Cat B activity. However, infection with M. smegmatis 
or MTB resulted in a drastic reduction of cathepsin expression and activity for 
the three cathepsins. Regarding mDCs, Cat B showed a minor increase in 
protein expression only when the cells were infected while that did not translate 
in an increased enzymatic activity. Cat S expression was up-regulated by 50% 
due to TNF-α maturation alone yet it became severely up-regulated when 
mDCs were infected with M. smegmatis, an effect that was even more 
prominent during MTB infection. Still, we could not observe differences in Cat S 
enzymatic activity. For Cat L, maturation induced a 100% up-regulation of its 
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protein expression. Furthermore, during infection we could observe a correlation 
between protein expression and cathepsin activity with a small decrease upon 
M. smegmatis infection and very significant decrease upon MTB infection. It is 
worth mentioning that for DCs the enzymatic essay might have hindered rapid 
saturation of the signal, thus explaining the why we could observe down-
regulatory effects whereas the up-regulatory effects were unperceivable. This 
effect might be due to the increased expression of cathepsins in DCs relative to 
macrophages (Figure 2.1). 
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Figure 2.6. Gene expression of cathepsin B, S and L in IFN-γ-treated macrophages 
and TNF-α-mature DCs infected with MTB or M. smegmatis.  
Values are depicted relative to unstimulated uninfected control. (*p<0.05 and **p<0.01 
relative to uninfected control). 
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Figure 2.7. Protein expression of cathepsin B, S and L in in IFN-γ-treated 
macrophages and TNF-α-mature DCs infected with MTB or M. smegmatis for 24 h.  
Bar plots represent protein expression relative to unstimulated uninfected control and 
were obtain by densitometry analysis of the western blots. 
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Figure 2.8. Enzymatic activity of cathepsin B, S and L in IFN-γ-treated macrophages 
and TNF-α-mature DCs infected with MTB or M. smegmatis for 24 h. 
Cathepsin activity was measured with a fluorimetric substrate that is activated by 
cleavage of a cathepsin-specific sequence. Values are depicted relative to 
unstimulated uninfected control (*p<0.05 and **p<0.01 relative to uninfected control). 
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2.4.5.   Inhibition of cathepsin activity with chemical inhibitors or with 
cystatin C resulted in increased MTB survival in macrophages and DCs 
Our previous results revealed that MTB impairs the increase in cathepsin 
expression and activity that is elicited by non-pathogenic bacteria such as M. 
smegmatis. This prompted us to question if this weakened proteolytic response 
might benefit MTB survival in its host cells. Our first approach was to use 
available chemical inhibitors to inactivate cathepsin B, S and L and then 
measure the consequences on intracellular survival in macrophages and DCs. 
Moreover, we also tested a general inhibitor of cysteine cathepsins E-64d and 
cystatin C, the endogenous inhibitor of Cat B, S and L. Prolonged exposure of 
MTB-infected cells with these inhibitors produced significant cytotoxic effects 
which compelled us to limit our analysis to the first 24 h of infection. Our results 
revealed that treatment with chemical inhibitors of cathepsins (Figure 2.9A) 
results in a significant increase in MTB intracellular survival in IFN-γ-activated 
macrophages, with a 10-fold increased survival when using Cat B inhibitors and 
approximately 5-fold increased survival when using Cat S and Cat L inhibitors. 
In mDCs, Cat L inhibition produced the highest results with a 15-fold increased 
MTB survival while Cat B or Cat S inhibition resulted in approximately 5-fold 
increase in intracellular bacilli. The general inhibitor E-64d also produced very 
significant results in mDCs, yet was not as effective in macrophages as the 
specific inhibitors. In resting macrophages and immature DCs the inhibitors 
failed to produce any significant results so we decided to treat these cells with 
cystatin C (Figure 2.9B). Our results showed that treatment with cystatin C led 
to a significant increase of MTB survival of 5-fold in macrophages and 3-fold in 
DCs. 
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Figure 2.9. Effect of cathepsin B, S and L inhibition on MTB survival.  
Cathepsin activity was inhibited using 20µM of specific inhibitors or cystatin C 24 h 
prior to infection or 10µM of the general cysteine cathepsin inhibitor E-64d after 
infection. Values are depicted relative to untreated control (*p<0.5; **p<0.01 relative to 
untreated control). 
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2.4.6.   Cathepsins silencing results in increased survival of MTB in 
macrophages 
Our results with chemical inhibitors and cystatin C revealed the relevance of 
cathepsin activity for MTB killing. However, since we were limited to a 24 h 
analysis due to cytotoxic effects, we decided to employ a more specific 
inhibition of cathepsin activity by targeting their gene expression by siRNA. We 
performed this silencing only in macrophages since, for cathepsins the 
transfection protocol turned out to be very aggressive for DCs, resulting in very 
few viable cells. Still, we were able to achieve approximately 80% reduction in 
protein expression and cathepsin activity using this technique in macrophages, 
which enabled us to analyze the full kinetic of MTB survival throughout 5 days 
of infection. Our results reveal that all three cathepsin are important for MTB 
control (Figure 2.10). While the most significant results occurred at day 3 of 
infection, for Cat S siRNA we could observe a significant increase in MTB 
survival throughout the entire infection. 
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Figure 2.10. Effect of cathepsin B, S and L silencing on MTB survival in macrophages 
and DCs.  
Each cathepsin was silenced by siRNA 3 days prior to infection in order to achieve 
maximum silencing. (*p<0.5; **p<0.01 relative to control). 
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2.4.7.   Cathepsin silencing increases the surface expression of HLA-DR 
Cathepsins are known to participate in protein processing and generation of 
antigenic peptides to be presented by HLA class II molecules (Rudensky and 
Beers, 2005). Furthermore, Cat S also participates in the maturation of HLA-
class II molecules (Beers et al., 2005). So far, we have established that not only 
cathepsins are negatively regulated by MTB but they are also important for the 
control of intracellular infection. Following this evidence we decided to explore 
the impact of cathepsin silencing in antigen presentation. For this, we applied a 
similar methodology used for screening molecules involved in HLA-class II 
antigen presentation, as described elsewhere (Paul et al., 2011). We measured 
the surface expression of HLA-DR by flow cytometry on cathepsin-silenced and 
infected macrophages and DCs. First we observed that M. smegmatis induced 
a higher expression than MTB of HLA-DR in both cell types, indicating that MTB 
inhibits antigen presentation via HLA-DR. Second, by comparing the histograms 
of macrophages and DCs our results showed that basal levels of HLA-DR 
surface expression is much higher (≈10-fold) on DCs than on macrophages 
suggesting that DCs are the major antigen presenting cells responding to MTB 
infection. Third, silencing of cathepsin expression in both cell types resulted in 
an increased surface expression of HLA-DR. This was statistically significant for 
all three cathepsins in macrophages, but only for Cat S in DCs, suggesting a 
common unspecific mechanism. 
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Figure 2.11. Effect of cathepsin B, S and L silencing on HLA-DR surface expression in 
macrophages and DCs.  
Each cathepsin was silenced by siRNA 3 days prior to infection in order to achieve 
maximum silencing. After 24 h of infection macrophages and DCs were recovered and 
analyzed by flow cytometry. Values in bar plots depict mean fluorescence intensity of 
the population (*p<0.5, relative to control or pairwise as indicated above the bars). 
Fluorescence intensity histograms of MTB-infected cells are presented below the bar 
plots. 
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2.5.   Discussion 
2.5.1.   Cathepsins are differentially regulated in macrophages and DCs 
Lysosomal proteolysis is a crucial cell process for maintaining homeostasis. 
Proteolytic enzymes participate in the recycling of cell components, elimination 
of toxic molecules, processing of other host proteins and digestion of up taken 
peptides by phagocytosis (Turk et al., 2012). MTB is an intracellular parasite par 
excellence, and is able to persist by resisting and avoiding the degradative 
mechanisms of the endocytic pathways. The type of cell which MTB infects 
produces different responses that are adequate for their general functions, and 
for stimulation of bystander or primed cells surrounding it. Comparing 
macrophages and DCs, our results show a lower expression of cathepsins L, S 
and K. Cathepsins L and S are described to participate in antigen processing or 
in HLA-class II maturation (Rudensky and Beers, 2005). In dendritic cells, these 
processes were proposed to be tightly regulated to avoid the destruction of 
immunogenic peptides and thus improve the efficiency of their presentation to T 
cells (Savina and Amigorena, 2007).  
Another example of DC regulation is shown by the increased levels of cystatin 
C in immature DCs. This cystatin is a major inhibitor of cathepsin S. It is well 
established that immature dendritic cells possess high phagocytic activity yet 
express few antigen presentation molecules at their surface (Driessen et al., 
1999). The opposite is true when these cells are matured by stimulation with 
pathogen-associated molecular patterns (PAMPs) or by TNF-α treatment. As 
we observed, DC maturation led to a significant decrease in cystatin C 
expression which is in accordance with the model proposing that this reduction 
leads to the activation of cathepsin S and processing of HLA class II complexes 
(Pierre and Mellman, 1998; Zavasnik-Bergant et al., 2005). Moreover, our 
analysis of the kinetics of cathepsins B, S and L, shows that although 
maturation resulted in an early decrease of expression it was immediately 
followed by a time-dependent increase. On one hand, these results show that 
maturation switches the cell tend towards an increased expression of 
cathepsins involved in antigen presentation and lower expression of an 
inhibitory cystatin. On the other hand, this increase in expression need not 
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translate into more activity, since other forms of regulation, such as pH-
dependent regulation will keep their activity under control avoiding over-
degradation of antigenic peptides (Savina and Amigorena, 2007; Savina et al., 
2006).  
The differential expression of cathepsin K was very significant between 
macrophages and DCs. Cat K is known to be expressed by macrophages, 
participating in extracellular matrix remodeling and bone resorption. Cat K was 
also described to be expressed in multi-nucleated macrophages in pulmonary 
lesions from patients suffering from sarcoidosis, tuberculosis or with 
granulomas caused by foreign materials (Bühling et al., 2001). This role of 
macrophages in lung remodeling might serve in the future as a potential 
biomarker of disease (Reghellin et al., 2010). Macrophages activated with IFN-γ 
showed a severe increase in the expression of several cathepsins, possibly 
related with their role in antimicrobial killing. Yet, similarly with DCs, pH-
dependent regulation induced by the potent oxidative response of these cells is 
thought to moderate cathepsin activity (Yates et al., 2007), so this increase in 
expression might not result in a higher proteolytic activity. Accordingly, our 
results show that although Cat B gene expression is highly increased upon 
macrophage activation, the proteolytic activity is decreased by 75 %. Cat S is 
known to maintain stability and activity even at neutral pH (Brix et al., 2008). 
Beers and colleagues (2003) have already revealed that IFN-γ stimulation of 
macrophages results in increased processing of HLA class II-invariant chain 
complex. Our results are in concordance with this, since we show that Cat S 
overall proteolytic activity increases by 60% in activated macrophages and thus 
arguing that this cathepsin is a relevant contributor to proteolysis in a less acidic 
phagosome. 
 
2.5.2.   MTB inhibits pathogen-induced cathepsin expression 
The role played by cathepsins in protein processing and digestion suggest their 
activity might be important for MTB killing and processing of its antigens. MTB 
improves its intracellular survivability by inhibiting cellular processes that may 
lead to its destruction, such as phagosome maturation and fusion with 
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lysosomes. Still, depending on the route of entry, recognition and external 
stimuli, a portion of the MTB-phagosomes fully mature (Armstrong and Hart, 
1975; Brooks et al., 2011; Jordao et al., 2008) leading to the recruitment and 
activation of lysosomal cathepsins. Moreover, some of these cathepsins are 
already active in early endosomes (Rudensky and Beers, 2005) suggesting they 
may come in contact with MTB even when phagosome maturation is arrested. 
We propose that one of the mechanisms that MTB uses to persist inside host 
cells is by avoiding the degradative action of lysosomal cathepsins by inhibiting 
their expression and/or impairing their activity. Our results show that MTB 
infection of host macrophages and DCs results in a general down-regulation of 
cathepsin expression when compared to the regular cathepsin expression 
profile elicited upon infected with the non-pathogenic M. smegmatis. The 
strongest effect was visible in macrophages where all cathepsins were down-
regulated relative to M. smegmatis infection. Macrophage response to 
M. smegmatis included an overexpression of cathepsins K, L, S and also 
cathepsin H. Cat H has been detected in early endosomes and phagosomes of 
the mouse macrophage cell line J774 (Claus et al., 1998) and was found to 
become concentrated in late endosomes of mature DCs (Lautwein et al., 2002) 
suggesting its relevance in antigen processing. 
The major down-regulations promoted by MTB compared to M. smegmatis in 
macrophages included cathepsins B, D and S. Cat B and Cat D have been 
shown to regulate cell death in response to microbial infection by inducing 
pyroptosis in response to inflammasome activation (Cat B) (Mishra et al., 2010; 
Willingham et al., 2007) or by inducing apoptosis (Cat D) (Bewley et al., 2011). 
By Inhibiting cell death during the first stages of infection, MTB is able to 
replicate in its intracellular niche, generating a higher burden of bacilli before 
erupting from a necrotic cell. In DCs our results produced the clearest 
distinguishable pattern of cathepsin expression between the two bacteria. M. 
smegmatis was a potent inducer of cathepsin expression while MTB prevented 
or diminished this increase. Cathepsins B, C, D, L, S and cystatin C were the 
most differentially expressed between bacteria. A strong decrease in cathepsins 
B, S and L activity was observed when activated macrophages were infected 
either with MTB or M. smegmatis. Again, this might be a general mechanism to 
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reduce proteolysis in activated macrophages in order to preserve peptide 
antigens to be presented. However, Yates and colleagues (2007) described that 
although in activated macrophages this reduction might be dependent on pH 
regulation, when activated macrophages were stimulated with LPS the 
phagosomes readily acidified. This indicates another type of regulation. In fact, 
our results show that this regulation appears to occur at the protein level, since 
we observed a strong depletion of cathepsins B, S and L. A reduction in Cat L 
protein expression has already been described by Nepal and colleagues (2006) 
in response to infection of IFN-γ-stimulated mouse bone marrow macrophages 
with live or heath killed MTB and M. avium. This is in accordance with our data 
showing that even the infection with the non-pathogenic M. smegmatis could 
induce this depletion of CatL. Still this group failed to obtain these results for 
CatB and CatS. 
In mature DCs, infection with M. smegmatis further stimulated cathepsin 
expression at 24 h post infection. Yet, the phenotype was very similar to that of 
infected immature DCs. This might indicate that M. smegmatis infection is a 
good inducer of DC maturation. On the contrary, MTB infection of mDCs 
resulted in almost no alterations in cathepsin expression when compared to 
uninfected mDCs. MTB is described to inhibit antigen presentation 
(Ramachandra et al., 2001) and this silencing phenotype might be another 
indication of MTB’s attempt to avoid triggering adaptive immunity. While 
measuring cathepsin activity in DCs we encountered some drawbacks related 
to saturation of signal. Cathepsin activity appeared to be higher in dendritic cells 
than macrophages, and this led to quick processing of our fluorescent activity 
probes. While we could still quantify those cases where infection or stimulus 
induced decreased activity, such as those of Cat B and Cat L, for the situations 
where stimulation occurred, our measurements likely represent an under-
estimation of the true values. 
 
2.5.3.   Cathepsins B, S and L are required for the control of MTB infection 
Our previous results shown that while M. smegmatis stimulates cathepsins 
expression, MTB induces a lower expression. We wondered if this down-
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regulation would have a direct impact in the intracellular survival of MTB. We 
approached this problem by inhibiting cathepsin activity through a diverse set of 
techniques, using specific chemical inhibitors of Cat B, Cat S and Cat L, a 
general inhibitor of cysteine cathepsins E-64D, their natural inhibitor cystatin C, 
and also by silencing their gene expression with siRNA. All these methods 
converged to the same conclusion, that inhibition of cathepsins B, S and L 
results in increased survival of MTB. It is still noteworthy that we could only 
obtain statistically significant results with the chemical inhibitors in activated 
macrophages and mDCs. This might be due to the decrease in cathepsin 
activity observed when infecting those cells. That effect, coupled with chemical 
inhibition would possibly produce a drastic ablation of cathepsin activity that 
could be more easily measured. However, in mDCs a decrease in cathepsin 
activity was less evident. Nonetheless, inhibition with cystatin C proven to be a 
very effective way to increase MTB survival whereas our use of siRNA silencing 
allowed us to profile this increased MTB survival throughout 5 days of infection. 
Altogether, our results consistently show that cathepsins B, S and L are relevant 
for the intracellular control of MTB infection in macrophages and DCs. 
 
2.5.4.   Silencing of cathepsins B, S and L increases the surface 
expression of the HLA class II complex, HLA-DR 
Cathepsins are involved in antigen processing and in the processing of the 
antigen presentation machinery itself. Cathepsins S and L have been implicated 
in processing the invariant chain bound to HLA class II complexes. 
Furthermore, Cat L was also shown to be required for the production of peptide 
antigens to be presented to CD4 T cells (Honey et al., 2002; Nakagawa, 1998). 
By analyzing the surface expression of HLA-DR we intended to disclose 
possible defects in the maturation of HLA class II molecules, as was previously 
demonstrated in an siRNA screen in a human melanoma cell line (Paul et al., 
2011). We observed MTB inhibition of HLA-DR expression comparatively with 
M. smegmatis, an observation already described in several reports (Hmama et 
al., 1998; Pai et al., 2003; Pennini et al., 2006; Sendide et al., 2005; Wang et 
al., 2005). Still, we could only observe this in macrophages, where M. 
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smegmatis induced a significant increase in HLA-DR while MTB did not. 
Previous studies related TLR signaling with HLA class II expression (Harding 
and Boom, 2010; Pai et al., 2003, 2004; Pennini et al., 2006; Wang et al., 
2005). In macrophages, chronic stimulation (15-24 h) of TLRs induced a down-
regulation of class II transactivator (CIITA), the main transcriptional regulator of 
HLA class II molecules, resulting in their decreased expression. In DCs 
however, TLR stimulation induces maturation and increased HLA class II 
expression due to post-translational increased stability of class II molecules 
(Cella et al., 1997b; De Smedt et al., 1996). The differences between these two 
cell types might account for why we could only observe a significant impairment 
of HLA-DR induction comparatively with M. smegmatis in macrophages. 
However, contrary to what we were expecting, when we silenced cathepsins B, 
S and L we saw an increase in HLA-DR expression in infected and uninfected 
cells. Our results show a significant 3-fold increase of HLA-DR expression in 
macrophages silenced for the three cathepsins while in DCs, only Cat S yielded 
significant results. In fact, previously reported results showed that BCG-infected 
macrophages attenuate HLA-DR surface expression by inhibiting Cat S 
expression via IL-10 expression (Sendide et al., 2005). While we have observed 
a reduction in Cat S in MTB-infected macrophages concomitantly with an 
attenuation of HLA-DR expression, our results show that these events are not 
related and that this inhibition is not Cat S-dependent. Another study 
engineered a Cat S-expressing BCG (Soualhine et al., 2007). They were able to 
reverse MHC class II inhibition with this strategy, yet the bacilli showed a 10-
fold reduction in survivability and depicted increased phagosome-lysosome 
fusion. This might explain why these studies observed recovery of HLA-DR 
expression when adding or expressing Cat S. Our results revealed that Cat S is 
important for MTB-killing and thus, increasing its expressing might also increase 
phagosome maturation and the availability bacterial antigens to be presented. 
Moreover, both studies relied on BCG, and the intracellular fitness of these 
bacteria is significantly lower than MTB, which might explain our discrepant 
results. 
The reason why cathepsin silencing leads to an increased HLA class II 
expression is likely to be related to unspecific alterations in the proteolytic 
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environment of the phagolysome, since we could observe a similar phenotype 
for the three cathepsins. One explanation might be that decreased proteolytic 
activity will lead to an increase in the HLA class II pool by limiting the recycling 
of these molecules. In fact, as mentioned above, in DCs TLR stimulation results 
in maturation and increase in HLA class II molecules and increased stability of 
these molecules was proposed to be crucial for this to occur (Askew et al., 
2000; Cella et al., 1997b). On the contrary, macrophages show the opposite 
regulation and this was proposed to be a defense mechanism against an 
exacerbated induction of Th1 cellular immunity at the infection locus (Harding 
and Boom, 2010). By silencing important lysosomal cathepsins we might be 
interfering with normal molecular turnover, explaining the increase in HLA class 
II surface expression. Further studies should focus on analyzing what is 
occurring throughout the HLA class II pathway to identify the steps where this 
deregulation of cathepsin activity occurs. It is also important to evaluate the 
impact of cathepsin S on other HLA class II molecules and to determine the 
consequences in T cell priming; this increase might or might not have functional 
repercussions in antigen presentation since we do not yet know whether or not 
the HLA complexes are being properly processed. 
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3.1.   Abstract 
Tuberculosis is a global health problem made worse by the increased incidence 
of drug resistant strains, prompting an urgent need for the development of new 
strategies to kill the etiologic agent, Mycobacterium tuberculosis. The success 
of M. tuberculosis relies on the ability to manipulate host gene expression 
pathways related with their intracellular survival. Among these, we recently 
investigated the manipulation of miRNAs that regulate immunity-related 
molecules of the host and increase the success of the pathogen. Devising 
approaches to control miRNAs during the infection with M. tuberculosis might 
favor the host response and improve clearance of the pathogen, limiting the 
emergence of drug resistant strains. Here, we propose that miR-106b-5p is 
actively manipulated by M. tuberculosis. This miRNA is being up-regulated upon 
infection and this leads to an increased, the survival of the bacteria. We also 
show that up-regulation of this miRNA targets cathepsin S expression, an 
important lysossomal protease involved in bacterial killing and processing of 
bacterial antigens and the antigen presentation machinery. 
  
3.2.   Introduction 
Mycobacterium tuberculosis (MTB) is the causative agent of tuberculosis and 
one of the greatest worldwide killer diseases due to a single infectious agent. 
Although only a small portion of infected individuals will develop tuberculosis, 
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the fact that one third of the human population is estimated to be latently 
infected with the bacteria leads to a staggering 8.6 million people developing 
tuberculosis in 2012 and a worldwide prevalence of 12 million diseased (WHO, 
2013a). In spite of these numbers, the global effort to stop tuberculosis has 
yielded significant results, with a decrease of 2% in TB incidence in 2012. The 
greatest threat emerging from this disease is the emergence of drug-resistant 
strains resulting in multidrug resistant TB (MDR-TB) which accounts for 
approximately 3.6% of the new TB cases and 20.2% of re-incident cases 
(WHO, 2013a). This fact prompted us to address the problem of tuberculosis 
from a different perspective than antibiotic treatment. Since in most cases the 
bacteria are contained, understanding the immune factors relevant for this 
control might provide us with mechanisms to improve immune-dependent 
pathways that will help TB treatment and reduce the emergence of drug-
resistant strains. 
One of the hallmarks of M. tuberculosis pathogenesis is its ability to persist in 
host immune phagocytes such as macrophages (Russell et al., 1997). This 
persistence is enabled by the control of host cells functions, particularly those 
involved in phagosome maturation and fusion with lysosomes. Usually these 
processes lead to the acidification of the phagosome and activation of 
lysosomal enzymes such as proteases and lipases (Russell et al., 2009), but 
during MTB infection these events are halted and the bacteria persist in a less 
degradative environment (Deretic et al., 2006; Jordao et al., 2008; Russell, 
2001).  
So far, several mechanisms and molecules have been proposed for this ability 
of MTB to survive in macrophages. MicroRNAs are predictable intermediates in 
this process due to their wide regulatory role. These molecules are small, non-
coding regulator RNAs with 19-22 nucleotides long and are involved in post-
transcriptional gene expression control (Bartel, 2004). They silence their targets 
expression by forming complexes with the RNA-induced silencing complex 
(RISC) and then binding their 7 nucleotide-long “seed region” with a 
complementary region of mRNA, leading to termination of translation and/or 
mRNA degradation (Lu et al., 2005; O’Donnell et al., 2005). There are already 
several studies proposing modulation of miRNAs by mycobacteria in order to 
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increase the success of their infection by impairing the release of pro-
inflammatory cytokines (Ma et al., 2011; Rajaram et al., 2011), controlling 
phagocytosis (Bettencourt et al., 2013), preventing cell recruitment to the locus 
of infection (Dorhoi et al., 2013) and miRNAs are also proposed as biomarkers 
of TB disease (Fu et al., 2011; Maertzdorf et al., 2012; Meng et al., 2014; Miotto 
et al., 2013; Wang et al., 2011; Yi et al., 2012). 
In this study, we followed up on two of our previous works that showed that 
MTB is able to inhibit cathepsin up-regulation upon infecting macrophages (see 
“Chapter 2”) and identified the impact of mycobacterial infection on miRNA 
expression in macrophages (Bettencourt et al., 2013). We propose that the 
regulation of one of those cathepsins, cathepsin S, is under the control of a 
novel miRNA involved in MTB immunity, miR-106b-5p. We show that the 
expression of miR-106b-5p is being specifically up-regulated by M. tuberculosis 
infection relative to the non-pathogenic M. smegmatis. Our data show that the 
consequence of this manipulation is an increase of the intracellular survival of 
the bacteria and increased HLA class II surface expression in human 
macrophages, similar to what occurs during siRNA silencing of cathepsin S. We 
propose that manipulation of this miRNA might be used to enhance the innate 
and adaptive immune response of the host. 
 
3.3.   Materials and Methods 
3.3.1.   Cell lines and culture conditions 
Human monocyte-derived macrophages were obtained from healthy blood 
donors provided by the national blood institute (Instituto Português do Sangue, 
Lisbon, Portugal). Differentiation of the monocytes into macrophages proceeded 
as previously described (Wang et al., 2010). When required, macrophages were 
stimulated with 100 IU/ml IFN-γ 24 h prior to infection. 
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3.3.2.   Bacterial Cultures 
The strain Mycobacterium smegmatis mc2155, containing a p19 (long lived) 
EGFP plasmid was kindly provided by Dr. Douglas Young (London School of 
Hygiene and Tropical Medicine, London, UK), and the green fluorescent protein 
(GFP)-expressing strain of M. tuberculosis (H37Rv-pEGFP) plasmid was a kind 
gift from G. R. Stewart (University of Surrey, United Kingdom). M. smegmatis 
was grown in medium containing Middlebrook's 7H9 Medium (Difco), Nutrient 
broth (Difco) supplemented with 0.5 % glucose and 0.05 % Tween 80 at 37 ºC 
on a shaker at 200 r.p.m. (Anes et al., 2003). M. tuberculosis H37Rv was grown 
in Middlebrook's 7H9 medium and supplemented with 10 % OADC Enrichment 
(Difco) (Anes et al., 2003). 
 
3.3.3.   Infection of macrophages 
Bacterial cultures on exponential grown phase were centrifuged, washed in 
phosphate-buffered saline (PBS). Bacteria were then resuspended in the 
desired culture medium without antibiotics. In order to dismantle bacterial 
clumps, the bacterial suspension was passed through a 21 G needle followed 
by 5 min ultrasonic bath. Residual clumps were removed by 1 minute 
centrifugation at 500 x g. Single-cell suspension was verified by fluorescence 
microscopy. Macrophages were infected with an MOI of 1 for 3 h at 37 ºC with 
5 % CO2. Following internalization, cells were washed three times with PBS and 
resuspended in appropriate culture medium without antibiotics. 
 
3.3.4.   qPCR 
Macrophages were seeded in 6-well plates at a density of 2 x 106 cells per well. 
RNA was isolated and purified from infected cells using Trizol reagent (Life 
Technologies) and following the manufacturer protocol. miRNA expression was 
quantified using miRCURY LNA™ Universal RT miRNA PCR system (Exiqon) 
according to the manufacturer protocol and using the Exiqon LNA™ PCR 
primer sets: hsa-miR-106b-5p (nº 205884), hsa-miR-23a-3p (nº 204772), hsa-
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miR-23b-3p (nº 204790) and hsa-miR-24-3p (nº 204260). The qPCR was 
performed using an ABI 7300 Real Time PCR. The reaction proceeded as 
follows: 1 cycle of 95 ºC for 10 min, followed by 40 cycles of 95 ºC for 10 s and 
60 ºC for 1min. The miRNA expression profiles were normalized to the average 
obtained between miR-23a, miR-23b, and miR-24, whose expression levels 
were stable under the experimental conditions applied in this study (Bettencourt 
et al., 2013). 
 
3.3.5.   Transfection 
Transfection with anti-cathepsin S siRNA or with miR-106b-5p mimics and 
inhibitors was performed with Biontex K2® Transfection System. Macrophages 
were first incubated for 2 h with 4 µl/ml of K2 Multiplier reagent in culture 
medium. Then, they were incubated for 24 h with the transfection reagent and 
100 nM of SMARTpool ON-TARGETplus human CTSS siRNA or with 
miRIDIAN miRNA human hsa-miR-106b-5p mimics or hairpin inhibitors and the 
respective siRNA or miRNA non targeting controls (GE Dharmacon) in a ratio of 
5 ulreagent:1 ugsiRNA in antibiotic-free medium. Following that, transfection 
medium was removed and the cells were incubated for 3 days in fresh medium 
prior to any experiment in order to achieve maximum silencing (data not 
shown). The transfection efficiency achieved was approximately 95 %, as 
evaluated by flow cytometry using siGLO Green Transfection Indicator (GE 
Dharmacon). 
 
3.3.6.   miR-106b-5p target validation 
A 413 bp fragment of the 3’-UTR of the human cathepsin S gene (CTSS) 
containing a sequence complementary to the seed region of miR-106b-5p, was 
amplified by PCR using the Phusion® Hot Start II DNA Polymerase (New 
England BioLabs®, MA, USA), following the manufacturer’s instructions 
(forward primer: 5’-GCGAGCTCCAAGAAATATGAAGCACTTTCTC-3’, reverse 
primer: 5’-CCCTCGAGTTTTTTGAAACAGAGTCTCCACT-3’). The fragment 
was inserted into the pmirGLO Dual Luciferase miRNA Target Expression 
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Vector (Promega Corporation), between the SacI and XhoI restriction sites, to 
originate a recombinant plasmid expressing the 3’-UTR fragment of the human 
cathepsin S gene All restriction enzymes and the DNA ligase used were from 
New England BioLabs®. PCR products and restriction products were purified 
using the illustra™ GFX™ PCR DNA and Gel Band Purification Kit (GE 
Healthcare). Recombinant plasmids were stored and propagated inside JM109 
E. coli cells. The constructed plasmid, miR-106b-5p mimics and miRNA 
negative controls were transfected into HEK 293T cells using HiPerFect® 
Transfection Reagent (QIAGEN), following the manufacturer’s instructions. After 
transfection, the dual luciferase assay was initiated using the Dual-Luciferase® 
Reporter (DLR™) Assay System kit (Promega Corporation), following all the 
manufacturer’s instructions. 
 
3.3.7.   Western Blotting 
Macrophages were seeded in 6-well plates at a density of 2 x 106 cells per well. 
Total proteins were recovered with 200 µl of Laemmli buffer (Sigma-Aldrich). 
Protein extracts were subjected to electrophoresis in 12 % SDS-PAGE gels, 
transferred to a nitrocellulose membrane and blocked with 0.1% Tween20, 5% 
of low fat milk TBS (Tris Buffered Saline). The nitrocellulose membrane was 
then incubated with primary antibodies specific for human cathepsin S, 
cathepsins B, cathepsin L and β-tubulin (abcam), overnight at 4 °C. All 
membranes were washed and incubated with secondary HRP-conjugated 
antibodies. The bands were visualized with a chemiluminiscence reagent 
(Merck Millipore) and quantified using ImageJ (Schneider et al., 2012). 
 
3.3.8.   Flow Cytometry 
Macrophages were seeded in 24-well plates at a density of 3 x 105 cells per 
well. Macrophages were recovered with a 5 mM EDTA/PBS solution and fixed 
with 4 % paraformaldehyde for 30 min. Following that, cells were stained for 30 
min with antibodies specific for human HLA-DR (clone L243, Biolegend) and 
then analysed in Guava easyCyte™ 5HT flow cytometer. 
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3.3.9.   Bacteria survival 
Macrophages were seeded in 96-well plates at a density of 5 x 104 cells per 
well. When required, infected cells were lysed in 0.05 % Igepal solution. Serial 
dilutions of the resulting bacterial suspension were plated in Middlebrook 7H10 
with 10 % OADC (Difco) and incubated for 2-3 weeks at 37 ºC before colonies 
were observable. 
 
3.4.   Results 
3.4.1.   MTB induces the expression of miR-106b-5p in human 
macrophages 
We have previously shown that MTB blacks up-regulation of several cathepsins 
in response to infection in macrophages via an unknown mechanism (see 
“Chapter 2”). Moreover, in a previously published study, we revealed the full 
miRNA expression profile induced by mycobacteria as well as a novel 
mechanism for phagocytosis regulation via MTB-dependent manipulation of a 
miRNA (Bettencourt et al., 2013). Therefore, we decided the search our 
previous results for putative miRNAs regulating cathepsins. Using target 
prediction tools based on the miRanda (Betel et al., 2008) and MiRtaget2 
(Wang, 2008) methods we identified cathepsin S as a predicted target of miR-
106b-5p. Our previous results indicated that miR-106b-5p was down-regulated 
early upon M. smegmatis infection of the mouse macrophage cell line J77A 
(Bettencourt et al., 2013). 
To confirm that this miRNA is being regulated during infection by mycobacteria 
we decided to compare its expression when macrophages were infected with 
MTB or M. smegmatis. Our analysis revealed a distinct phenotype between the 
two species (Figure 3.1B), with M. smegmatis inducing a small insignificant 
increase in miR-106b-5p expression at 1 h and maintaining it until 24 h while 
MTB-infection led to an increase in miR-106b-5p expression, starting from 
similar levels as M. smegmatis and then suffering an significant 2-fold increase 
at 4 h which was maintained until 24 h. This demonstrates that miR-106b-5p is 
being specifically regulated by MTB and that this regulation is distinct from that 
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induced by M. smegmatis in primary human macrophages (Figure 3.1), or 
mouse macrophages (Bettencourt et al., 2013). 
 
 
Figure 3.1. miR-106b-5p expression in macrophages infected with M. tuberculosis and 
M. smegmatis. 
It is represented miR-106b-5p expression 24 h after infection (A) and full expression 
kinetics (B). Values depict gene expression relative to the uninfected control (*p<0.01). 
 
3.4.2.   miR-106b-5p targets cathepsin S mRNA 
Our initial results portrayed an induction of miRNA-106b-5p in MTB-infected 
macrophages fitting our previous findings that cathepsin S is down-regulated by 
MTB. To confirm this interaction we used a dual luciferase reporter vector 
system in which we inserted a fragment of the 3’-UTR sequence for cathepsin S 
into the pmirGLO dual-luciferase target expression vector. This fragment 
included one putative sequence complementary to the “seed region” of miR-
106b-5p. Using this system we were able to assess the specific interaction 
between the miRNA and the 3’-UTR sequence by analyzing the resulting 
decrease in luciferase expression in HEK293T cells transfected with both the 
plasmid and the miRNA. Our results show a significant reduction in luciferase 
expression during co-transfection with miR-106b-5p and 3’-UTR CTSS plasmid 
relative to the control, thereby confirming their specific interaction (Figure 3.2A). 
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Figure 3.2. miR-106b targets cathepsin S. 
In (A) luminescence was measured in HEK293T cell line transfected with CTSS 3’UTR 
plasmid only or in combination with miR-106b-5p mimic. Values are relative to CTSS 
3’UTR-only control cells. In (B) cathepsin S protein expression in human macrophages 
transfected with miR-106b-5p mimics or inhibitors. Values are relative to the 
untransfected control (*p<0.001 relative to their respective controls). 
 
3.4.3.   miR-106b-5p regulates cathepsin S expression in resting and 
infected macrophages 
So far, our results show an early MTB-dependent up-regulation of miR-106-5p 
and a specific interaction between this miRNA and CatS. This correlates with 
our previous findings showing that MTB induces the down-regulation of CatS at 
24 h, suggesting that miR-106b-5p might be tied to this regulation. To further 
test this hypothesis we asked if we could modulate the expression of cathepsin 
S by overexpressing or inhibiting the miR-106b-5p.For this, we transfected 
primary human macrophages with miR-106b-5p mimics or inhibitors and 
analyzed the protein expression of cathepsin S by western blotting. With this 
methodology we were able to identify up-regulation or down-regulation 
cathepsin S expression by manipulating mir-106b-5p (Figure 3.2). Next, we 
decided to test if we could produce the same results in macrophages infected 
with MTB. We proceeded as before, and quantified the protein expression of 
cathepsin S at several time points of infection (Figure 3.3). Throughout the 
infection we could consistently observe a reduction in cathepsin S expression in 
cells transfected with miR-106b-5p mimics, confirming that we could regulate 
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cathepsin S with this miRNA during infection. Furthermore, we were able to 
enhance CatS down-regulation induced by MTB after 24 h of infection. 
 
Figure 3.3. miR-106b-5p regulates cathepsin S during infection with M. tuberculosis. 
Cathepsin S protein expression in human macrophages transfected with miR-106b-5p 
mimics and posteriorly infected with MTB. Values are relative to the untransfected 
uninfected (T0) control (*p<0.05 relative to the respective untransfected control). 
 
3.4.4.   miRNA-106b-5p interferes with the antigen presentation machinery 
Since this miRNA is being over-expressed during MTB infection we decided to 
analyze the consequences of this overexpression in infected macrophages. To 
achieve this, we infected the transfected macrophages and searched for 
changes in surface expression of HLA class II complexes using flow cytometry 
(Figure 3.4). When we analyzed human leukocyte antigen (HLA)-DR we 
observed a severe increase in surface expression in cells transfected with miR-
106b-5p, while with the inhibitors there was lead to no significant alterations in 
HLA-DR expression. To assess if this phenotype was related with a decrease in 
cathepsin S expression we compared the resulting effect of transducing 
macrophages with miR-106b-5p mimic or with siRNA specific for cathepsin S. 
Our results show that we were able to achieve similar results with both methods 
of cathepsin silencing, providing evidence that the increase in HLD-DR 
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expression induced by miR-106b-5p mimics is probably a result of cathepsin S 
down-regulation. Additionally, we tested if we could produce similar results in 
IFN-γ activated cells since this cytokine is reported to regulate CatS and HLA 
class II molecules (Beers et al., 2003, 2005; Pai et al., 2002). However, over-
expression of miR-106b-5p yielded similar results in untreated or IFN-γ 
activated cells suggesting that HLA-DR regulation via this miRNA is 
independent of IFN-γ signaling pathways. 
 
Figure 3.4. Surface expression of HLA-DR on macrophages transfected with miR-
106b-5p and infected with M. tuberculosis. 
HLA-DR surface expression was measured on macrophages infected with MTB and 
transfected with miR-106b-5p mimics, inhibitors or anti-cathepsin S siRNA. Values in 
bar plots (A) are presented as mean fluorescence intensity of the population relative to 
untransfected control cells (*p<0.001 relative to the respective untransfected controls). 
Raw values are presented in the fluorescence intensity histograms (B). 
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3.4.5.   miR-106b-5p over-expression results in increased intracellular 
survival of mycobacteria 
Since MTB is manipulating miR-106b-5p expression we hypothesized that this 
regulation will be reflected in its ability to survive inside host cells. To address 
this we analyzed the intracellular survival of MTB during 5 days in human 
macrophages transfected with the miRNA mimics or inhibitors. As expected, we 
could observe an increase in survival, relative to the control, that peaked at day 
3 post infection (Figure 3.5A) while in macrophages transfected with the 
inhibitors we did not observe significant alterations (Figure 3.5B). MTB already 
possesses mechanisms to subvert the host so we decided to also test if we 
could achieve the same results using M. smegmatis, a species more 
susceptible to the killing mechanisms of the host and thus potentially benefit 
more from a decrease in the host antibacterial response. By executing the same 
experiment we could observe a significant increase in M. smegmatis survival in 
cells transfected with the miR-106b-5p mimics (Figure 3.5C), while no 
statistically significant differences were observed in cells transfected with the 
inhibitors (Figure 3.5D). Next, we expected that since miR-106b-5p targets 
cathepsin S, we should observe a similar increase in MTB survival when we 
silence cathepsin S expression using siRNAs. Comparing the effects of 
transfecting cells with miR-106b-5p mimics and cathepsin S siRNAs we could 
produce similar results in MTB intracellular survival (Figure 3.5E) and thus we 
validate the interaction between miR-106b-5p and cathepsin S. 
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Figure 3.5. Intracellular survival of mycobacteria in macrophages transfected with miR-
106b-5p. 
Bacterial intracellular survival was measured in macrophages transfected with miR-
106b-5p mimics or inhibitors and infected with MTB (A and B) or with M. smegmatis (C 
and D) or transfected with miR-106b-5p mimics or CatS siRNA and infected with MTB 
(E). Values depict mean colony-forming units (*p<0.5; **p<0.01). 
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3.5.   Discussion 
Our recent work implicated miRNAs in the control of the internalization stage of 
phagocytosis during infection with mycobacteria (Bettencourt et al., 2013). M. 
tuberculosis has been found to exploit this mechanism of gene regulation in 
order to impair the detrimental mechanisms of host macrophages and improve 
its survival. Pathogenic mycobacteria manipulate miRNAs to inhibit caspase-
dependent apoptosis (Fink, 2005), pro-inflammatory cytokine production (Ma et 
al., 2011; Rajaram et al., 2011; Tili et al., 2007) and TLR-mediated signaling 
(Liu et al., 2009, 2012). 
Our results indicate that another miRNA, miR-106b-5p modulates lysosomal 
proteolysis by regulating cathepsin S expression. Cathepsin S is predominantly 
expressed in antigen presenting cells such as macrophages and DCs (Hsing 
and Rudensky, 2005) and is a major protease in antigen presentation by 
processing HLA class II molecules (Rudensky and Beers, 2005). Here we show 
that MTB-infection results in a decreased expression of Cat S in macrophages 
and DCs comparatively with M. smegmatis. In addition, this down-regulation 
improves MTB intracellular survival and also increases surface expression of 
HLA class II molecules. This effect was most prominent after 24 h of infection, 
although an increase in miR-106b-5p expression was already detected early at 
4 h of infection. This period between miRNA up-regulation and Cat S decreased 
protein expression is probably related with the half-life of Cat S reported to be 
approximately 16-18 h (Nissler et al., 1999). Other mechanisms have been 
proposed for Cat S regulation involving post-translational mechanisms 
controlling Cat S activity, such as pH regulation or cystatin-mediated inhibition. 
Macrophage activation by IFN-γ is reported to induce a strong oxidative 
response which increases the phagosomal pH and results in lower proteolytic 
activity (Yates et al., 2007) possibly due to the instability of acidic cathepsins at 
that range of pH values. However Cat S is an exception since it is stable and 
retains its activity at neutral or slightly alkaline pH (Kirschke et al., 1989). 
Moreover, this activation results in the down-regulation of cystatin C, a major 
inhibitor of CatS activity (Pierre and Mellman, 1998; Zavasnik-Bergant et al., 
2005). Accordingly, when we activated macrophages with IFN-γ, the surface 
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expression of HLA-DR suffered a severe increase. Yet macrophages 
transfected with miR-106b-5p developed the same phenotype and were able to 
enhance HLA-DR surface expression as well as in non-activated macrophages, 
suggesting this regulation is independent of IFN-γ. This might also argue 
against another IFN-γ-induced mechanism of HLA class II regulation (Pai et al., 
2002), dependent on an indirect inducer of HLA class II transcription, the class 
II transactivator (CIITA) (Boss and Jensen, 2003). Another study described a 
different mechanism for CatS regulation involving the induction of IL-10 
secretion via infection with M. bovis BCG (BCG) (Sendide et al., 2005). These 
authors proposed that BCG regulates CatS by inhibiting IFN-γ-dependent 
activation of CatS and by inducing the secretion of IL-10 in infected 
macrophages. More recently others have also shown that induction of IL-10 
results in decreased CatS and HLA class II expression (Chan et al., 2010). 
Although in our previous studies we have observed that MTB inhibits HLA-DR 
surface expression and CatS expression, relative to the infection with M. 
smegmatis, our results disproved any causal relation between those events 
(see “Chapter 2”). On the contrary, our proposed mechanism via induction of 
miR-106b-5p resulted in a similar outcome in mycobacteria survival and antigen 
presentation, to that of CatS siRNA silencing. This provides a strong evidence 
for direct regulation of CatS by the manipulation of a miRNA by MTB. We 
cannot rule out the possibility that miR-106b-5p is regulating other genes. 
Indeed, miRNAs are known to target several genes, resulting in complex 
regulatory networks. Nonetheless, our results indicate a strong impact of miR-
106b-5p in macrophage-mediated response to MTB. Our study opens the door 
for future manipulation of miR-106b-5p to enhance the anti-microbial activity of 
innate immune cells. Future studies should focus on better characterizing the 
mycobacterial effectors leading to this regulation and also on the development 
of methods to counter it. This miRNA might also serve as an additional 
biomarker of tuberculosis. Several studies have also focused on the relevance 
of miRNAs as biomarkers of disease since they were found in circulating 
PBMCs (Liu et al., 2011; Wu et al., 2012), serum (Fu et al., 2011) and sputum 
(Yi et al., 2012) of tuberculosis patients. Additionally, CatS is an established 
relevant enzyme in cancer and other pathologies (Fonović and Turk, 2014b; 
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
176 
Mohamed and Sloane, 2006). Further studies of this miRNA might also prove to 
be useful for those diverse fields of biomedical research. 
3.6.   Acknowledgments 
We are thankful to Intituto Português do Sangue for providing blood samples; to 
BEI resources (and Colorado State Univ., USA) for proteins and strains; to the 
Centre for AIDS Reagents, NIBSC (United Kingdom) for providing IFN-γ 
donated by Genentech Inc.; to the National Foundation for Science, FCT, with 
the support by fellowship SFRH/BD/63747/2009 to DP and project grants 
PIC/IC/82859/2007, PTDC/BIA-BCM/102123/2008 and PTDC/Sau-
MII/098024/2008 to EA. 
 
3.7.   Bibliography 
Anes, E., Kühnel, M.P., Bos, E., Moniz-pereira, J., Habermann, A., and Griffiths, G. (2003). 
Selected lipids activate phagosome actin assembly and maturation resulting in killing of 
pathogenic mycobacteria. Nat. Cell Biol. 5, 793–802. 
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 
281–297. 
Beers, C., Honey, K., Fink, S., Forbush, K., and Rudensky, a. (2003). Differential Regulation 
of Cathepsin S and Cathepsin L in Interferon  -treated Macrophages. J. Exp. Med. 197, 
169–179. 
Beers, C., Burich, A., Kleijmeer, M.J., Griffith, J.M., Wong, P., and Rudensky, A.Y. (2005). 
Cathepsin S controls MHC class II-mediated antigen presentation by epithelial cells in 
vivo. J. Immunol. 174, 1205–1212. 
Betel, D., Wilson, M., Gabow, A., Marks, D.S., and Sander, C. (2008). The microRNA.org 
resource: targets and expression. Nucleic Acids Res. 36, D149–53. 
Bettencourt, P., Marion, S., Pires, D., Santos, L.F., Lastrucci, C., Carmo, N., Blake, J., 
Benes, V., Griffiths, G., Neyrolles, O., et al. (2013). Actin-binding protein regulation by 
microRNAs as a novel microbial strategy to modulate phagocytosis by host cells: the case 
of N-Wasp and miR-142-3p. Front. Cell. Infect. Microbiol. 3, 19. 
Boss, J.M., and Jensen, P.E. (2003). Transcriptional regulation of the MHC class II antigen 
presentation pathway. Curr. Opin. Immunol. 15, 105–111. 
Chan, L.L.Y., Cheung, B.K.W., Li, J.C.B., and Lau, A.S.Y. (2010). A role for STAT3 and 
cathepsin S in IL-10 down-regulation of IFN-gamma-induced MHC class II molecule on 
primary human blood macrophages. J. Leukoc. Biol. 88, 303–311. 
Deretic, V., Singh, S., Master, S., Harris, J., Roberts, E., Kyei, G., Davis, A., de Haro, S., 
Naylor, J., Lee, H.-H., et al. (2006). Mycobacterium tuberculosis inhibition of 
phagolysosome biogenesis and autophagy as a host defence mechanism. Cell. Microbiol. 
8, 719–727. 
Dorhoi, A., Iannaccone, M., Farinacci, M., Faé, K.C., Schreiber, J., Moura-Alves, P., 
Nouailles, G., Mollenkopf, H., Oberbeck-Müller, D., Jörg, S., et al. (2013). MicroRNA-
223 controls susceptibility to tuberculosis by regulating lung neutrophil recruitment. J. Clin. 
Invest. 123, 4836–4848. 
Chapter 3:   Mycobacterium tuberculosis manipulates cathepsin S expression by up-regulating 
miR-106b-5p in macrophages 
177 
Fink, S. (2005). Apoptosis, Pyroptosis, and Necrosis: Mechanistic Description of Dead and 
Dying Eukaryotic Cells. Infect. Immun. 73, 1907–1916. 
Fonović, M., and Turk, B. (2014). Cysteine cathepsins and their potential in clinical therapy 
and biomarker discovery. Proteomics. Clin. Appl. 8, 416–426. 
Fu, Y., Yi, Z., Wu, X., Li, J., and Xu, F. (2011). Circulating microRNAs in patients with active 
pulmonary tuberculosis. J. Clin. Microbiol. 49, 4246–4251. 
Hsing, L.C., and Rudensky, A.Y. (2005). The lysosomal cysteine proteases in MHC class II 
antigen presentation. Immunol. Rev. 207, 229–241. 
Jordao, L., Bleck, C.K.E., Mayorga, L., Griffiths, G., and Anes, E. (2008). On the killing of 
mycobacteria by macrophages. Cell. Microbiol. 10, 529–548. 
Kirschke, H., Wiederanders, B., Brömme, D., and Rinne, A. (1989). Cathepsin S from bovine 
spleen. Purification, distribution, intracellular localization and action on proteins. Biochem. 
J. 264, 467–473. 
Liu, P.T., Schenk, M., Walker, V.P., Dempsey, P.W., Kanchanapoomi, M., Wheelwright, M., 
Vazirnia, A., Zhang, X., Steinmeyer, A., Zügel, U., et al. (2009). Convergence of IL-
1beta and VDR activation pathways in human TLR2/1-induced antimicrobial responses. 
PLoS One 4, e5810. 
Liu, P.T., Wheelwright, M., Teles, R., Komisopoulou, E., Edfeldt, K., Ferguson, B., Mehta, 
M.D., Vazirnia, A., Rea, T.H., Sarno, E.N., et al. (2012). MicroRNA-21 targets the vitamin 
D-dependent antimicrobial pathway in leprosy. Nat. Med. 18, 267–273. 
Liu, Y., Wang, X., Jiang, J., Cao, Z., Yang, B., and Cheng, X. (2011). Modulation of T cell 
cytokine production by miR-144* with elevated expression in patients with pulmonary 
tuberculosis. Mol. Immunol. 48, 1084–1090. 
Lu, R., Maduro, M., Li, F., Li, H.W., Broitman-Maduro, G., Li, W.X., and Ding, S.W. (2005). 
Animal virus replication and RNAi-mediated antiviral silencing in Caenorhabditis elegans. 
Nature 436, 1040–1043. 
Ma, F., Xu, S., Liu, X., Zhang, Q., Xu, X., Liu, M., Hua, M., Li, N., Yao, H., and Cao, X. (2011). 
The microRNA miR-29 controls innate and adaptive immune responses to intracellular 
bacterial infection by targeting interferon-γ. Nat. Immunol. 12, 861–869. 
Maertzdorf, J., Weiner, J., Mollenkopf, H.-J., Bauer, T., Prasse, A., Müller-Quernheim, J., 
and Kaufmann, S.H.E. (2012). Common patterns and disease-related signatures in 
tuberculosis and sarcoidosis. Proc. Natl. Acad. Sci. U. S. A. 109, 7853–7858. 
Meng, Q.-L., Liu, F., Yang, X.-Y., Liu, X.-M., Zhang, X., Zhang, C., and Zhang, Z.-D. (2014). 
Identification of latent tuberculosis infection-related microRNAs in human U937 
macrophages expressing Mycobacterium tuberculosis Hsp16.3. BMC Microbiol. 14, 37. 
Miotto, P., Mwangoka, G., Valente, I.C., Norbis, L., Sotgiu, G., Bosu, R., Ambrosi, A., 
Codecasa, L.R., Goletti, D., Matteelli, A., et al. (2013). miRNA signatures in Sera of 
patients with active pulmonary tuberculosis. PLoS One 8, e80149. 
Mohamed, M.M., and Sloane, B.F. (2006). Cysteine cathepsins: multifunctional enzymes in 
cancer. Nat. Rev. Cancer 6, 764–775. 
Nissler, K., Strubel, W., Kreusch, S., Rommerskirch, W., Weber, E., and Wiederanders, B. 
(1999). The half-life of human procathepsin S. Eur. J. Biochem. 263, 717–725. 
O’Donnell, K.A., Wentzel, E.A., Zeller, K.I., Dang, C. V, and Mendell, J.T. (2005). c-Myc-
regulated microRNAs modulate E2F1 expression. Nature 435, 839–843. 
Pai, R.K., Askew, D., Boom, W.H., and Harding, C. V (2002). Regulation of class II MHC 
expression in APCs: roles of types I, III, and IV class II transactivator. J. Immunol. 169, 
1326–1333. 
Pierre, P., and Mellman, I. (1998). Developmental regulation of invariant chain proteolysis 
controls MHC class II trafficking in mouse dendritic cells. Cell 93, 1135–1145. 
Rajaram, M.V.S., Ni, B., Morris, J.D., Brooks, M.N., Carlson, T.K., Bakthavachalu, B., 
Schoenberg, D.R., Torrelles, J.B., and Schlesinger, L.S. (2011). Mycobacterium 
tuberculosis lipomannan blocks TNF biosynthesis by regulating macrophage MAPK-
activated protein kinase 2 (MK2) and microRNA miR-125b. Proc. Natl. Acad. Sci. U. S. A. 
108, 17408–17413. 
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
178 
Rudensky, A., and Beers, C. (2005). Lysosomal Cysteine Proteases and Antigen 
Presentation. In Cytokines as Potential Therapeutic Targets for Inflammatory Skin 
Diseases, R. Numerof, C.A. Dinarello, and K. Asadullah, eds. (Springer Berlin Heidelberg), 
pp. 81–95. 
Russell, D.G. (2001). Mycobacterium tuberculosis: here today, and here tomorrow. Nat. Rev. 
Mol. Cell Biol. 2, 569–577. 
Russell, D.G., Sturgill-Koszycki, S., Vanheyningen, T., Collins, H., and Schaible, U.E. 
(1997). Why intracellular parasitism need not be a degrading experience for 
Mycobacterium. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 352, 1303–1310. 
Russell, D.G., Vanderven, B.C., Glennie, S., Mwandumba, H., and Heyderman, R.S. (2009). 
The macrophage marches on its phagosome: dynamic assays of phagosome function. 
Nat. Rev. Immunol. 9, 594–600. 
Schneider, C.A., Rasband, W.S., and Eliceiri, K.W. (2012). NIH Image to ImageJ: 25 years of 
image analysis. Nat. Methods 9, 671–675. 
Sendide, K., Deghmane, A.-E., Pechkovsky, D., Av-Gay, Y., Talal, A., and Hmama, Z. 
(2005). Mycobacterium bovis BCG attenuates surface expression of mature class II 
molecules through IL-10-dependent inhibition of cathepsin S. J. Immunol. 175, 5324–
5332. 
Tili, E., Michaille, J.-J., Cimino, A., Costinean, S., Dumitru, C.D., Adair, B., Fabbri, M., 
Alder, H., Liu, C.G., Calin, G.A., et al. (2007). Modulation of miR-155 and miR-125b 
levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in 
regulating the response to endotoxin shock. J. Immunol. 179, 5082–5089. 
Wang, X. (2008). miRDB: a microRNA target prediction and functional annotation database with 
a wiki interface. RNA 14, 1012–1017. 
Wang, C., Peyron, P., Mestre, O., Kaplan, G., van Soolingen, D., Gao, Q., Gicquel, B., and 
Neyrolles, O. (2010). Innate immune response to Mycobacterium tuberculosis Beijing and 
other genotypes. PLoS One 5, e13594. 
Wang, C., Yang, S., Sun, G., Tang, X., Lu, S., Neyrolles, O., and Gao, Q. (2011). 
Comparative miRNA expression profiles in individuals with latent and active tuberculosis. 
PLoS One 6, e25832. 
WHO (2013). Global Tuberculosis Report 2013 (Geneva, Switzerland: World Health 
Organization Press). 
Wu, J., Lu, C., Diao, N., Zhang, S., Wang, S., Wang, F., Gao, Y., Chen, J., Shao, L., Lu, J., 
et al. (2012). Analysis of microRNA expression profiling identifies miR-155 and miR-155* 
as potential diagnostic markers for active tuberculosis: A preliminary study. Hum. 
Immunol. 73, 31–37. 
Yates, R.M., Hermetter, A., Taylor, G. a, and Russell, D.G. (2007). Macrophage activation 
downregulates the degradative capacity of the phagosome. Traffic 8, 241–250. 
Yi, Z., Fu, Y., Ji, R., Li, R., and Guan, Z. (2012). Altered microRNA signatures in sputum of 
patients with active pulmonary tuberculosis. PLoS One 7, e43184. 
Zavasnik-Bergant, T., Repnik, U., Schweiger, A., Romih, R., Jeras, M., Turk, V., and Kos, 
J. (2005). Differentiation- and maturation-dependent content, localization, and secretion of 
cystatin C in human dendritic cells. J. Leukoc. Biol. 78, 122–134. 
 
 
  
 
 
 
 
Chapter 4:   Ion channel blockers act as 
antimicrobial agents and enhancers of 
macrophage killing activity against drug 
resistant Mycobacterium tuberculosis 
  
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
180 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Diana Machado, David Pires, João Perdigão, Isabel Couto, Isabel Portugal,  
Marta Martins Leonard Amaral Elsa Anes and Miguel Viveiros 
 
In this chapter, I contributed in the design, execution and analysis of all the 
macrophage/bacteria interaction experiments, the ATP and nitric oxide 
experiments in bacteria and I contributed to the writing of the manuscript. 
Chapter 4:   Ion channel blockers act as antimicrobial agents and enhancers of macrophage 
killing activity against drug resistant Mycobacterium tuberculosis 
181 
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enhancers of macrophage killing activity against drug 
resistant Mycobacterium tuberculosis 
 
Diana Machado, David Pires, João Perdigão, Isabel Couto, Isabel Portugal, 
Marta Martins, Leonard Amaral, Elsa Anes and Miguel Viveiros 
 
4.1.   Abstract 
Here we investigate the antimycobacterial properties of ion channel blockers 
verapamil, thioridazine, chlorpromazine, flupenthixol and haloperidol, by 
deciphering their inhibitory effects directly in M. tuberculosis in vitro and in 
infected human monocyte-derived macrophages. In vitro, all compounds 
exhibited synergistic inhibitory activities when combined with the main first line 
drugs, isoniazid and rifampicin, and were able to inhibit active efflux. Gene 
expression analysis of the bacteria showed that efflux genes were 
overexpressed in response to antibiotic exposure, in vitro and ex vivo, indicating 
that M. tuberculosis drug resistance within macrophages is also mediated by 
the expression of efflux pumps. The compounds displayed a rapid and high 
killing activity for M. tuberculosis, correlated with a decrease in bacterial ATP 
levels. We show that the compounds lead to a significant decrease in the 
intracellular mycobacterial load, consequence of ion channel blocking at the 
level of endocytic membranes leading to phagosome acidification and activation 
of lysosomal hydrolases. Altogether, we demonstrate that these inhibitors 
display a dual antimycobacterial inhibitory effect as they target both the bacteria 
and the host cell. Disruption of the proton motive force (PMF), due to inhibition 
of the respiratory chain, results in the inhibition of M. tuberculosis PMF 
dependent efflux systems, therefor promoting the retention of antibiotics subject 
to active efflux. Concerning the host cell side, the phagosomal acidification 
stimulated by these compounds synergize with several components of the host 
immune response, restricting M. tuberculosis intracellular growth. In conclusion, 
we provide direct, experimental evidence that these ion channel blockers act as 
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
182 
antimicrobial agents and enhancers of macrophage killing activity. This work 
further highlights the value of these compounds as adjuvants of drug resistant 
tuberculosis chemotherapy. 
 
4.2.   Introduction 
Mycobacterium tuberculosis is a challenging pathogen, mostly due to its 
impenetrable cell wall coupled with a long generation time, a plastic metabolism 
and a remarkable ability to establish persistent and opportunistic infections. 
Consequently, the therapeutic regimen for tuberculosis requires a prolonged 
antibiotic treatment of, at least, 6 months in order to attain a favourable clinical 
outcome (Mitchison and Davies, 2012). Although infections with drug-
susceptible M. tuberculosis (MTB) strains can be effectively treated with the 
current regimen of first-line antituberculosis drugs, the increase of antibiotic 
resistant MTB strains represents an ongoing threat to the control of the disease. 
According to the World Health Organization, in 2012, there were an estimated 
450 000 new cases of multidrug resistant tuberculosis (MDRTB, simultaneous 
resistance to isoniazid and rifampicin) worldwide. The average proportion of 
MDRTB cases with extensively drug resistance (XDRTB, MDR plus resistance 
to quinolones, aminoglycosides and cyclic peptides) was 9.6% (WHO, 2013a). 
Regrettably, these numbers indicate that, despite all efforts, antibiotic resistance 
in tuberculosis continues to increase. 
Resistance to antituberculosis drugs are assumed to be a consequence of the 
development of spontaneous mutations in defined genes or its promoter regions 
and the resulting resistance levels can be influenced by the type of alteration in 
the target gene (Böttger, 2011). However, in a proportion of strains, the 
resistance to a certain drug cannot be solely explained by classical gene 
mutations, which suggests the presence of additional mechanisms of resistance 
(Louw et al., 2011; Machado et al., 2012). In mycobacteria, the physiological 
resistance is generally attributed to the low permeability of the cell wall, which 
may limit the entry of antibiotics. Besides this reduced permeability, efflux 
systems also promote the development of resistance by the extrusion of 
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molecules entering the cell prior to their access to the intended target (Louw et 
al., 2009). 
Previous studies have stated the contribution of efflux mechanisms to antibiotic 
resistance in MTB describing several putative efflux pumps of different classes 
shown to be involved in the transport of different compounds (Viveiros et al., 
2012). Furthermore, it has been demonstrated that the overexpression of efflux 
pumps contributes to drug-resistance by allowing the bacteria to survive for a 
longer period of time in the presence of sub-inhibitory concentrations of 
antibiotics, until mutations emerge (Machado et al., 2012). Concomitantly, it was 
demonstrated that the resistance level to a given antibiotic can be significantly 
reduced by an efflux inhibitor despite the presence of a mutation, highlighting 
the contribution of active efflux to the overall resistance level of a drug resistant 
strain of MTB (Louw et al., 2011; Machado et al., 2012).  
The combination of an efflux inhibitor to with tuberculosis chemotherapy can 
enhance antimycobacterial killing, prevent the emergence of drug resistance 
(Adams et al., 2011; Machado et al., 2012; Rodrigues et al., 2012) and reduce 
the duration of tuberculosis treatment (Adams et al., 2011; Gupta et al., 2013). 
To date, several compounds have been appointed as potential efflux inhibitors. 
These compounds are ion channel blockers and comprised the phenotiazines 
thioridazine (TZ), chlorpromazine (CPZ) and its derivative flupenthixol (FPX) a 
high-potency thioxanthene; haloperidol (HAL) a butyrophenone structurally and 
clinically related with phenothiazines; verapamil (VP), a phenylalkylamine 
(Viveiros et al., 2012). These compounds are FDA approved drugs, used to 
treat several mental disorders or hypertension, with well-characterized 
pharmacology and toxicology profiles. 
Ion channel blockers such as TZ and VP have been shown to actively inhibit 
efflux and in vitro growth of MTB strains, alone or in combination with 
antimycobacterial drugs (Amaral et al., 1996, 2007; Machado et al., 2012; Silva 
et al., 2001). TZ demonstrated significant activity against MDRTB in a murine 
model (van Soolingen et al., 2010) and it has been successfully employed to 
treat XDRTB patients on the basis of compassionate reasons (Abbate et al., 
2012). VP has been shown to be the most potent mycobacterial inhibitor to 
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date, being able to enhance the inhibitory activity of isoniazid (Machado et al., 
2012; Rodrigues et al., 2012) and rifampicin (Louw et al., 2011) in MTB clinical 
strains. Recently, Gupta et al. (2014) demonstrated that efflux inhibition by VP 
can potentiate the activity of bedaquiline, a diarylquinoline recently approved for 
the treatment of MDR-TB (WHO, 2013b). It has also been shown that the 
addition of VP accelerates the bactericidal and sterilising activities of 
tuberculosis therapy in the mouse model (Gupta et al., 2013). Beyond their 
antimycobacterial activity, these compounds also present immunomodulatory 
abilities on MTB-infected macrophages. Previously, we had shown that 
inhibitors of calcium and potassium can enhance the killing of MTB by 
macrophages (Martins et al., 2008; Ordway et al., 2003). Afterwards, it was 
demonstrated that the inhibition of macrophage calcium channels increases 
calcium influx, which, consequently, activates an immune response against 
intracellular MTB (Gupta et al., 2009). Further evidence in favour of the 
usefulness of the ion channel blockers is reported in the elegant studies by 
Adams et al. (2011, 2014), wherein the selective pressure exerted by the 
macrophage on internalized MTB can induce the bacteria efflux pumps and 
thereby drug-tolerance. Additionally, the authors also show that this 
macrophage drug-induced tolerance can be reduced by VP or derived 
metabolites (Adams et al., 2011, 2014). 
Having established the significance of the use of ion channel blockers as 
adjuvants in tuberculosis chemotherapy, it is important to understand their 
antimycobacterial properties both in vitro and in the macrophage model. In this 
study, we demonstrate that these compounds are efflux inhibitors with direct 
antimycobacterial activity towards MTB. We show that they can enhance the 
inhibitory activities of the antibiotics against MTB in vitro and enhance the killing 
activity of the macrophage against intracellular MTB. Furthermore, we 
demonstrate that these compounds are able to induce phagosome acidification, 
whose combined effect with other antimicrobial macrophage factors, promote 
the elimination of the internalized mycobacteria. Our findings contribute to a 
better understanding of the mode of action of these ion channel blockers and 
provide insights to identify the mediators of their antimycobacterial and 
immunomodulatory activity.   
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4.3.   Materials and Methods 
 
4.3.1.   Mycobacterial strains and growth conditions.  
A panel of nine M. tuberculosis strains were selected for this study: M. 
tuberculosis H37Rv ATCC27294T, M. tuberculosis H37RvΔkatG (Machado et 
al., 2012) and seven drug-resistant clinical strains obtained from the culture 
collection of the Mycobacteriology laboratory of the Instituto de Higiene e 
Medicina Tropical, Universidade Nova de Lisboa (Table 4.1). M. bovis BCG 
Pasteur ATCC35734 expressing green fluorescent protein (BCG-GFP) was 
kindly provided by Prof. M. Niederweis (University of Alabama). Cultures of M. 
tuberculosis were routinely grown in MGIT media (Becton Dickinson, Diagnostic 
Systems, Sparks, MD, USA) supplemented with 10% OADC (oleic 
acid/albumin/dextrose/catalase) (Becton-Dickinson), except when indicated 
otherwise. Susceptibility testing, semi-quantitative drug susceptibility testing and 
minimum inhibitory concentration determinations (MIC) were conducted using 
the BACTECTM MGITTM 960 system (MGIT960). 
 
4.3.2.   Antibiotics and chemicals.  
Isoniazid, rifampicin, ofloxacin, amikacin, capreomycin, verapamil (VP), 
flupenthixol (FPX), thioridazine (TZ), chlorpromazine (CPZ), haloperidol (HAL), 
and the efflux substrate ethidium bromide (EtBr), were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All drugs were prepared in sterile deionized water 
except rifampicin and haloperidol which were prepared in dimethyl sulfoxide 
(DMSO). The lyophilized drugs (BACTECTM MGITTM 960 SIRE and PZA kits; 
SIRE: streptomycin, isoniazid, rifampicin and ethambutol; PZA: pyrazinamide) 
used in standard susceptibility testing were purchased from Becton Dickinson 
and the stock solutions prepared as per manufacturer’s instructions.  
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4.3.3.   Susceptibility testing.  
(i)   First and second line drug susceptibility testing.  
The MGIT960 was used for first and second line drug susceptibility testing 
according to the manufacturer’s instructions. MGIT tubes were inoculated with 
0.8 ml SIRE supplement (Becton Dickinson), 0.1 ml of antibiotic at the critical 
concentrations (0.1 µg/ml for isoniazid, 1 µg/ml for rifampicin, 1 µg/ml for 
streptomycin, 5 µg/ml for ethambutol, 100 µg/ml for pyrazinamide, 1 µg/ml for 
amikacin, 2.5 µg/ml for capreomycin, and 1 µg/ml for ofloxacin) and 0.5 ml of 
the suspension of the strain. For preparation of the drug-free proportional 
control strain suspension was diluted 1:100 (1:10 for PZA) and 0.5 ml 
inoculated in the tube. The results were interpreted as follows: at the time of 
positivity of the proportional control (Growth units [GU] = 400), the comparison 
between this tube and the tubes containing the drugs(s) was performed. If the 
GU of the tubes containing the drug were >100, they were considered to be 
resistant to that concentration. If the GU of the tube containing the drug was 
<100 they were considered susceptible (Springer et al., 2009). Growth of the 
cultures was monitored with the Epicenter V5.80A software equipped with the 
TB eXIST module. 
(ii)   MIC determination of antibiotics and inhibitors. 
MIC determination was done within MGIT960 and the growth monitored with the 
Epicenter V5.80A software. Verapamil and haloperidol were tested at 
concentrations ranging from 16 to 512 μg/ml; thioridazine, chlorpromazine and 
flupenthixol were tested at concentrations from 3.75 to 60 μg/ml. Isoniazid was 
tested a concentration ranging from 0.1 to 120 μg/ml, rifampicin and amikacin 
were tested from 1 to 640 μg/ml and ofloxacin was tested from 1 to 10 μg/ml. At 
the time of testing, two-fold serial dilutions were prepared to achieve the desired 
concentrations. The MIC was considered as the lowest concentration with GU 
<100 when the drug-free control tube reached a GU value of 400.  
(iii)   Quantitative drug susceptibility testing of antibiotics in presence and 
absence of inhibitors. 
Quantitative drug susceptibility (qDST) testing of rifampicin, isoniazid, ofloxacin 
and amikacin was conducted using the MGIT960 and the Epicenter V5.80A/TB 
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eXIST. Isoniazid was tested at 0.1, 0.4, 1, 3 and 10 µg/ml, rifampicin and 
amikacin at 1, 4 and 20 µg/ml, and ofloxacin at 1, 2 and 10 µg/ml. The 
interpretation of the results was performed as per Springer et al. (2009). For the 
quantification of the resistance levels of each strain, the following criteria was 
used: isoniazid low-level resistance when resistant (R) at 0.1 and susceptible 
(S) at 1 µg/ml; isoniazid high-level resistance when R ≥ 1; rifampicin and 
amikacin low-level resistance when R at 4 and S at 20 µg/ml; rifampicin and 
amikacin high-level resistance when R ≥ 20 µg/ml; ofloxacin low-level 
resistance when R at 1 and S at 2 µg/ml; ofloxacin high-level resistance when R 
≥ 2 µg/ml. The inhibitors were used at ½ of the respective MIC. 
(iv)   Determination of the synergistic effect of the inhibitors. 
The analysis of the effect of drug combination was achieved by calculating the 
fractional inhibitory concentration (FIC) index as follows: FIC= MICATB in 
combination/MICATB alone. The FIC was interpreted as: FIC≤0.5, synergism; >0.5-1, 
indifference; and >1, antagonism (Lorian, 1996).  
 
4.3.4.   Time-kill kinetics. 
To assess the bactericidal activity of the inhibitors, time-kill studies were 
performed with two strains: the reference strain H37Rv (drug-susceptible) and 
one clinical strain, 149/09 (drug-resistant with XDR pattern – see Table 4.1). 
Mid-log phase cultures were diluted to 1×105 CFU/ml and challenged with the 
compounds alone or in combination with antibiotics. Strains were inoculated in 
100 ml of MB7H9 (DIFCO, Madrid, Spain) containing 10 % OADC enrichment, 
0.05 % Tween 80 and the compounds at five times the MIC. A drug-free control 
was included in the assay to monitor the normal growth of the strains. Cultures 
were sampled for CFU determination after 1, 2, 3 and 7 days of incubation at 
37ºC. For CFU determination, the samples were pelleted once by centrifugation 
at 16060 x g for 10 minutes to reduce drug carry-over and resuspended in drug-
free MB7H9. Colony forming units’ were determined with the MGIT960 and the 
Epicenter software. Briefly, to generate calibration curves, the number of viable 
cells was first determined by standard plate counting method. Cell suspensions 
were grown to an optical density at 600 nm (OD600) of 0.8 and 1 ml was added 
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to 9 ml of MB7H9. Tenfold serial dilutions (100 to 10-7) were made in MB7H9 
and 100 µl from each dilution plated onto MB7H11 plates (DIFCO) 
supplemented with 10 % OADC. Plates were sealed and the CFU´s determined 
after incubation at 37ºC during 21 days. Simultaneously, MGIT tubes 
supplemented with 10 % OADC were inoculated in triplicate with 100 µl of the 
same serial dilutions, incubated in the MGIT960 system and the TTD recorded. 
Calibration growth curves for each dilution were generated with the Epicenter 
software and the TTD for each dilution plotted against log10 CFU. To obtain the 
cell concentration for each drug exposed culture, CFU´s were predicted by the 
theoretical log10 CFU based TTD multiplied by the corresponding dilution factor. 
The killing effect of the compounds on in vitro M. tuberculosis growth was 
defined as the lack of growth in MGIT tubes after 100 days of incubation 
(Filippini et al., 2010).  
 
4.3.5.   Quantification of intracellular ATP  
Intracellular ATP was quantified by using the ATP Determination Kit (Invitrogen, 
Life Technologies, Paisley, UK) according to the manufacturer’s instructions. 
Briefly, strains were exposed to the compounds and at various time points, 
aliquots of 1 ml of bacteria were collected, heat inactivated and immediately 
deep frozen. Cell lysates were transferred into white flat bottom 96-well plates 
and the ATP content measured using a Tecan’s Infinite® M200 plate reader 
(Tecan Trading AG, Switzerland) and expressed as relative luminescence units. 
ATP standards were used in all experiments as internal controls. Sample ATP 
levels were calculated from the calibration curve, with correction for background 
luminescence. Isoniazid and rifampicin were used as controls. Cultures were 
sampled for CFU determination as described above.  
 
4.3.6.   Growth rate measurements  
Cell suspensions were adjusted to 150 GU with sterile saline solution and 0.5 
ml transferred into a MGIT tube containing 10 % OADC. Growth rates were 
measured at 37 °C with the MGIT960 and the Epicenter software. First, we 
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determined the time to detection, i.e. the time to reach the threshold of 75 GU, 
as a measure of the capacity of the strain to adapt to a new environment. The 
relative growth rates were determined according to Gullberg et al. (2011) with 
modifications. The calculations were based on TTD values between 75 and 400 
GU which corresponds to OD600 values between ≈0.02 and 0.1 (data not 
shown). The relative growth rates were determined as the ratio between the 
growth rate of each strain and the growth rate of the control strain. Data was 
normalized against the control strain M. tuberculosis H37Rv. 
 
4.3.7.   Mutation frequency determinations 
M. tuberculosis H37Rv was grown in 200 ml erlenmeyer flasks supplemented 
with 10 % OADC and 0.05 % Tween 80 and incubated at 37 ºC until they reach 
an OD600 of 0.8-0.9. Cultures were diluted to 1×10
4 CFU/ml in MB7H9. 
Spontaneous mutants resistant to the inhibitors were detected by plating 0.1 ml 
of this dilution onto MB7H11 agar plates containing the compounds at 
concentrations five times the MIC. Plates were sealed in plastic bags and the 
colonies counted after three weeks of incubation at 37 ºC. The mutation 
frequency corresponds to the ratio of the average number of mutants per 
milliliter to the total number of cells per milliliter (David, 1970). 
 
4.3.8.   Detection of catalase activity 
Catalase activity was assessed according to the protocol described by David 
(1989), at room temperature. The M. tuberculosis H37Rv strain served as a 
positive control. 
 
4.3.9.   Acid resistance evaluation 
M. tuberculosis H37Rv was grown in 25 ml of MB7H9 containing 10 % OADC 
and 0.05 % Tween 80 until they reach an OD600 of 0.8. Cells were washed by 
centrifugation at 2940 x g during 3 minutes, to remove Tween 80. Washed cells 
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were diluted to 1×105 CFU/ml in 100 ml of MB7H9 at different pH’s ranging from 
6.8 to 3.5 plus 10 % OADC without Tween 80 (Vandal et al., 2008). Cultures 
were sampled for CFU determination after 1, 2, 3 and 7 days of incubation at 
37 ºC. For CFU determination, samples were washed once by centrifugation at 
16060 x g for 10 minutes and resuspended in MB7H9. Colony forming units 
were determined with the MGIT960 and the Epicenter software as described 
above.  
 
4.3.10.   Antimycobacterial activity on infected macrophages 
(i)   Mycobacterial cultures. 
M. tuberculosis strains and M. bovis BCG-GFP were cultured in Middlebrook 
7H9 broth supplemented with 10 % OADC and 0.05 % tyloxapol (Sigma-
Aldrich) at 37 ºC, with occasional shaking. For BCG-GFP, 50 µg/ml hygromycin 
(Sigma-Aldrich) were added to the media. Prior to any experiment, bacteria 
were prepared in order to achieve a single cell suspension. Bacterial cultures on 
exponential growth phase were centrifuged at 3000 x g for 10 minutes, washed 
in PBS and resuspended in cell culture medium without antibiotics. In order to 
disrupt bacterial clumps, the cell suspension was passed through a 21 G 
needle. Residual clumps were removed by 1 minute centrifugation at 500 x g.  
(ii)   Isolation and culture of human monocyte-derived macrophages. 
Human monocyte-derived macrophages (HMDMs) were obtained from buffy 
coat preparations kindly donated by Instituto Português do Sangue. The buffy 
coat was diluted (1:1) in PBS containing 0.5 % bovine serum albumin (BSA) 
and 2 mM EDTA and then gently overlaid on Ficoll-Paque Plus (GE Healthcare, 
Freiburg, Germany) at a ratio of 2:1 followed by 800 x g centrifugation for 20 
minutes at room temperature. The interface was then recovered and washed 
two times. Selection of CD14 monocytes was performed using MACS LS cell 
separation system (MiltenyiBiotec, Cologne, Germany) according to the 
manufacturer instructions. Briefly, cells were incubated during 30 minutes at 
4 ºC with anti-CD14 MicroBeads (MiltenyiBiotec) and then passed through a 
magnetic separator. CD14 monocytes were recovered and differentiated into 
macrophages during 7 days in macrophage medium containing RPMI-1640 
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medium with 10 % fetal calf serum (FCS), 1 % GlutaMAX™, 1 mM sodium 
pyruvate, 10 mM HEPES at pH 7.4, 100 IU/ml penicillin and 100 µg/ml 
streptomycin (Gibco, Life Technologies), and 20 ng/ml M-CSF (Immunotools, 
Friesoythe, Germany) and incubated at 37 ºC in 5 % CO2 atmosphere. Fresh 
medium was added at day 4 post isolation. 
(iii)   Determination of macrophage viability after treatment with compounds. 
HMDMs were seeded 3x105 cells per well in 24-well plates and treated with the 
compounds. After 3 days of treatment, cell viability was determined using 
AlamarBlue (Molecular Probes, Life Technologies) following the manufacturer’s 
indications. Briefly, 10 % AlamarBlue reagent was added to each well and 
incubated for 4 hours at 37 ºC and 5 % CO2. Then, reduction of resazurin to 
resorufin was measured, through the fluorescence emission, at an excitation of 
570 nm and emission of 595 nm in a Tecan’s Infinite M200 plate 
spectrophotometer. For the subsequent intracellular assays, the compounds 
were used at concentrations that were shown to be non-toxic to the 
macrophages. Isoniazid was used at critical concentration of 0.1 µg/ml. 
(iv)   Quantification of intracellular bacterial survival. 
HMDMs were infected with M. tuberculosis strains at MOI 1 and were allowed to 
uptake the bacteria for 3 hours. Next, they were washed three times with PBS 
and maintained in macrophage medium without antibiotics. At 3 hours, and 1, 3, 
5 and 7 days post-infection, cells were lysed with 0.05 % Igepal (Sigma-Aldrich) 
solution in water. Serial dilutions of the lysate were plated on MB7H11 medium 
supplemented with 10 % OADC. Colony forming units were counted upon 3 
weeks of incubation at 37 ºC. The capacity of intracellular growth of each strain 
was calculated as the ratio between the CFU during the 5 day protocol and the 
CFU on day 0 (Rey-Jurado et al., 2011). 
(v)   Quantification of compound-induced macrophage acidification. 
HMDMs were infected with BCG-GFP at MOI 10 as described above. At 24 
hours post-infection, cells to be analysed by fluorescence microscopy were 
incubated with 100 nM LysoTracker Red for 2 hours or 1 µM LysoSensor™ 
Green (Molecular Probes) for 10 minutes and then washed and observed under 
a fluorescence microscope. Quantification of acidified cells by flow cytometry 
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
192 
was performed by detaching the cells with 0.05 % Trypsin-EDTA (Sigma-
Aldrich). After cells were washed with PBS and further incubated with 100 nM 
LysoTracker Red (Molecular Probes) for 2 hours at 37 ºC and 5 % CO2. Cells 
were washed and analyzed on an easyCyte™ 5HT flow cytometer (Millipore 
Corporation, Billerica, MA, USA). 
(vi)   Measurement of cathepsin B activity. 
HMDMs were infected with M. tuberculosis H37Rv at MOI 1 for 3 hours as 
described above. The cells were then incubated with the compounds during 24 
hours at 37 ºC with 5 % CO2. Cathepsin B activity was measured using a 
fluorometric cathepsin B activity assay kit (BioVision, California, USA) in 
accordance with the manufacturer's instructions.  After 24 hours of infection the 
cells were harvested, lysed in chilled cathepsin B cell lysis buffer for 10 minutes 
and mixed with equal volume of reaction buffer. The suspensions were 
transferred to black flat bottom 96-well plates and incubated with 200 µM 
cathepsin B substrate (Ac-RR-AFC) during 2 hours at 37 °C.Cathepsin B 
activity was measured at 400 nm excitation and 505 nm emission using a 
Tecan’s Infinite® M200 plate reader and expressed as relative fluorescence 
units (RFU).  
 
4.3.11.   Assessment of efflux activity. 
The detection of ethidium bromide efflux was performed by a semi-automated 
fluorometric method using a Rotor-Gene 3000TM thermocycler (Corbett 
Research, Sidney, Australia) (Viveiros et al., 2010) with a modified protocol for 
M. tuberculosis (Machado et al., 2012). The semi-automated fluorometric 
method was applied to all strains. Briefly, the strains were grown in 10 ml of 
MB7H9 medium containing 10 % OADC enrichment (Becton Dickinson) and 
0.05 % Tween 80. Cultures were incubated at 37ºC, without stirring, until they 
reached an OD600 of 0.8. After the cultures reached the desired OD600, cultures 
were centrifuged at 2940 x g, during 3 minutes at 25 ºC. After this, the 
supernatant were discarded, the pellet washed, resuspended in PBS and 
centrifuged as before.  
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(i)   Accumulation of ethidium bromide. 
For the ethidium bromide accumulation assays, the washed cells were 
resuspended in PBS and the OD600 adjusted to 0.8. In order to determine the 
lowest concentration of ethidium bromide that causes accumulation, 50 µl of the 
bacterial suspension was added to 0.2 ml PCR tubes containing different 
concentrations of ethidium bromide that ranged from 0.125 to 5 µg/ml and 
glucose at a final concentration of 0.4 %. The final OD600 of the bacterial 
suspension in the assay was 0.4. The assays were conducted at 37 ºC in a 
Rotor-Gene 3000TM, and the fluorescence of ethidium bromide was measured 
(530/585 nm) at the end of each cycle of 60 seconds, for 60 minutes. After 
determining the higher concentration of ethidium bromide that do not causes 
accumulation, the effect of the inhibitors on the accumulation of ethidium 
bromide was evaluated. These assays were performed like described above 
with each efflux inhibitor at ½ of the MIC (a subinhibitory concentration that do 
not affect bacterial viability but inhibits efflux), ethidium bromide at the higher 
concentration that do not cause accumulation (determined for each strain), 
37 ºC and with and without glucose. To better evaluate the effect of the 
inhibitors in the accumulation of ethidium bromide, for each assay we 
determined the relative final fluorescence (RFF) at the last time point (minute 
60) of the assay in comparison with the control condition using the formula RFF 
= (RFtreated- RFnon-treated)/(RFnon-treated) (Machado et al., 2011). Here, RFtreated 
corresponds to the relative fluorescence for each strain treated with the 
compound at the last time point of the accumulation assay and the RFnon-treated 
corresponds to the relative fluorescence of the cells only in the presence of 
ethidium bromide at the same time point. High RFF values indicated that cells 
accumulate more ethidium bromide under the condition used than those of the 
control (non-treated cells). Negative RFF values indicated that treated cells 
accumulated less ethidium bromide than those of the control condition. Each 
assay was performed in triplicate and the results presented correspond to the 
average ±SD of three independent assays.  
(ii)   Efflux of ethidium bromide. 
For the efflux assays, the washed cells were resuspended in PBS and the 
OD600 adjusted to 0.4. The ethidium bromide loaded cells were prepared by 
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incubating the bacterial suspension, in glass test tubes, with the higher 
concentration of ethidium bromide that do not cause accumulation (determined 
above), under conditions that promote accumulation: the most effective efflux 
inhibitor at ½ of the MIC, absence of glucose at 25 ºC during 60 minutes. For all 
strains tested in this work, the most effective inhibitor was verapamil. After 
ethidium bromide accumulation, the cells were collected by centrifugation at 
4860 x g during 5 minutes at 25 ºC and resuspended in PBS to an OD600 of 0.8. 
After adjusting de OD600, 50 µl of the bacterial suspension was added to 0.2 ml 
PCR tubes containing (1) PBS only; (2) PBS plus glucose, to a final 
concentration of 0.4 %; (3) verapamil at ½ of MIC only; and (4) glucose to a final 
concentration of 0.4 % plus verapamil at ½ of MIC. The final OD600 of the 
bacterial suspension in the assay was 0.4. The fluorescence of ethidium 
bromide was measured, as described above. The fluorescence was acquired 
first, at the end of 15 seconds and at the end of every 30 seconds during the 
following 30 minutes. The efflux activity was quantified by comparing the 
fluorescence data obtained for the cells under conditions that allow maximum 
efflux (incubation at 37 ºC in the presence of glucose and absence of a 
compound) against the data from the control tube that contains the ethidium 
bromide-load cells under conditions that inhibit the efflux (with a compound and 
absence of glucose).  
 
4.3.12.   Efflux pump gene expression.  
(i)   RNA extraction. 
Total RNA was isolated from the cells using a GTC/Trizol based method. 
Briefly, cultures were centrifuged at 2940 x g during 16 minutes. Then, 
supernatant was removed leaving about 500 µl above the pellet. Five volumes 
of a 5 M GTC solution were added to each culture and incubated 5 minutes at 
room temperature. The mixture was then centrifuged at 2940 x g for 30 minutes 
and the supernatant was discarded. The pellet was resuspended in 1 ml of TRI 
reagent (Sigma). The suspension was transferred to lysis tubes containing 
glass beads (QIAGEN, GmbH, Hilden, Germany) and sonicated at 35 kHz 
(Gen-Probe, California, USA) during 3 x 5 minutes with 1 minute of cooling on 
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ice between intervals. The disrupted cells were incubated at room temperature 
during 10 minutes and centrifuged at 16060 x g for 45 seconds. Supernatant 
above the beads and cellular debris were transferred to a tube containing 300 μl 
of chloroform: isoamyl alcohol (24:1). Afterwards, the mixture was incubated 
during 7 minutes at room temperature followed by centrifugation at 16060 x g 
for 10 minutes. The top aqueous layer was then transferred to a clean tube 
containing an equal volume of isopropanol and the mixture incubated overnight 
at -20 °C. Precipitated nucleic acids were recovered by centrifugation at 
18000 x g for 30 minutes at 4 oC and RNA pellet washed twice with 1 ml ice 
cold 70 % ethanol. RNA was dissolved in RNase-free water and contaminating 
chromosomal DNA was digested with RNase-free DNase I (QIAGEN) at room 
temperature during 30 minutes. RNA was purified with phenol: chloroform (4:1) 
during 10 minutes of incubation on ice and the mixture centrifuged at 18000 x g 
for 10 minutes at room temperature. The top aqueous layer was transferred to a 
new tube, to which 0.1 volumes of RNase-free sodium acetate pH 5.2 and 2.5 
volumes of 100 % RNase-free ethanol were added. Samples were incubated 
overnight at -20°C. After this incubation, RNA was collected by centrifugation at 
18000 x g for 30 minutes at 4 ºC, and washed twice with 1 ml ice cold 70 % 
ethanol. The purified RNA was air-dried and then dissolved in 70 µl RNase-free 
water. Quantity and quality of the purified RNA was measured using a 
NanoDrop 1000 spectrophotometer (Thermo Scientific, Waltham, USA).  
(ii)   RT-qPCR analysis. 
The relative expression level of 10 efflux genes that code for membrane efflux 
transporters in M. tuberculosis and the transcriptional regulator whiB7 (Table 6 
and 7) were analysed by RT-qPCR in the strains exposed to sub-inhibitory 
concentrations of isoniazid or rifampicin. The primers employed are available 
upon request. The RT-qPCR procedure was performed in a Rotor-GeneTM 3000 
thermocycler and followed the protocol recommended for use with the 
QuantiTect SYBR Green RT-PCR Kit (QIAGEN). The following amplification 
program was used: reverse transcription for 30 minutes at 50 ºC; initial 
activation step for 15 min at 95ºC; 35 cycles of denaturation at 94 ºC for 
30 seconds, annealing at 52ºC for 30 seconds and extension at 72ºC for 
30 seconds; a final extension step at 72 ºC for 5 minutes; and an additional step 
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at 50 ºC for 15 seconds followed by melt analysis (50-99 ºC). The determination 
of the relative mRNA expression level was performed using the comparative 
quantification cycle (Cq) method (Livak and Schmittgen, 2001). The relative 
expression of the 11 genes was determined by comparison of the relative 
quantity of the respective mRNA in the presence of the antibiotic to the non-
exposed condition. Each strain was assayed in triplicate using total RNA 
obtained from three independent cultures. Data was normalized to the M. 
tuberculosis 16S rDNA reference gene and presented as the mean fold change 
(±SD) compared with the control.  
(iii)   RNA extraction and RT-qPCR from infected macrophages. 
Total RNA was isolated from control and isoniazid-treated M. tuberculosis-
infected macrophages at day 1, 3, 5 and day 7 post-infection as described 
above. The RT-qPCR procedure was performed in a Rotor-GeneTM 3000 
thermocycler and followed the protocol recommended for use with the 
QuantiTect SYBR Green RT-PCR Kit. The amplification program was as 
follows: reverse transcription for 30 minutes at 50 ºC; initial activation step for 
15 min at 95 ºC; 45 cycles of denaturation at 94 ºC for 1 minute, annealing at 
52 ºC for 1 minute and extension at 72 ºC for 1 minute; a final extension step at 
72 ºC for 5 minutes; and an additional step at 50 ºC for 15 seconds followed by 
melt analysis. Data was normalized to the M. tuberculosis 16S rDNA reference 
gene and presented as the mean fold change (±SD) compared with the control.  
 
4.3.13.   Genetic characterization.  
(i)   Detection of mutations associated with resistance. 
Genomic DNA was extracted using the QIAamp DNA mini kit (QIAGEN) 
according to the manufacturer’s instructions. The most common mutations in 
katG gene and inhA regulatory region were investigated using the Genotype 
MTBDRplus (HainLifescience GmbH, Nehren, Germany). For the detection of 
the most frequent mutations in gyrA and rrs genes was used the Genotype 
MTBDRsl (HainLifescience) according to the manufacturer’s instructions. 
Genomic analysis of the complete inhA gene and eis promoter region was 
performed by PCR amplification and DNA sequencing using the primers 
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described previously (Leung et al., 2006; Morlock et al., 2003; Perdigão et al., 
2013). The reaction mixtures were prepared for a total reaction volume of 50 µl 
consisting of 1x Taq buffer (Fermentas, Ontario, Canada), 1.5 mM MgCl2, 
200 mM of each dNTP, 20 pmol of each primer (10 pmol for eis), 1.5U Taq DNA 
Polymerase (Fermentas), and 5 µl of chromosomal DNA. The PCR reactions 
were performed with the following amplification profile: initial denaturation at 
94 ºC for 5 min, followed by denaturation at 94 ºC for 1 minute, annealing at 
60 ºC (56 ºC for eis) for 1 minute and extension at 72 ºC for 1 minute during 40 
cycles. The final extension occurred at 72 ºC for 10 minutes.  
(ii)   Detection of mutations in drug transporters. 
The genes were analysed by PCR amplification and DNA sequencing to search 
for mutations. The primer sequences are available upon request from the 
authors. The reaction mixtures were prepared for a total reaction volume of 
50 µl consisting of 1x Taq buffer (Fermentas), 1.5 mM MgCl2, 200 mM of each 
dNTP, 20 pmol of each primer, 1.5U Taq DNA Polymerase (Fermentas), and 
5 µl of chromosomal DNA. The PCR reactions were performed with the 
following amplification profile: initial denaturation at 94 ºC for 5 min, followed by 
denaturation at 94 ºC for 1 minute, primer dependent annealing temperature for 
1 minute and extension at 72 ºC for 1 minute during 40 cycles. The final 
extension occurred at 72 ºC for 10 minutes. 
(iii)   Strain typing. 
Mycobacterial Interspersed Repetitive Unit – Variable Number of Tandem 
Repeats (MIRU-VNTR) genotyping was performed for each strain by multiplex 
PCR amplification 24 MIRU–VNTR loci, as described by Supply et al. (2006). 
The genotype of these strains was analysed using the MIRU-VNTRplus web 
application (Allix-Béguec et al., 2008) and the SITVITWEB database (Demay et 
al., 2012) when relevant. 
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4.4.   Results 
4.4.1.   Ion channel blockers enhance the inhibitory activity of antibiotics 
against M. tuberculosis.  
To determine whether the selected ion channel blockers known to act as efflux 
inhibitors show synergistic activity when combined with the antituberculosis 
drugs against the drug susceptible and resistant panel of MTB strains used in 
this study, the susceptibility of isoniazid, rifampicin, amikacin and ofloxacin was 
investigated in the presence and absence of subinhibitory concentrations of VP, 
TZ, CPZ, FPX and HAL. The in vitro interaction of two agents in combination 
can be interpreted as synergistic, indifferent, or antagonistic depending on 
whether the activity of the combination is superior than, comparable to, or 
smaller than, respectively, the activities of the individual drugs. The efficiency of 
the drug combination was determined through the calculation of the fractional 
inhibitory concentration (FIC) indexes (Lorian, 1996). The characterization of 
the nine MTB strains is presented in Table 4.1. The MICs and FICs obtained 
with the combinations of the inhibitors and the antibiotics against the MTB 
strains are listed in Table 4.2. As can be observed, the combination of isoniazid 
with the five compounds consistently demonstrated synergy, with FIC indexes 
ranging from 0.15 to 0.5, for the five clinical multi- and extensively drug resistant 
strains. For these, the MIC values of isoniazid were reduced from 2- to 20-fold 
depending on the strain and the inhibitor tested. No effect of the compounds 
was observed on the MIC of the isoniazid-monoresistant strains H37RvΔkatG 
and 294/09 (single inhA promoter C-15T mutation). However, the combination 
between the phenotiazines with isoniazid demonstrated synergistic effect 
against the isoniazid-monoresistant strain 269/03 (single katG S315T mutation), 
being able to reduce 6-fold the MIC of isoniazid (FIC of 0.3). Contrary to the 
study by Warman et al. (2013) we did not detect antagonistic activity between 
isoniazid and the three phenotiazines in study. For rifampicin, significant 
synergistic activity was observed mainly with VP and CPZ. The combination of 
VP and rifampicin reduced the MIC values of rifampicin 16-fold in four strains 
and 4-fold in one strain, all carrying the rpoB S531L mutation. The FIC index for 
this combination was 0.06 and 0.25, respectively. CPZ reduced the MIC of 
rifampicin 16-fold in three strains and 4-fold in one strain, showing a FIC of 0.06 
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and 0.05, respectively. For strain 286/09, the MIC of rifampicin was reduced 20-
fold by CPZ and FPX, and 4-fold by VP, TZ and HAL, originating a FIC of 0.05 
and 0.25, respectively. For strains 149/09 and 29/12 rifampicin MIC values were 
reduced 8-fold. Only in one isolate (69/11), an heteroresistant strain for 
amikacin with simultaneous presence of drug susceptible and drug resistant 
genotype carrying the rrs A1401G mutation, was observed significant synergy 
when the combination of the compounds and amikacin was evaluated. For this 
strain, the MIC values were reduced 40-fold, to which corresponds a FIC index 
of 0.03 for all the five inhibitors tested. For the remaining three amikacin-
resistant strains carrying the rrs A1401G mutation, none of the inhibitors, except 
CPZ, demonstrated any synergy. CPZ was found to have a FIC value of 0.13 
for strains 149/09 and 29/12. The combination of the compounds with ofloxacin, 
for the three ofloxacin-resistant strains, was interpreted has being indifferent, 
with FIC indexes of 1 for all the compounds tested. Collectively, these results 
support the hypothesis that using synergistic combinations of inhibitors with 
antituberculosis drugs can significantly enhance the activities of first and second 
line antituberculosis drugs. However, can this enhancement bring back the 
clinical and therapeutic effect of the antibiotics that became non-effective due to 
the presence of mutations associated with resistance? To address this 
question, we performed quantitative drug susceptibility testing for the four 
antibiotics in the presence of the inhibitors to assess the levels resistance and 
correlate them with the mutations associated with clinical resistance. 
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Table 4.1. Molecular characterization, resistance pattern, and MIC values of the antibiotics and inhibitors for the nine M. tuberculosis strains. 
 
Δ, deletion; MDR, multidrug resistant; XDR, extensively drug resistant; INH, isoniazid; RIF, rifampicin; AMK, amikacin; CAP, capreomycin; 
OFX, ofloxacin; VP, verapamil; TZ, thioridazine; CPZ, chlorpromazine; FPX, flupenthixol; HAL, haloperidol. *mixed pattern: simultaneous 
presence of drug susceptible and drug resistant genotype. *VNTR international type 21 (see text for details). LAM, Latino-American-
Mediterranean. 
 
Strain Genotype 
Resistance  
pattern 
Gene mutations  
Antibiotics (µg/ml)  Inhibitors (µg/ml) 
INH RIF AMK OFX  VP TZ CPZ FPX HAL 
H37Rv H37Rv Susceptible none  0.1 1 1 1  256 15 30 30 64 
H37RvΔkatG H37Rv INH  katG deletion  128 1 1 1  128 15 30 30 32 
82/09 LAM –Lisboa3 INH; RIF - MDR inhA C-15T/S94A; rpoB S531L  3 320 1 1  256 15 30 30 64 
149/09 LAM – Q1 
INH; RIF; AMK; CAP; 
OFX - XDR 
inhA C-15T/I194T; rpoB 531L; gyrA D94A; 
 rrs A1401G  
 
 
3 320 640 10  256 15 30 30 64 
286/09 LAM –Lisboa3 
INH; RIF; AMK; OFX – 
XDR 
inhA C-15T/S94A; rpoB S531L; gyrA S91P; 
 eis G-10A 
 
 
20 80 4 10  128 15 30 30 32 
69/11 Beijing 
INH; RIF; AMK; CAP; 
OFX - XDR 
katG S315T; rpoB S531L; rrs A1401G/wt*  20 320 40 1  256 15 30 30 32 
29/12 LAM – Q1 
INH; RIF; AMK; CAP; 
OFX - XDR 
inhA C-15T/I194T; rpoB S531L; gyrA D94A;  
rrs A1401G 
 
 
3 320 640 10  256 15 30 30 64 
269/03 Unclustered* INH  katG S315T  10 1 1 1  256 15 30 30 64 
294/09 
LAM – 
unclustered 
INH  inhA C-15T  0.4 1 1 1  256 15 30 30 64 
 
Chapter 4:   Ion channel blockers act as antimicrobial agents and enhancers of macrophage 
killing activity against drug resistant Mycobacterium tuberculosis 
201 
Table 4.2. Fractional inhibitory concentration (FIC) indexes of the inhibitors when 
combined with isoniazid, rifampicin, amikacin or ofloxacin, against the nine 
M. tuberculosis strains. 
 
Δ, deletion; INH, isoniazid; RIF, rifampicin; AMK, amikacin, OFX, ofloxacin; VP, 
verapamil; TZ, thioridazine; CPZ, chlorpromazine; FPX, flupenthixol; HAL, haloperidol. 
The lowest concentration tested corresponds to the critical concentration for each 
antibiotic (See Material and Methods section for details). The FIC was interpreted as: 
FIC≤0.5, synergism; >0.5-1, indifference; and >1, antagonism (Lorian, 1996). 
Drug 
combinations 
M. tuberculosis strains [MIC in combination(µg/ml)/FIC] 
H37Rv 
H37Rv 
ΔkatG 
82/09 149/09 286/09 69/11 29/12 269/03 294/09 
INH 0.1/1 128/1 3/1 3/1 3/1 20/1 3/1 10/1 0.4/1 
INH + VP 0.1/1 128/1 1/0.33 1/0.33 1/0.05 10/0.50 1/0.33 10/1 0.4/1 
INH + TZ 0.1/1 128/1 1/0.33 1/0.33 20/1 3/0.15 3/1 3/0.30 0.4/1 
INH + CPZ 0.1/1 128/1 1/0.33 1/0.33 1/0.05 3/0.15 1/0.33 3/0.30 0.4/1 
INH + FPX 0.1/1 128/1 1/0.33 1/0.33 1/0.05 3/0.15 1/0.33 3/0.30 0.4/1 
INH + HAL 0.1/1 128/1 1/0.33 1/0.33 1/0.05 10/0.50 1/0.33 10/1 0.4/1 
RIF 1/1 - 320/1 320/1 80/1 320/1 320/1 - - 
RIF + VP 1/1 - 20/0.06 20/0.06 20/0.25 20/0.06 20/0.06 - - 
RIF + TZ 1/1 - 320/1 320/1 20/0.25 320/1 320/1 - - 
RIF + CPZ 1/1 - 320/1 20/0.06 4/0.05 20/0.06 20/0.06 - - 
RIF + FPX 1/1 - 320/1 320/1 4/0.05 320/1 320/1 - - 
RIF + HAL 1/1 - 320/1 320/1 20/0.25 320/1 320/1 - - 
AMK 1/1 - - 640/1 4/1 40/1 640/1 - - 
AMK + VP 1/1 - - 640/1 4/1 1/0.03 640/1 - - 
AMK+ TZ 1/1 - - 640/1 4/1 1/0.03 640/1 - - 
AMK + CPZ 1/1 - - 40/0.13 4/1 1/0.03 40/0.13 - - 
AMK + FPX 1/1 - - 640/1 4/1 1/0.03 640/1 - - 
AMK + HAL 1/1 - - 640/1 4/1 1/0.03 640/1 - - 
OFX 1/1 - - 10/1 10/1 - 10/1 - - 
OFX + VP 1/1 - - 10/1 10/1 - 10/1 - - 
OFX+ TZ 1/1 - - 10/1 10/1 - 10/1 - - 
OFX + CPZ 1/1 - - 10/1 10/1 - 10/1 - - 
OFX + FPX 1/1 - - 10/1 10/1 - 10/1 - - 
OFX + HAL 1/1 - - 10/1 10/1 - 10/1 - - 
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4.4.2.   Ion channel blockers reduce the resistance level of first and 
second line anti-tuberculosis drugs. 
To assess the clinical effect of these compounds in combination with 
antituberculosis drugs in respect to their levels of resistance, and evaluate its 
correlation with the presence of mutations associated with resistance, the levels 
of resistance to isoniazid, rifampicin, amikacin, and ofloxacin were evaluated 
with the MGIT960 system and the TB eXIST software. The results are 
presented in Table 4.3. The addition of the compounds promotes a significant 
reduction of the resistance levels for all antibiotics except for ofloxacin.  
In Figure 4.1 is shown the growth curves for strain 29/12, with and without VP, 
in the presence of isoniazid, as an example. This strain, which was initially 
resistant at 1 µg/ml of isoniazid, upon addition of ½ MIC of VP had his high level 
of resistance decreased to low level resistance (<1 µg/ml) (see full vs dotted 
pink line in Figure 4.1). The resistance levels to isoniazid were reduced from 
high level to low level in 4/8 of the resistant strains, with VP, FPX and CPZ and 
2/8 with TZ. The strain is considered resistant when the number of drug-
resistant bacteria present in the drug-containing tube at critical concentration is 
greater than 1 %, when compared with the drug-free growth control and 
correlates well with an effective clinical outcome (see Materials and Methods for 
critical concentrations) (Canetti et al., 1963). None of the strains had reversal of 
resistance since the resistance levels did not drop below the isoniazid critical 
concentration of 0.1 µg/ml (Table 4.3). Correlating the resistance levels to the 
antibiotics with the presence of mutations associated with resistance: four 
strains for which the resistance level was reduced in the presence of the 
inhibitors harbored double mutations in inhA gene, 2 with C-15T/S94A and 2 
with C-15T/I194A replacements. The four remaining strains, where residual or 
no change of the resistance level was noticed in presence of the inhibitors, 
possessed single mutations: the C-15T mutation in inhA promoter in one strain, 
two strains with the S315T mutation in katG, and one with a complete deletion 
of katG. Strain H37RvΔkatG was included in the study as a negative control, as it 
harbors a complete deletion of the katG gene and demonstrates no efflux 
activity (Machado et al., 2012). Regarding the strains with the katG S315T 
mutation, only a slight enhancement of the antimicrobial effect of isoniazid was 
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observed for both strains in the presence of the phenothiazines TZ, CPZ and 
FPX (Table 4.3). However, this potentiation was not enough to reach low level 
isoniazid resistance. Regarding the strain 294/09 with the C-15T mutation in the 
promoter region of inhA gene, low level resistance was due to the 
overexpression of inhA and the effect of this overexpression on isoniazid 
resistance cannot be overcome by the inhibitors tested. Concerning rifampicin, 
all strains presented high level resistance due to the presence of the mutation 
S531L in rpoB. The resistance level was remarkably reduced from high to low 
level in presence of VP (5/5), CPZ (4/5), and TZ, FPX and HAL (1/5) (Table 4.2 
and Table 4.3). Four strains presented resistance to amikacin due to a mutation 
in a gene associated with amikacin resistance, three of them in rrs1400 region 
and one strain in the eis promoter region. The high level resistance conferred by 
mutations in rrs could not be reduced in the presence of the inhibitors in 2/3 
strains. Nevertheless, resistance to amikacin was reversed in strain 69/11. The 
amikacin resistance profile changed from high level resistance to susceptible in 
presence of the five compounds. In this case, rrs hybridization pattern given by 
Genotype MTBDRsl assay indicated heteroresistance, i.e. the coexistence of a 
population of bacilli susceptible and resistant to amikacin. This is especially 
important since heteroresistance plays a role in the development of resistance 
in MTB (Hofmann-Thiel et al., 2009) and our data demonstrates that these 
inhibitors are capable to prevent the development of resistance to 
antituberculosis drugs. Amikacin resistance due to the mutation in eis promoter 
region could not be reduced. Again, this indicates that resistance due to the 
overexpression of the target gene cannot be altered. For ofloxacin, low level 
resistance was detected in three strains and correlated with mutations in gyrA 
gene. With this panel of strains, ofloxacin resistance could not be reduced by 
any of the inhibitors tested. 
With this methodology, we have been able to demonstrate that the addition of 
ion channel blockers enhances the clinical effect of the main antituberculosis 
drugs, isoniazid and rifampicin, in multi- and extensively drug resistant strains, 
despite the presence of a mutation conferring resistance. However, their effect 
on isoniazid resistance seems to be limited to strains with mutations in inhA 
gene. The fact that strains changed their resistance profile from high level to low 
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level upon the addition of the inhibitors brings clinical implications. The serum 
concentrations of isoniazid and rifampicin attained in vivo, 7 and 10 µg/ml 
respectively, are much higher than the respective MICs for the majority of 
strains (Lorian, 1996). In the presence a high-level resistance strain (see 
Material and Methods section for breakpoints), these drugs are predicted to be 
useless. However, in the presence of a low-level resistance strain it is possible 
to reach high drug concentrations in vivo, since, the effectiveness of the 
synergistic combination of these inhibitors with conventional therapy, seen in 
vitro, is expected to be beneficial to reduce the resistance level of the strain. 
 
 
Figure 4.1. Quantitative drug susceptibility testing of isoniazid for the M. tuberculosis 
29/12 strain, in the presence or absence of verapamil.  
Quantitative drug susceptibility testing of isoniazid was conducted using the BACTEC 
960 system and the Epicenter V5.80A software equipped with the TB eXIST module. 
Full and dotted dark-blue line indicates the drug-free proportional and absolute growth 
control, respectively. Coloured full lines correspond to the growth curves of the strain in 
the presence of isoniazid; the dotted lines correspond to the growth curves with 
isoniazid in combination with verapamil. At the time of growth of the proportional growth 
control (GU=400), the comparison between this tube and the tubes containing the 
drugs(s) was performed. If the GU of the tubes containing the drug were >100, they 
were considered to be resistant to that concentration. If the GU of the tube containing 
the drug was <100 they were considered susceptible. Isoniazid was tested at 0.1, 0.4, 
1, 3 and 10 µg/ml with and without ½ MIC verapamil. 
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Table 4.3. Molecular characterization, resistance pattern, and MIC values of the antibiotics and inhibitors for the nine M. tuberculosis strains. 
 
Δ, deletion; MDR, multidrug resistant; XDR, extensively drug resistant; INH, isoniazid; RIF, rifampicin; AMK, amikacin; CAP, capreomycin; OFX, 
ofloxacin; VP, verapamil; TZ, thioridazine; CPZ, chlorpromazine; FPX, flupenthixol; HAL, haloperidol. *mixed pattern: simultaneous presence of 
drug susceptible and drug resistant genotype. *VNTR international type 21 (see text for details). LAM, Latino-American-Mediterranean. 
 
Strain 
Isoniazid Rifampicin 
 
Amikacin 
 
Ofloxacin 
 
Conc. 
(µg/ml) 
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Conc. 
(µg/ml
) 
- 
EI 
+V
P 
+TZ 
+CP
Z 
+FP
X 
+HAL 
Conc. 
(µg/ml
) 
- 
EI 
+V
P 
+TZ 
+CP
Z 
+FP
X 
+HAL 
H37Rv 
 
0.1 S S S S S S 1 S S S S S S 1 S S S S S S 1 S S S S S S 
0.4 S S S S S S 4 S S S S S S 4 S S S S S S 2 S S S S S S 
1 S S S S S S 20 S S S S S S 20 S S S S S S 10 S S S S S S 
3 S S S S S S                      
10 S S S S S S                      
H37Rv 
ΔkatG 
0.1 R R R R R R 
ND 
      
ND 
      
ND 
      
0.4 R R R R R R                   
1 R R R R R R                   
3 R R R R R R                   
10 R R R R R R                    
82/09 
0.1 R R R R R R 1 R R R R R R 
ND 
      
ND 
      
0.4 R R R R R R 4 R R R R R R             
1 R S S S S S 20 R S R R R R             
3 S S S S S S                    
10 S S S S S S                    
149/09 
0.1 R R R R R R 1 R R R R R R 1 R R R R R R 1 R R R R R R 
0.4 R R R R R R 4 R R R R R R 4 R R R R R R 2 R R R R R R 
1 R S S S S S 20 R S R S R R 20 R R R R R R 10 S S S S S S 
3 S S S S S S                      
10 S S S S S S                      
286/09 
0.1 R R R R R R 1 R R R R R R 1 R R R R R R 1 R R R R R R 
0.4 R R R R R R 4 R R R S S R 4 S S S S S S 2 R R R R R R 
1 R S R S S S 20 R S S S S S 20 S S S S S S 10 S S S S S S 
3 R S R S S S                      
10 R S R S S S                      
69/11 
0.1 R R R R R R 1 R R R R R R 1 R S S S S S 
ND 
      
0.4 R R R R R R 4 R R R R R R 4 R S S S S S       
1 R R R R R R 20 R S R S R R 20 R S S S S S       
3 R R S S S R                     
10 R S S S S S                     
29/12 
0.1 R R R R R R 1 R R R R R R 1 R R R R R R 1 R R R R R R 
0.4 R R R R R R 4 R R R R R R 4 R R R R R R 2 R R R R R R 
1 R S R S S S 20 R S R S R R 20 R R R R R R 10 S S S S S S 
3 S S S S S S                      
10 S S S S S S                      
294/09 
0.1 R R R R R R 
ND 
      
ND 
      
ND 
      
0.4 S S S S S S                   
1 S S S S S S                   
3 S S S S S S                   
10 S S S S S S                   
269/03 
0.1 R R R R R R 
ND 
      
ND 
      
ND 
      
0.4 R R R R R R                   
1 R R R R R R                   
3 R R S S S R                   
10 S S S S S S                   
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4.4.3.   The ion channel blockers display rapid and high killing activity. 
One of the prerequisites for the development of new anti-tuberculosis drugs 
includes the need for compounds that have bactericidal activity in order to 
prevent the development of drug resistance and act rapidly in order to reduce 
the duration of the treatment (Ginsberg, 2010). To characterize the bactericidal 
activity of the ion channel blockers and evaluate if they can enhance the 
bactericidal efficacy of the anti-tuberculosis drugs, we measured their anti-
mycobacterial killing activity against the strains H37Rv (drug-susceptible) and 
149/09 (drug-resistant) through time-kill studies. The time-kill kinetics of the 
compounds and antibiotics on MTB cultures are shown in Figure 4.2. All the 
compounds exhibit time-dependent bactericidal activity. After seven days, FPX, 
CPZ, TZ, HAL, and VP were able to eliminate all MTB cells. FPX reduced the 
cell number to zero at day 1, CPZ and TZ at day 2, and VP and HAL at day 7. 
Moreover, at the end of 100 days all cultures remain negative. Isoniazid, 
rifampicin, amikacin, and ofloxacin were not able to reduce the viable number of 
MTB cells to zero by the end of the seven days. On the seventh day of 
incubation, a 3log10 CFU/ml decrease by rifampicin, amikacin, and ofloxacin 
was observed. For isoniazid was notice a 2log10 reduction in the same time 
frame.  
The most effective ion channel blocker previously tested, VP, was selected for 
the evaluation of the synergistic effect with the antibiotics through time-kill 
studies. The data presented in Figure 4.2B corresponds to the measurement of 
time-kill kinetics for VP with isoniazid, rifampicin, amikacin and ofloxacin for 
H37Rv. It can be observed that the activity of the antibiotics was strongly 
potentiated. By the end of day seven no bacteria remained viable for the five 
combinations tested. The combination of VP plus amikacin reduced the CFU/ml 
to zero at day two, VP and rifampicin at day three, VP and ofloxacin also at day 
three and VP and isoniazid at day seven. Similar results were obtained for the 
multidrug resistant strain (data not shown). These results demonstrate that 
FPX, CPZ, TZ, HAL, and VP have direct bactericidal activity and when 
combined with the antibiotics they can stimulate a rapid and high killing effect 
against both drug susceptible and multidrug resistant MTB, therefore fulfilling 
both criteria mentioned above. 
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Figure 4.2. Time-kill curves for flupenthixol, chlorpromazine, thioridazine, haloperidol, 
verapamil and the anti-tuberculosis drugs isoniazid, rifampicin, amikacin and ofloxacin. 
Compounds were used at 5X MIC and CFU/ml was determined at day 1, 2, 3 and 7. A) 
Killing activity of efflux inhibitors; B) Killing activity of the antibiotics in the presence or 
absence of verapamil. In the figure, is represented the assay for the H37Rv strain. Data 
corresponds to the average of two experiments.  VP, verapamil; TZ, thioridazine; CPZ, 
chlorpromazine; HAL, haloperidol; FPX, flupenthixol; INH, isoniazid; RIF, rifampicin; 
AMK, amikacin; OFX, ofloxacin. 
 
 
4.4.4.   ATP depletion occurs in response to the treatment with the ion 
channel blockers. 
To determine whether the treatment with the ion channel blockers could have 
an effect on intracellular ATP levels, we monitored the intracellular ATP levels 
over seven days. ATP levels and killing activity was recorded after day 1, 2, 3 
and 7 of exposure to the compounds. The mycobacterial ATP levels in cultures 
of M. tuberculosis H37Rv, exposed to 5X the MIC for each compound, are 
shown in Fig. 3A and viability, in Figure 4.3B. A rapid drop in intracellular ATP 
levels of M. tuberculosis H37Rv was noticed after 1 day of exposure with all 
compounds, which progressively falls until the seventh day of exposure. This 
decrease in the ATP levels was correlated with an increased killing activity. 
Isoniazid and rifampicin do not have a significant effect on the ATP levels. 
These results confirm that ATP depletion occurs in consequence of exposure to 
the compounds and indicates that the metabolic state of the cells is directly 
affected by them with anticipated effects on the available bacterial energy for 
active efflux. 
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Figure 4.3. Mycobacterial intracellular ATP levels and viability. 
Cultures of M. tuberculosis H37Rv were exposed to the inhibitors during 7 days. ATP 
was determined by using a luciferin-luciferase bioluminescence detection system at 
day 1, 2, 3 and 7. Cell viability was measured in parallel with MGIT960 system as 
described in Material and Methods. Isoniazid (INH) and rifampicin (RIF) were used as 
controls. 
 
4.4.5.   Inhibition of ethidium bromide efflux demonstrates the role of the 
ion channel blockers as efflux inhibitors.  
The ability of VP, TZ, CPZ, FPX and HAL to inhibit the efflux activity of the MTB 
strains used in this study was carried out using an semi-automated ethidium 
bromide fluorometric method (Viveiros et al., 2010) with a modified protocol for 
MTB (Machado et al., 2012). When data for the clinical strains were compared 
with those for the H37Rv strain, different levels of accumulation were observed 
0
20
40
60
Drug free VP TZ CPZ FPX HAL INH RIF
R
LU
Compounds
Day 1
Day 2
Day 3
Day 7
A
B
0
3
6
9
Drug free VP TZ CPZ FPX HAL INH RIF
lo
g1
0
 C
FU
/m
l
Compounds
Day 0
Day 1
Day 2
Day 3
Day 7
Chapter 4:   Ion channel blockers act as antimicrobial agents and enhancers of macrophage 
killing activity against drug resistant Mycobacterium tuberculosis 
209 
for all isolates. The results showed that the clinical strains are able to handle 
higher ethidium bromide concentrations than H37Rv. This means that the 
clinical strains have higher efflux capacity than that of the reference strain as 
previously described (Machado et al., 2012). These assays were then 
performed in the presence of the same compounds at sub-inhibitory 
concentrations. The inhibitory indexes of activity of each compound against the 
MTB strains are presented in Table 4.4. The relative final fluorescence index 
corresponds to a measure of how efficient is the inhibitory effect of the 
compounds on efflux by comparison of the final fluorescence of the cells 
exposed to ethidium bromide plus the compound against cells exposed only to 
ethidium bromide (taken as 0). The accumulation of ethidium bromide increased 
in presence of all inhibitors. VP promoted the largest increase in accumulation 
in all strains, except H37RvΔkatG (7/8), followed by the phenotiazines. Among 
this class of compounds, FPX demonstrated the highest inhibitory effect (3/7), 
followed by TZ and CPZ, which demonstrated similar activity against 2/7 of the 
multidrug resistant strains. HAL was the compound that demonstrated the 
lowest effect on the accumulation of ethidium bromide. The multidrug resistant 
strains showed significantly higher levels of ethidium bromide accumulation in 
presence of the inhibitors, whereas the clinical isoniazid monoresistant strains 
accumulated significantly lower levels of ethidium bromide when compared with 
those from the multidrug resistant strains. For the katG deleted strain, only a 
minor effect was observed with VP.  
To directly assess efflux, we selected VP to measure the inhibition of ethidium 
bromide efflux on these strains. The results showed that the ethidium bromide 
efflux is greatly inhibited in the presence of VP. Therefore, from the analysis of 
Figure 4.4B we correlate these results with the effect on the ethidium bromide 
accumulation observed in Figure 4.4A and conclude that the inhibition of efflux 
pumps retain ethidium bromide inside the cells. All together, the effects we 
observed on the MICs followed the same pattern as in the ethidium bromide 
accumulation promoted by the inhibitors, correlating the resistance levels of 
these strains with their ability to efflux noxious compounds.  
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Table 4.4. Relative final fluorescence (RFF) based on the accumulation of ethidium 
bromide for the M. tuberculosis strains in the presence of the inhibitors. 
 
VP, verapamil; TZ, thioridazine; CPZ, chlorpromazine; FPX, flupenthixol; HAL, 
haloperidol. Strain 286/09 was not evaluated due to poor growth under the conditions 
required for the accumulation assays. Results in bold face indicate significant inhibition. 
 
 
 
Figure 4.4. Effect of the inhibitors on the accumulation and efflux of ethidium bromide 
by the M. tuberculosis strains. 
In the figure is presented an assay for the strain 29/12 as an example. A) Accumulation 
and B) efflux of ethidium bromide. Ethidium bromide was tested at 0.25 µg/ml. Efflux 
inhibitors were tested at ½ the MIC. EtBr, ethidium bromide; VP, verapamil; TZ, 
thioridazine; CPZ, chlorpromazine; HAL, haloperidol; FPX, flupenthixol. 
 
Strain  
RFF of the inhibitors 
VP TZ CPZ FPX HAL 
H37Rv 1.58 0.97 0.84 0.90 0.32 
H37RvΔkatG 0.37 0.09 0.03 0.15 -0.06 
82/09 2.17 0.96 0.63 1.24 0.44 
149/09 2.31 1.13 1.16 1.45 0.58 
69/11 1.19 0.23 0.47 0.95 0.21 
29/12 2.00 1.14 1.04 1.03 0.24 
294/09 1.21 0.52 0.44 0.98 -0.18 
269/03 0.73 0.17 0.07 0.35 -0.02 
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4.4.6.   Overexpression of efflux pumps in response to the antibiotic 
pressure leads to increased tolerance towards antibiotics. 
In a previous work we have been able to correlate the increased ethidium 
bromide efflux in MTB with efflux-mediated increased isoniazid resistance as 
the result of the activity of several overexpressed efflux pumps working in 
combination (Machado et al., 2012). Here, we assess the contribution of the 
MTB membrane transporters for the increased levels of resistance towards 
isoniazid and rifampicin previously seen for the multidrug resistant MTB strains. 
For that, these strains were exposed to sub-inhibitory concentrations of 
isoniazid or rifampicin and the expression levels of genes that code for 10 efflux 
pumps and the global regulator whiB7 were evaluated by RT-qPCR. Table 4.5 
and Table 4.6 show the results obtained for the quantification of gene expression 
of the cells exposed to isoniazid and rifampicin, respectively. As can be 
observed, the majority of the efflux genes are overexpressed in response to 
isoniazid and rifampicin exposure. Although we cannot observe a specific 
pattern of expression, the genes mmr, mmpl7, p55, Rv1217c and efpA showed 
a significantly increased in their expression levels in the presence of isoniazid. 
Regarding the exposure to rifampicin, we can observe an increase in the 
expression of the majority of the genes albeit at lower absolute levels than 
those obtained for the isoniazid exposed strains. Of all pumps studied, P55 a 
major facilitator superfamily efflux-pump described in 2001 by Silva et al. 
(2001), was found to be consistently expressed in all strains, presenting a 1.54 
to 9.88-fold increase in presence of rifampicin. 
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Table 4.5. Average quantification of the relative expression level, by RT-qPCR, of the 
genes that code for efflux pumps in the M. tuberculosis exposed to isoniazid. 
 
The relative expression of the 11 genes was determined by comparison of the relative 
quantity of the respective mRNA in the presence of isoniazid to the non-exposed 
condition. Data was normalized to the M. tuberculosis 16S rDNA reference gene and 
presented as the mean fold change (±SD) compared with the control. Results in bold 
were considered overexpressed. 
 
Table 4.6. Average quantification of the relative expression level, by RT-qPCR, of the 
genes that code for efflux pumps in the M. tuberculosis exposed to rifampicin.  
 
The relative expression of the 11 genes was determined by comparison of the 
relative quantity of the respective mRNA in the presence of rifampicin to the non-
exposed condition. Data was normalized to the M. tuberculosis 16S rDNA reference 
gene and presented as the mean fold change (±SD) compared with the control. 
Results in bold were considered overexpressed. 
 
Gene 
Relative expression level ± SD 
82/09 149/09 286/09 29/12 69/11 294/09 269/03 
mmr 6.29 ± 3.23 2.22 ±0.11 0.78 ± 0.22 1.63 ± 0.16 0.76 ± 0.07 0.64 ± 0.03 0.74 ± 0.04 
mmpl7 0.49 ± 0.38 2.49 ± 0.49 2.23 ± 0.33 4.03 ± 2.87 0.76 ± 0.00 0.83 ± 0.24 0.72 ± 0.21 
Rv1258c 0.79 ± 0.40 1.34 ± 0.26 0.48 ± 0.40 2.22 ± 0.11 0.79 ± 0.30 0.85 ± 0.12 0.64 ± 0.03 
p55 26.06 ± 2.55 1.65 ± 0.92 0.67 ± 0.13 4.04 ± 0.78 0.86 ± 0.41 1.38 ± 0.20 0.69 ± 0.17 
whiB7 3.38 ± 1.29 0.19 ± 0.01 0.71 ± 0.07 0.87 ± 0.00 0.61 ± 0.15 0.67 ± 0.13 2.55 ± 1.32 
1217c 5.94 ± 1.44 0.08 ± 0.01 0.60 ± 0.30 5.12 ± 1.96 0.69 ± 0.17 1.33 ± 0.26 0.62 ± 0.06 
1218c 1.36 ± 0.91 0.04 ± 0.00 0.50 ± 0.00 2.17 ± 0.42 0.44 ± 0.08 1.28 ± 0.06 0.72 ± 0.13 
efpA 10.11 ± 3.82 1.38 ± 0.21 0.80 ± 0.18 1.76 ± 0.34 1.39 ± 0.33 0.81 ± 0.00 1.52 ± 0.15 
Rv2459 0.44 ± 0.15 1.62 ± 0.00 0.44 ± 0.26 1.86 ± 0.63 0.68 ± 0.19 0.73 ± 0.04 0.94 ± 0.09 
pstB 1.54 ±0.66 1.12 ± 0.16  0.49 ± 0.24 1.94 ± 0.28 0.74 ± 0.11 1.08 ± 0.21  0.55 ± 0.11  
iniA 0.26 ± 0.05 0.05 ± 0.00 1.41 ± 0.23 1.53 ± 0.30 0.46 ± 0.02 1.00 ± 0.00 0.38 ± 0.18 
 
Gene 
Relative expression level ± SD 
82/09 149/09 286/09 69/11 29/12 
mmr 1.31 ± 0.62 0.73 ±0.49 2.49 ± 0.49 1.00 ± 0.33 0.71 ± 0.00 
mmpl7 1.85 ± 0.87 0.46 ±0.23 3.23 ± 1.09 0.39 ± 0.08 1.02 ± 0.30 
Rv1258c 1.40 ± 0.66 1.31 ± 0.44 0.94 ± 0.18 0.20 ± 0.03 0.93 ± 0.31 
p55 4.27 ± 1.44 2.30 ± 0.23 9.88 ± 0.97 1.54 ± 0.66 2.59 ± 0.63 
whiB7 0.87 ± 0.29 1.61 ± 0.76 1.04 ± 0.16 2.47 ± 0.24 1.83 ± 0.44 
1217c 0.71 ± 0.07 0.52 ± 0.07 0.98 ± 0.76 0.14 ± 0.08 1.12 ± 0.57 
1218c 0.72 ± 0.40 0.36 ± 0.12 0.69 ± 0.10 0.51 ± 0.05 1.44 ± 0.62 
efpA 1.94 ± 0.09 1.83 ± 0.44 1.41 ± 0.47 1.81 ± 0.27 3.47 ± 1.17 
Rv2459 0.69 ± 0.35 0.41 ± 0.04 0.74 ± 0.04 0.28 ± 0.08 1.08 ± 0.21 
pstB 0.41 ± 0.30 0.46 ± 0.11 0.47 ± 0.04 0.22 ± 0.01 1.41 ± 0.47 
iniA 1.94 ± 0.28 0.89 ± 0.25 54.50 ± 21.35 1.47 ± 0.21 3.11 ± 1.20 
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 This systematic increase in efflux pumps gene expression after isoniazid 
and rifampicin exposure, correlated with increased efflux and antibiotic 
resistance, can occur due two possible mechanisms. First, increase in gene 
expression due to a mutation in a regulatory or promoter region of the efflux-
pump gene leading to constitutive gene expression and second, this increase 
can be due to the induction promoted by the compounds. To clarify which 
inductive mechanism is promoting this overexpression, we searched for 
mutations on the transporters studied. Despite missense and silent mutations in 
the coding regions of these genes, no other mutations were found on putative 
promoter or regulatory regions in these strains (Table 4.7). This indicates that 
the overexpression detected in these strains is induced by the antibiotic 
substrates and is not constitutive.  
 
Table 4.7. Genetic characterization of the efflux transporters studied. 
 
Wt, wild type. 
 
 
Afterwards, we sought to see if the expression of some of these pumps can be 
induced upon macrophage residence. As proof of evidence, we selected one 
multidrug resistant strain, the MTB 82/09, to study the expression of five efflux 
genes, mmr, mmpl7, Rv1258c, p55 and efpA, and determined their expression 
level upon exposure to isoniazid inside macrophages. The results show that 
MTB efflux pumps are also expressed inside the macrophages upon exposure 
to isoniazid (Figure 4.5) demonstrating that MTB drug resistance in 
macrophages is mediated by the expression of pumps that help the bacteria to 
 
Gene 
 Strain 
 82/09 149/09 286/09 69/11 29/12 269/03 294/09 
iniA 
 del GCG after 
nt 285 
wt 
del GCG after 
nt 285 
wt wt wt wt 
Rv1258
c 
 
wt wt wt C194del wt wt wt 
p55  wt Q506 Q506 Q506 Q506 wt Q506 
Rv1217
c 
 
wt A531 A531 
A173T/S204/
A531 
A531 wt wt 
Rv1218
c 
 
wt wt wt Q243R wt wt wt 
pstB  T61M T61M T61M wt T61M wt T61M 
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reduce the intracellular concentration of the antibiotic. Our results are in 
agreement with other previously reported data (Adams et al., 2011, 2014). 
Collectively, these results reinforce the concept that induction of efflux pumps is 
one of the mechanisms involved in drug resistance in MTB. Similar to our 
previous work, here we see that efflux pumps are promiscuous in their activity 
as we could not associate extrusion of isoniazid or rifampicin to a specific pump 
(Machado et al., 2012). Moreover, the results indicate that the compounds are 
not acting on a specific pump but on multiple pumps, and induction of efflux 
pumps seems to be a general stress response to the presence of noxious 
compounds, instead of a specific response of a specific pump. The differences 
observed in the gene expression profiles in each clinical strain most probably 
reflect their history of different antibiotic pressures in the clinical settings.  
 
 
 
Figure 4.5. Relative expression of genes coding for efflux pumps in M. tuberculosis 
82/09 strain during intracellular growth when exposed to isoniazid. 
M. tuberculosis infected macrophages were exposed to 0.1 µg/ml isoniazid during 3 
days. Relative expression of isoniazid-treated cells was compared with untreated 
control cells. 
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4.4.7.   The ion channel blockers possess antibacterial activity against 
intracellular M. tuberculosis. 
Macrophages are phagocytic cells devoted to kill microorganisms. MTB has 
evolved a large and diverse array of virulence factors well suited to interfere 
with or stimulate a variety of host-cell responses in order to invade, survive and 
replicate within macrophages. Therefore compounds to be applied as 
antimicrobials or enhancers of antimycobacterial agents should demonstrate 
activity against intracellular MTB. For this purpose, we examined the 
intracellular activity of VP, FPX, TZ, CPZ, and HAL, and their ability to 
potentiate isoniazid activity, on human monocyte-derived macrophages. 
Isoniazid was chosen due to be one of the most effective anti-tuberculosis 
agents known to date (Mitchison and Davies, 2012). We used one susceptible 
strain, H37Rv, and four isoniazid resistant strains with commonly described 
isoniazid-associated resistance mutations in katG and inhA. The intracellular 
killing activity promoted by the compounds and their combined effect with 
isoniazid after 3 days of infection is presented in Figure 4.6. We found that all 
the compounds impaired growth of intracellular MTB for both wild-type and 
resistant strains while had the highest activity. TZ enhanced the killing of 
mycobacteria by 58 % to 88 %, whereas the remaining compounds 
demonstrated rates of killing of 12 % to 64 % with VP, 37 % to 60 % with CPZ, 
27 % to 43 % with FPX, and 11 % to 37 % with HAL. The co-administration of 
isoniazid with any of the compounds studied in this work conducted to a strong 
enhancement of the killing activity against the H37Rv strain. Conversely, no 
additional killing was observed in the isoniazid-resistant strains when isoniazid 
was used in combination with the compounds, as expected. This result is in 
agreement with the fact that all strains, except H37Rv, harbored a mutation that 
confers isoniazid resistance. Collectively, these results allow us to show that 
VP, FPX, TZ, CPZ, and HAL strengthen the killing activity against intracellular 
MTB. 
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Figure 4.6. Anti-mycobacterial activity of the ion channel blockers on M. tuberculosis infected macrophages. 
Effect of the inhibitors on the intracellular survival of M. tuberculosis within human monocyte-derived macrophages 3 days post infection. INH 
was tested at 0.1 µg/ml, VP, 10 µg/ml; TZ, 2.5 µg/ml; CPZ, 1.25 µg/ml; HAL, 1.25 µg/ml; FPX, 1.25 µg/ml. INH: isoniazid; VP: verapamil; TZ: 
thioridazine; CPZ: chlorpromazine; HAL: haloperidol; FPX: flupenthixol. The results are presented as mean percentage of the survival ± SD 
(*p<0.05; p<0.01) 
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4.4.8.   The ion channel blockers promote intracellular acidification. 
One of the virulence mechanisms of MTB in macrophages is the blockade of 
MTB-containing phagosome maturation into a phagolysosome. Consequently, 
the bacilli will persist within a vacuole that does not acidify neither acquires 
proteolytic enzymes, although even if acquired they would not be active due to 
lack acidification. It was previously demonstrated that restriction of 
mycobacterial growth requires acidification of phagosomes (Jordao et al., 2008; 
Welin et al., 2011).  Since we showed the inhibitors to possess efflux pumps 
inhibitor activity in bacteria, we hypothesized these compounds may have a 
similar ion channel blocker effect directly on the host vacuolar membrane 
inducing phagosome acidification and consequently enhancing macrophage-
mediated killing of mycobacteria. To test this hypothesis, human monocyte-
derived macrophages infected with M. bovis BCG (BCG) expressing GFP were 
treated with the compounds and stained with LysoTracker Red, a 
lysosomotropic probe that emits fluorescence at low pH. We used BCG 
because similarly to MTB, BCG blocks phagosome acidification (Jordao et al., 
2008) while the confocal or flow cytometry analysis of live cells needn’t be 
performed in a BSL-3 environment. In addiction BCG is more sensitive to the 
killing effects of low pH than MTB (Jordao et al., 2008) being a better model to 
sense the killing effects of phagosome acidification. As shown in Figure 4.7, 
comparing control infected cells with ion channel blocker-treated cells, the 
LysoTracker staining revealed an increased co-localization of BCG with acidic 
vesicles. In order to determine if the acidification of BCG-containing 
phagosomes is occurring due to increased phagosome maturation we also 
stained BCG infected macrophages with LAMP-2, a characteristic marker of late 
phagosomes yet we could not observe co-localization of BCG with LAMP-2 
(data not shown) revealing that the ion channel blockers are not increasing 
phagosome maturation and thus, the acidification observed is occurring via an 
independent mechanism.  
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Figure 4.7. Phagosomal acidification in BCG GFP-infected macrophages stained with 
LysoTracker. 
Human macrophages were infected with BCG-GFP and treated thioridazine (TZ) 2.5 
µg/ml. Cells were stained with Lysotracker Red and analyzed by fluorescence 
microscopy. 
 
To further quantify the extent of vesicle acidification in human monocyte-derived 
macrophages we measured the accumulation of Lysotracker Red by flow 
cytometry and Lysosensor Green by fluorescence microscopy. Unlike 
LysoTracker, Lysosensor correlates an increase in fluorescence with a 
decrease in pH. Using this combined strategy we could use flow cytometry to 
quantify the increase in acidic vesicles inside macrophages while using 
fluorescence microscopy to assess if vesicular pH as decreasing.  First we 
analysed the effects of the compounds in non-infected cells. The results 
showed that all the compounds significantly increased the percentage of cells 
stained positive for Lysotracker RED (Figure 4.8A, dot plots). Next, we 
measured the increase on the overall number of Lysotracker RED stained 
vesicles per cell (average fluorescence intensity), and we observed that all the 
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compounds increase the number of stained vesicles (Figure 4.8A, bat plot). In 
both cases, VP, TZ and HAL induced the strongest effects. These results 
clearly show that the compounds are able to induce the increase of acidified 
vesicles in macrophages. Then, we analysed the fluorescence intensity of 
Lysosensor in treated cells (Figure 4.8B). As is observable, treated 
macrophages display a severe increase in fluorescent vesicles. This suggests 
that the ion channel blockers are inducing a general increase of vesicular 
acidification in the macrophages.  Has previously published by our group 
(Jordao et al., 2008), pH alone may have a killing effect on mycobacteria-
containing phagosomes. While BCG is more sensitive to acidification, MTB is 
able to survive, to some extent, in the acidic environment of the phagolysosome 
of activated macrophages and its survival or elimination depends on the ability 
of the macrophage to activate its pH-depended lysosomal hydrolases (Vandal 
et al., 2008). Following this rational, we assessed the impact of pH on the 
survival of MTB in vitro and we observed that MTB is able to persist in an acidic 
environment and that acidification only causes a significant reduction in MTB 
survival in non-physiological pH values (Figure 4.9).  
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Figure 4.8. Relative quantification of phagosomal acidification in BCG GFP-infected 
macrophages stained with LysoTracker or Lysosensor. 
Human macrophages were infected with BCG-GFP and treated with verapamil (VP) 10 
µg/ml, thioridazine (TZ) 2.5 µg/ml, chlorpromazine (CPZ) 1.25 µg/ml, flupenthixol (FPX) 
1.25 µg/ml, and haloperidol (HAL) 1.25 µg/ml, stained with Lysotracker Red and 
analyzed by flow cytometry (A) or with Lysosensor Green and analyzed by 
fluorescence microscopy (B). All treatments were statistically significant (p<0.001). 
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Figure 4.9. Effect of pH on survival of M. tuberculosis H37Rv. 
Cells, at a concentration of 105, were incubated in MB7H9, without Tween 80, at pHs 
from 6.8 to 3.5 during 7 days. CFU was determined with BACTEC MGIT 960 as 
described in Materials and Methods section. 
 
However, the combination of low pH on the phagosomal lumen with other 
antimicrobial factors such as acid-dependent lysosomal hydrolases may render 
MTB far more sensitive to the killing by the host cell. Therefore, we measured 
the activity of cathepsin B, a lysosomal cysteine protease, which enters in the 
phagosome early in its maturation (Sturgill-Koszycki et al., 1996). Increased 
activity of cathepsin B was detected in cultures treated with the compounds 
(Figure 4.10). When compared with the untreated control cultures, cathepsin B 
activity was induced by 21% by VP, 42% by TZ, 33% by CPZ and FPX, and 
32% by HAL, in average regardless the macrophage is infected or not infected. 
These observations indicate that the inhibitors prompted the acidification of the 
phagosomes containing MTB and thus enhanced the proteolytic activity of 
cathepsin B. These results show that phagosome acidification is important for 
the function of degradative hydrolases as well other phagosomal functions, as 
previously suggested (Vandal et al., 2008). 
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Figure 4.10. Determination of cathepsin B activity. 
Human monocyte-derived macrophages were treated with verapamil, thioridazine, 
chlorpromazine, flupenthixol, and haloperidol. Cathepsin activity was evaluated also 
with cultures infected with M. tuberculosis H37Rv and treated with the compounds. VP 
was tested at 10 µg/ml; TZ at 2.5 µg/ml; CPZ at 1.25 µg/ml; HAL at 1.25 µg/ml; FPX at 
1.25 µg/ml. INH: isoniazid; VP: verapamil; TZ: thioridazine; CPZ: chlorpromazine; HAL: 
haloperidol; FPX: flupenthixol (*p< 0.05; **p<0.01). 
 
 
4.4.9.   Multidrug resistant M. tuberculosis strains demonstrate enhanced 
fitness. 
We observed that the activity of the compounds was influenced by the genotype 
and fitness of the strains.  Accordingly, we characterized the genotype of these 
strains and evaluated the growth patterns in vitro and ex vivo as indicators of 
fitness. Five strains were found to belong to LAM genotype: two belonging to 
cluster Q1, two from cluster Lisboa3, and one non-clustered strain; one Beijing 
strain, and one strain with a non-defined genotype (Table 4.1). This strain was 
further analyzed at SITVITWEB database and the corresponding MIRU12-
VNTR pattern was designated as VNTR international type (VIT) number 21. 
Next, we determined the growth rates for all strains grown in liquid media. First, 
we examined the time necessary for the strains to adapt to a new environment 
in liquid culture starting with a well-defined inoculum. In general, except strains 
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286/09 and 69/11, all grow slightly faster when compared with the control strain, 
H37Rv (Figure 4.11). The isolates 286/09 and 69/11 grow relatively slower than 
all others strains. Second, we evaluate the growth rate, i.e., the time necessary 
to reach 400 GU (the acceleration phase). All strains demonstrated similar 
growth rates, except strains belonging to cluster Q1 (149/09 and 29/12) and the 
isoniazid resistant strain 294/09. We observed that strains belonging to cluster 
Q1 take more time to reach the same growth units than strains from cluster 
Lisboa3 and Beijing, and less than H37Rv (Figure 4.11). Strain 294/09 showed 
a dramatically slower replication rate when compared with the other strains with 
the same mutation. Whilst 294/09 is resistant just to isoniazid, the other strains 
are multidrug resistant. Collectively, the results show that multidrug resistant 
strains included in this study have a similar ability to adapt to a new 
environment but differ in their growth rates in vitro. 
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Figure 4.11. In vitro determination of the fitness of the M. tuberculosis strains. 
A) Comparison between the capacities of the strains to adapt to a new environment 
measured as the time to reach the positivity threshold of 75 GU; B) Relative growth 
rates determined as the ratio between the growth rate of each strain and the growth 
rate of the control strain. The growth rates which were based on the time to detection 
between 75 and 400 GU. 
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Next, we evaluate the ability of some of these strains to grow inside 
macrophages as a surrogate of intracellular fitness. For that, human monocyte-
derived macrophages were infected with multidrug resistant strains belonging to 
cluster Lisboa3 and Q1, the isoniazid monoresistant strains 294/09, 269/03, and 
the H37Rv katG deletion mutant. As a control, we used the H37Rv reference 
strain. We found that the MTB multidrug resistant strains have enhanced fitness 
when compared with susceptible or monoresistant strains. As can be observed 
in Figure 4.12, both strains grew more quickly in macrophages than all other 
strains. At the end of five days, the number of viable bacteria was significantly 
higher than the one reached by the susceptible strain H37Rv. Moreover, H37Rv 
was able to replicate much faster than the isoniazid monoresistant strains. 
Regarding H37RvΔkatG, this strain is highly resistant to isoniazid in vitro and 
does not have catalase activity (data not shown). We observed that this strain 
have reduced ability to survive in human macrophages. However, katG deletion 
mutants can cause disease in humans. One possible explanation is that the 
bacteria can acquire compensatory mutations to resist to oxidative burst in vivo 
(Sherman et al., 1996). We also observed a reduction of the fitness of the strain 
with mutation katG315. Strain 269/03 retains catalase activity and demonstrates 
a physiological cost inside macrophages. katG315 is the most common 
isoniazid resistance-conferring mutation found in clinical settings. Although, it is 
assumed that strains with katG315 can maintain katG activity and virulence in 
mice without significant loss of fitness (Pym et al., 2002b), others show that the 
MTB strains with katG315 mutation are less fit on murine macrophages (Rey-
Jurado et al., 2011). It has been shown that the genetic background of a strain 
influences the fitness of drug-resistant MTB (Gagneux et al., 2006). Altogether, 
it thus seems that intracellular fitness of the MTB strains varies according to 
their resistant pattern and the mutations associated and the multidrug resistant 
strains studied showed an increased replication rate inside macrophages 
indicating a higher fitness for strains with this genotype. Furthermore, 
overexpression of efflux pumps was more evident on multidrug resistant strains 
than in isoniazid monoresistant strains and the compounds shown to be more 
effective on the multidrug resistant strains. From these results we establish 
association between drug resistance, the genetic background and 
overexpression of efflux pumps.  
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Figure 4.12. Growth rate of M. tuberculosis strains in human monocyte-derived 
macrophages during a 5 days period. 
CFU were determined after 3h and 1, 3 and 5 days post infection. 
 
4.4.10.   Ion channel blockers increase the viability of MTB-infected human 
macrophages 
In order to evaluate the cytotoxicity of the inhibitors in human macrophages we 
measured their metabolic activity by quantifying the reduction of resazurin to 
resorufin through fluorescence emission. Our results show that the inhibitors 
possess diferent cytotoxic profiles (Figure 4.13A), measured after 3 days of 
treatment, with CPZ and FPX being the most toxic by showing a reduction of 
more than 50% of the viability with 5 g/ml treatment, and VP the less toxic 
displaying no significant toxicity in concentrations as high as 10 g/ml. Overall 
the concentrations used for the intracellular killing of mycobacteria and for 
promoting acidification of intracellular vesicles resulted in no decrease in 
macrophage viability. In fact, during the infection with H37Rv, the inhibitors 
actually improved macrophage viability (Figure 4.13B) by almost approximately 
20%. From these results we conclude that small concentrations of the inhibitors 
not only enhance mycobacterial killing and promote vesicle acification and 
proteolysis, they also improve the viability of MTB-infected macrophages. 
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Figure 4.13. Effect of the ion channel blockers on macrophage viability. 
Macrophage viability was measured by fluorescence quantification of resazurin 
reduction in uninfected macrophages (A) after 3 days of treatment with several 
concentrations of the inhibitors or in H37Rv infected macrophages (B) treated with VP 
at 10 µg/ml; TZ, 2.5 µg/ml; CPZ, 1.25 µg/ml; HAL, 1.25 µg/ml; FPX, 1.25 µg/ml. VP, 
verapamil; TZ, thioridazine; CPZ, chlorpromazine; HAL, haloperidol; FPX, flupenthixol. 
Values are depicted relative to uninfected untreated control. 
 
4.5.   Discussion 
The global emergence of multi- and extensively drug resistant tuberculosis has 
hampered the perspectives of tuberculosis control and elimination. Multidrug-
resistant tuberculosis requires a prolonged treatment with second line drugs 
that are less effective and more toxic. In addition, for extensively drug resistant 
tuberculosis the chances to achieve treatment success are further reduced. The 
therapeutic options for these patients can be limited to second-line oral 
bacteriostatic agents and to drugs with questionable reliability and 
reproducibility known as WHO Group V (WHO, 2008). Therefore, there is an 
urgent need for the identification of compounds with different mechanisms of 
action that can be used in combination with the existing anti-tuberculosis drugs 
in order to shorten the treatment. Some new drugs have been developed in the 
latest years and they demonstrated potential to achieve this objective (Rivers 
and Mancera, 2008). However, they are still limited in number emphasizing the 
need for new approaches. In this study, we provide evidence that VP, FPX, TZ, 
CPZ, and HAL act synergistically with the main first line antibiotics to restrict 
MTB growth either drug susceptible or resistant strains. However, they were not 
able to restore full drug susceptibility. Nevertheless, they substantially assist in 
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the reduction of the resistance level to the antibiotics and, by this manner, 
potentiate their activity. This evidence was confirmed by time-kill studies 
through which we were able to demonstrate that these compounds are capable 
to prevent the emergence of resistance and preserve the activity of the co-
administered antibiotics. Besides, the low mutation frequencies determined for 
each ion channel blocker tested (10-10-10-11) indicate that they are less subject 
to acquire spontaneous mutations for resistance. Assuming that the MTB 
burden in the lungs is around 108-109 and the mutations rates for isoniazid and 
rifampicin are approximately 10-8 and 10-10 (David, 1970), respectively, the ion 
channel blockers when combined with anti-tuberculosis drugs currently in use, 
will reduce the probability of development of spontaneous mutations during 
tuberculosis drug therapy.  
At this moment we do not know the exact mechanism or the assembly of 
mechanisms by which these inhibitors act as antimicrobial agents against MTB. 
We observed that all compounds lead to a significant decrease in the 
intracellular mycobacterial load as result of phagosome acidification inducement 
and enhanced activation of lysosomal hydrolases. Our previous research has 
lead us to propose that the enhancement of the killing activity of macrophages 
by these type of compounds was dependent upon the availability of potassium 
and calcium ions (Amaral et al., 2007; Martins et al., 2008; Viveiros et al., 
2012). The inhibition of the transport of calcium and potassium on the 
phagosome promote the accumulation of these ions, by diffusion from the 
cytoplasm into the phagosome. The role of calcium in phagocytosis is 
controversial, yet in the specific case of phagosome maturation, there are 
considerable evidences showing the need of cytosolic calcium increase for this 
process to occur (Nunes and Demaurex, 2010). In fact, several studies have 
shown that in MTB-infected macrophages this rise in calcium levels fails to 
occurs, correlating with the arrest of phagosome-lysosome fusion (Malik et al., 
2000, 2001, 2003; Thompson et al., 2005). Moreover, phagosomal acidification 
due to increased V-ATPase expression was recently proposed to be negatively 
controlled by the Abelson (Abl) tyrosine kinase (Bruns et al., 2012). Tyrosine 
kinase expression is dependent on calcium influx, partially through L-type 
channels (Raymond and Millhorn, 1997), thus the impact of calcium on tyrosine 
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inhibition can be associated with a decrease in the intracellular ATP availability 
and the increase of the expression of V-ATPase. This increase of phagosome 
acidification and calcium concentration in the cytosol would altogether result in 
phagosome maturation and enhanced bacterial killing (Bruns et al., 2012; 
Napier et al., 2011).  
Our results in vitro show that the ion-channel blockers are good anti-
mycobacterial agents, especially when used in combination with anti-
tuberculosis drugs, indicating that they interfere directly with the bacteria. In 
eukaryotic cells it is known that these drugs act by blocking receptors for 
neurotransmitters such as dopamine and their neuroleptic activity is attributed to 
their role on the mitochondrial electron transport chain; HAL and CPZ inhibit the 
mitochondrial NADH: ubiquinone oxidoreductase (complex I) (Balijepalli et al., 
1999). In MTB it is believed that phenotiazines also inhibit one of the key 
enzymes of the mycobacterial respiratory chain, the type II NADH: 
menaquinone oxidoreductase (NDH-2) (Warman et al., 2013; Weinstein et al., 
2005), also called as alternative NADH dehydrogenase (Kerscher, 2000). MTB 
possesses two NADH dehydrogenases: the NDH-1, encoded by the nuo 
operon, which is non-essential in MTB (Rao et al., 2008) and, the non-proton-
translocating NDH-2, encoded by the ndh gene, which is essential for MTB 
survival (Miesel et al., 1998). NDH-1 is an equivalent of mitochondrial complex 
I, while NDH-2 is a single subunit enzyme with NADH/quinol oxidoreductase 
activity (Yano et al., 2006). In MTB, energy generation is mainly performed by 
NDH-2 (Rao et al., 2008) whereas NDH-1 is mostly implicated on anti-apoptotic 
activity of host cells and, not on its original function of generation of energy 
(Velmurugan et al., 2007). Rao et al. (2008) established a link between NDH-2 
and the proton motive force (PMF) through the demonstration that the inhibition 
of NDH-2 by TZ dissipates the membrane potential. Since TZ and CPZ act as 
partial uncouplers of oxidative phosphorylation in mitochondria (Modica-
Napolitano et al., 2003) and besides their inhibitory effect on NDH-2 they also 
act as uncoplers of oxidative phosphorylation in Staphylococcus aureus 
(Schurig-Briccio et al., 2014), it is expected that they indirectly promote the 
collapse of PMF. Uncouplers of oxidative phosphorylation are able to transport 
protons across biological membranes (Gage and Neidhardt, 1993). By 
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transporting protons down the electrochemical potential gradient, these agents 
collapse PMF. The collapse of PMF has detrimental effects on the bacterial cell 
such as increased production of reactive oxygen species (ROS), inhibition of 
ATP synthesis (without affecting the respiratory chain and ATP synthase), and 
disruption of calcium homeostasis.  
All the compounds tested were able to promote intracellular accumulation of 
ethidium bromide, a broad substrate for PMF dependent efflux pumps, in both 
drug susceptible and resistant strains. Hence, we can conclude that ethidium 
bromide accumulation promoted by the ion channel blockers is a result of efflux 
pump inhibition caused by dissipation of PMF. This was previously shown in our 
studies with susceptible and antibiotic-adapted MTB strains (Machado et al., 
2012) and in this study it is now demonstrated, for the first time, on MTB 
multidrug resistant clinical strains. Moreover, we showed that several efflux 
pumps are induced upon exposure to isoniazid and rifampin in these multi- and 
extensively drug resistant clinical strains. We have detected a general and 
marked expression of almost all efflux genes tested, which is consistent with a 
stress response to a hostile environment. Afterwards, we sought to see if some 
of these pumps are also expressed within the macrophage. We found that some 
of the efflux genes were expressed inside macrophage upon drug exposure 
mimicking the inducible adaptative response seen in vitro. Using the zebrafish 
larval model, Adams et al. (2011) demonstrated that drug-tolerant bacteria 
originate in macrophages dependent on the inducible overexpression and 
activity of bacterial efflux pumps. In their model a bacterial subpopulation 
tolerant to drugs arise after few days post-infection, in response to host 
defenses, by the inducement of bacterial efflux pumps, that rendered the 
bacteria tolerant to several anti-tuberculosis drugs (Adams et al., 2011, 2014), 
further strengthening the importance of these findings to the design of rational 
strategies to prevent the emergence of drug resistance in MTB. Furthermore, 
during infection, pathogens like MTB have developed strategies to neutralize 
NADPH oxidase function and inhibit phagosomal generation of ROS. 
Velmurugan et al. (Velmurugan et al., 2007) identified nuoG gene of MTB, 
which encodes a subunit of the NADH dehydrogenase type I, as an anti-
apoptotic gene in MTB. Therefore, a complete functional NDH-1 complex 
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mediates the anti-apoptotic properties of the bacteria (Velmurugan et al., 2007). 
We hypothesize that the disruption the membrane potential triggered by the 
compounds, will lead to the impairment of the respiratory chain, promoting 
apoptosis during infection. It is not clear whether the inhibition promoted by the 
compounds is due to their interaction with specific target or is just a 
consequence of the dissipation of membrane potential. We have tried to obtain 
mutants for these compounds in an attempt to identify their target. So far, we 
were unable to isolate such mutants. The reason for this can be related with the 
reduced mutation rates for these compounds and also with essentiality of their 
putative targets as it is the case of ndh and the phenothiazines. Further 
analyses are under way to explore this subject.  
These compounds have been used for years as antipsychotics and anti-
hypertensives, are affordable and, can be taken as oral formulation. Several 
other drugs whose mechanism of action is known to affect mycobacterial 
metabolic energy and respiration are now in the pipeline. These include 
bedaquiline, an ATP synthase inhibitor (de Jonge et al., 2007b; Koul et al., 
2007), and PA-824 and demalanid, which targets cytochrome oxidase 
(Manjunatha et al., 2009). although HAL, TZ and CPZ are widely used for the 
treatment of psychosis, these compounds have significant toxic effects on 
mitochondrial bioenergetics function, which may result in serious tardive 
dyskinesia and Parkinson-like disease (Balijepalli et al., 1999; Modica-
Napolitano et al., 2003) and cardiotoxicity (Glassman and Bigger, 2001). As 
such, caution should be taken when design new compounds that target the 
respiratory chain, since that due to the impairment of the oxidative 
phosphorylation, mitochondria became unable to meet the energetic needs of 
cell. On the other hand, VP is shown to be extremely well tolerated with few 
side-effects documented (Singh et al., 1978). The significant differences 
observed in the effective concentrations of the ion-channel blockers required to 
inhibit MTB in vitro versus that needed to produce similar effects on 
macrophages indicates an interaction that involves the biochemical mechanism 
underlying the inhibitory effect of the drugs within the bacteria, the ability of the 
macrophages to concentrate the compounds (Ordway et al., 2003) so they can 
reach therapeutic concentrations, and the consequences of the stimulation of 
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macrophage bactericidal mechanisms, which altogether result in the elimination 
of the bacteria. The activity of VP, TZ, CPZ, FPX, and HAL against drug 
resistant MTB at concentrations usually reached in human serum when they are 
employed clinically was demonstrated. The results presented in this study 
enable us to propose the following mechanism of action for these compounds: 
a) in the bacteria: after entering the cell the compounds will generate a cascade 
of events which starts with the inhibition of the respiratory chain complexes, 
though we cannot say at the present moment if the respiratory chain is a direct 
target. The inhibition of the respiratory chain will lead to i) dissipation of 
membrane potential; ii) reduction of ATP levels; iii) ROS generation; iv) increase 
in intracellular calcium levels; and v) cell death; b) on the host cell, the 
treatment with the inhibitors will result in phagosome acidification that will 
synergize with several components of the host immune response, such as 
lysosomal hydrolases and reactive oxygen and nitrogen species leading to 
bacterial growth restriction. Furthermore the blocking on ion channels will 
stabilize the MTB infected cells (Mishra et al., 2010) consequently leading to 
lower necrotic cell death of infected macrophages and lower escape of 
intracellular bacilli from the hydrolytic activity of the phagolysosome. 
Ongoing work aims to test these hypotheses and determine the exact 
mechanism by which these compounds can eliminate MTB. Furthermore, it will 
be interesting to evaluate the impact of the genotype of the strains studied on 
their capacity to trigger the mechanisms described above. MTB strains of the 
Latino-American-Mediterranean (LAM) genotype, specifically the Lisboa3 and 
Q1 clusters, is the main genotype circulating in Lisbon (Perdigão et al., 2008). 
Our study provides evidence that strains from both clusters interact differently 
with the host, when compared with the other strains. Strains from Lisboa3 and 
Q1 clusters demonstrated enhanced fitness inside macrophages. Additionally, 
the experimental procedures used in this study can be applied to characterize 
and evaluate the bactericidal activity and efficacy of any combination of 
compounds and antibiotics. In conclusion, our study should provide valuable 
information for the improvement of known drugs and for the design and 
development of new ones. Such increased knowledge will allow for better 
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epidemiological predictions and assist in the development of new therapeutic 
strategies to fight drug resistant tuberculosis.  
 
4.6.   Acknowledgments 
This work was supported by grants PTDC-SAU-FCF-102807-2008 and 
PTDC/BIA-MIC/121859/2010, and partially supported by grants PTDC/SAU-
MII/098024/2008 and PTDC/BIA-BCM/102123/2008 from Fundação para a 
Ciência e a Tecnologia (FCT, Portugal). D. Machado, D. Pires, and J. Perdigão 
were supported by grants SFRH/BD/65060/2009, SFRH/BD/63747/2009, and 
SFRH/BD/45388/2008, respectively, from FCT.  
 
4.7.   References 
Abbate, E., Vescovo, M., Natiello, M., Cufré, M., García, A., Montaner, P.G., Ambroggi, M., 
Ritacco, V., and Van soolingen, D. (2012). Successful alternative treatment of 
extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, 
moxifloxacin and thioridazine. J. Antimicrob. Chemother. 67, 473–477. 
Adams, K.N., Takaki, K., Connolly, L.E., Wiedenhoft, H., Winglee, K., Humbert, O., 
Edelstein, P.H., Cosma, C.L., and Ramakrishnan, L. (2011). Drug tolerance in 
replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145, 
39–53. 
Adams, K.N., Szumowski, J.D., and Ramakrishnan, L. (2014). Verapamil, and its metabolite 
norverapamil, inhibit macrophage-induced, bacterial efflux pump-mediated tolerance to 
multiple anti-tubercular drugs. J. Infect. Dis. 210, 456–466. 
Allix-Béguec, C., Harmsen, D., Weniger, T., Supply, P., and Niemann, S. (2008). Evaluation 
and strategy for use of MIRU-VNTRplus, a multifunctional database for online analysis of 
genotyping data and phylogenetic identification of Mycobacterium tuberculosis complex 
isolates. J. Clin. Microbiol. 46, 2692–2699. 
Amaral, L., Kristiansen, J.E., Abebe, L.S., and Millett, W. (1996). Inhibition of the respiration 
of multi-drug resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: 
potential use for initial therapy of freshly diagnosed tuberculosis. J. Antimicrob. 
Chemother. 38, 1049–1053. 
Amaral, L., Martins, M., and Viveiros, M. (2007). Enhanced killing of intracellular multidrug-
resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux 
pumps. J. Antimicrob. Chemother. 59, 1237–1246. 
Balijepalli, S., Boyd, M.R., and Ravindranath, V. (1999). Inhibition of mitochondrial complex I 
by haloperidol: The role of thiol oxidation. Neuropharmacology 38, 567–577. 
Böttger, E.C. (2011). The ins and outs of Mycobacterium tuberculosis drug susceptibility 
testing. Clin. Microbiol. Infect. 17, 1128–1134. 
Bruns, H., Stegelmann, F., Fabri, M., Döhner, K., van Zandbergen, G., Wagner, M., 
Skinner, M., Modlin, R.L., and Stenger, S. (2012). Abelson tyrosine kinase controls 
phagosomal acidification required for killing of Mycobacterium tuberculosis in human 
macrophages. J. Immunol. 189, 4069–4078. 
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
234 
Canetti, G., Froman, S., Grosset, J., Hauduroy, P., Langerova, M., Mahler, H.T., Meissner, 
G., Mitchison, D.A., and Sula L (1963). Mycobacteria: Laboratory Methods for Testing 
Drug Sensitivity and Resistance. Bull. World Health Organ. 29, 565–578. 
David, H.L. (1970). Probability distribution of drug-resistant mutants in unselected populations 
of Mycobacterium tuberculosis. Appl. Microbiol. 20, 810–814. 
David, H.L. (1989). Méthodes de laboratoire pour mycobactériologie clinique. (Paris, France: 
Institut Pasteur). 
Demay, C., Liens, B., Burguière, T., Hill, V., Couvin, D., Millet, J., Mokrousov, I., Sola, C., 
Zozio, T., and Rastogi, N. (2012). SITVITWEB - A publicly available international 
multimarker database for studying Mycobacterium tuberculosis genetic diversity and 
molecular epidemiology. Infect. Genet. Evol. 12, 755–766. 
Filippini, P., Iona, E., Piccaro, G., Peyron, P., Neyrolles, O., and Fattorini, L. (2010). Activity 
of drug combinations against dormant Mycobacterium tuberculosis. Antimicrob. Agents 
Chemother. 54, 2712–2715. 
Gage, D.J., and Neidhardt, F.C. (1993). Adaptation of Escherichia coli to the uncoupler of 
oxidative phosphorylation 2,4-dinitrophenol. J. Bacteriol. 175, 7105–7108. 
Gagneux, S., Burgos, M. V., DeRiemer, K., Enciso, A., Muñoz, S., Hopewell, P.C., Small, 
P.M., and Pym, A.S. (2006). Impact of bacterial genetics on the transmission of isoniazid-
resistant Mycobacterium tuberculosis. PLoS Pathog. 2, 0603–0610. 
Ginsberg, A.M. (2010). Drugs in development for tuberculosis. Drugs 70, 2201–2214. 
Glassman, A.H., and Bigger, J.T. (2001). Antipsychotic drugs: prolonged QTc interval, torsade 
de pointes, and sudden death. Am. J. Psychiatry 158, 1774–1782. 
Gullberg, E., Cao, S., Berg, O.G., Ilbäck, C., Sandegren, L., Hughes, D., and Andersson, 
D.I. (2011). Selection of resistant bacteria at very low antibiotic concentrations. PLoS 
Pathog. 7, e1002158. 
Gupta, S., Salam, N., Srivastava, V., Singla, R., Behera, D., Khayyam, K.U., Korde, R., 
Malhotra, P., Saxena, R., and Natarajan, K. (2009). Voltage gated calcium channels 
negatively regulate protective immunity to Mycobacterium tuberculosis. PLoS One 4. 
Gupta, S., Tyagi, S., Almeida, D. V, Maiga, M.C., Ammerman, N.C., and Bishai, W.R. (2013). 
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux 
inhibitor. Am. J. Respir. Crit. Care Med. 188, 600–607. 
Gupta, S., Cohen, K.A., Winglee, K., Maiga, M., Diarra, B., and Bishai, W.R. (2014). Efflux 
inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. 
Antimicrob. Agents Chemother. 58, 574–576. 
Hofmann-Thiel, S., Van Ingen, J., Feldmann, K., Turaev, L., Uzakova, G.T., Murmusaeva, 
G., Van Soolingen, D., and Hoffmann, H. (2009). Mechanisms of heteroresistance to 
isoniazid and rifampin of Mycobacterium tuberculosis in Tashkent, Uzbekistan. Eur. 
Respir. J. 33, 368–374. 
De Jonge, M.R., Koymans, L.H.M., Guillemont, J.E.G., Koul, A., and Andries, K. (2007). A 
computational model of the inhibition of Mycobacterium tuberculosis ATPase by a new 
drug candidate R207910. Proteins 67, 971–980. 
Jordao, L., Bleck, C.K.E., Mayorga, L., Griffiths, G., and Anes, E. (2008). On the killing of 
mycobacteria by macrophages. Cell. Microbiol. 10, 529–548. 
Kerscher, S.J. (2000). Diversity and origin of alternative NADH:ubiquinone oxidoreductases. 
Biochim. Biophys. Acta - Bioenerg. 1459, 274–283. 
Koul, A., Dendouga, N., Vergauwen, K., Molenberghs, B., Vranckx, L., Willebrords, R., 
Ristic, Z., Lill, H., Dorange, I., Guillemont, J., et al. (2007). Diarylquinolines target 
subunit c of mycobacterial ATP synthase. Nat. Chem. Biol. 3, 323–324. 
Leung, E.T.Y., Ho, P.L., Yuen, K.Y., Woo, W.L., Lam, T.H., Kao, R.Y., Seto, W.H., and Yam, 
W.C. (2006). Molecular characterization of isoniazid resistance in Mycobacterium 
tuberculosis: Identification of a novel mutation in inhA. Antimicrob. Agents Chemother. 50, 
1075–1078. 
Livak, K.J., and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25, 402–408. 
Chapter 4:   Ion channel blockers act as antimicrobial agents and enhancers of macrophage 
killing activity against drug resistant Mycobacterium tuberculosis 
235 
Lorian, V. (1996). Antibiotics in laboratory medicine (Baltimore, USA: Lippincott Williams & 
Wilkins). 
Louw, G.E., Warren, R.M., Gey van Pittius, N.C., McEvoy, C.R.E., Van Helden, P.D., and 
Victor, T.C. (2009). A balancing act: efflux/influx in mycobacterial drug resistance. 
Antimicrob. Agents Chemother. 53, 3181–3189. 
Louw, G.E., Warren, R.M., Gey van Pittius, N.C., Leon, R., Jimenez, A., Hernandez-Pando, 
R., McEvoy, C.R.E., Grobbelaar, M., Murray, M., van Helden, P.D., et al. (2011). 
Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium 
tuberculosis through efflux. Am. J. Respir. Crit. Care Med. 184, 269–276. 
Machado, D., Couto, I., Perdigão, J., Rodrigues, L., Portugal, I., Baptista, P., Veigas, B., 
Amaral, L., and Viveiros, M. (2012). Contribution of efflux to the emergence of isoniazid 
and multidrug resistance in Mycobacterium tuberculosis. PLoS One 7, e34538. 
Machado, L., Spengler, G., Evaristo, M., Handzlik, J., Molnár, J., Viveiros, M., Kiec-
Kononowicz, K., and Amaral, L. (2011). Biological activity of twenty-three hydantoin 
derivatives on intrinsic efflux pump system of Salmonella enterica serovar Enteritidis 
NCTC 13349. In Vivo 25, 769–772. 
Malik, Z.A., Denning, G.M., and Kusner, D.J. (2000). Inhibition of Ca(2+) signaling by 
Mycobacterium tuberculosis is associated with reduced phagosome-lysosome fusion and 
increased survival within human macrophages. J. Exp. Med. 191, 287–302. 
Malik, Z.A., Iyer, S.S., and Kusner, D.J. (2001). Mycobacterium tuberculosis phagosomes 
exhibit altered calmodulin-dependent signal transduction: contribution to inhibition of 
phagosome-lysosome fusion and intracellular survival in human macrophages. J. 
Immunol. 166, 3392–3401. 
Malik, Z.A., Thompson, C.R., Hashimi, S., Porter, B., Iyer, S.S., and Kusner, D.J. (2003). 
Cutting edge: Mycobacterium tuberculosis blocks Ca2+ signaling and phagosome 
maturation in human macrophages via specific inhibition of sphingosine kinase. J. 
Immunol. 170, 2811–2815. 
Manjunatha, U., Boshoff, H.I., and Barry, C.E. (2009). The mechanism of action of PA-824: 
Novel insights from transcriptional profiling. Commun. Integr. Biol. 2, 215–218. 
Martins, M., Viveiros, M., and Amaral, L. (2008). Inhibitors of Ca2+ and K+ transport enhance 
intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 22, 69–75. 
Miesel, L., Weisbrod, T.R., Marcinkeviciene, J.A., Bittman, R., and Jacobs, W.R. (1998). 
NADH dehydrogenase defects confer isoniazid resistance and conditional- lethality in 
Mycobacterium smegmatis. J. Bacteriol. 180, 2459–2467. 
Mishra, B.B., Moura-Alves, P., Sonawane, A., Hacohen, N., Griffiths, G., Moita, L.F., and 
Anes, E. (2010). Mycobacterium tuberculosis protein ESAT-6 is a potent activator of the 
NLRP3/ASC inflammasome. Cell. Microbiol. 12, 1046–1063. 
Mitchison, D., and Davies, G. (2012). The chemotherapy of tuberculosis: past, present and 
future. Int J Tuberc Lung Dis 16, 724–732. 
Modica-Napolitano, J.S., Lagace, C.J., Brennan, W.A., and Aprille, J.R. (2003). Differential 
effects of typical and atypical neuroleptics on mitochondrial function in vitro. Arch. Pharm. 
Res. 26, 951–959. 
Morlock, G.P., Metchock, B., Sikes, D., Crawford, J.T., and Cooksey, R.C. (2003). ethA, 
inhA, and katG Loci of Ethionamide-Resistant Clinical Mycobacterium tuberculosis 
Isolates. Antimicrob. Agents Chemother. 47, 3799–3805. 
Napier, R.J., Rafi, W., Cheruvu, M., Powell, K.R., Zaunbrecher, M.A., Bornmann, W., 
Salgame, P., Shinnick, T.M., and Kalman, D. (2011). Imatinib-Sensitive tyrosine kinases 
regulate mycobacterial pathogenesis and represent therapeutic targets against 
tuberculosis. Cell Host Microbe 10, 475–485. 
Nunes, P., and Demaurex, N. (2010). The role of calcium signaling in phagocytosis. J. Leukoc. 
Biol. 88, 57–68. 
Ordway, D., Viveiros, M., Leandro, C., Bettencourt, R., Almeida, J., Martins, M., 
Kristiansen, J.E., Molnar, J., and Amaral, L. (2003). Clinical concentrations of 
thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob. 
Agents Chemother. 47, 917–922. 
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
236 
Perdigão, J., Macedo, R., João, I., Fernandes, E., Brum, L., and Portugal, I. (2008). 
Multidrug-resistant tuberculosis in Lisbon, Portugal: a molecular epidemiological 
perspective. Microb. Drug Resist. 14, 133–143. 
Perdigão, J., Macedo, R., Silva, C., Machado, D., Couto, I., Viveiros, M., Jordao, L., and 
Portugal, I. (2013). From multidrug-resistant to extensively drug-resistant tuberculosis in 
Lisbon, Portugal: The stepwise mode of resistance acquisition. J. Antimicrob. Chemother. 
68, 27–33. 
Pym, A.S., Saint-Joanis, B., and Cole, S.T. (2002). Effect of katG mutations on the virulence 
of Mycobacterium tuberculosis and the implication for transmission in humans. Infect. 
Immun. 70, 4955–4960. 
Rao, S.P.S., Alonso, S., Rand, L., Dick, T., and Pethe, K. (2008). The protonmotive force is 
required for maintaining ATP homeostasis and viability of hypoxic, nonreplicating 
Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 105, 11945–11950. 
Raymond, R., and Millhorn, D. (1997). Regulation of tyrosine hydroxylase gene expression 
during hypoxia: role of Ca2+ and PKC. Kidney Int. 51, 536–541. 
Rey-Jurado, E., Tudó, G., Borrell, S., Alcaide, F., Coll, P., Español, M., Martín-Casabona, 
N., Mick, V., Montemayor, M., Moure, R., et al. (2011). Impaired fitness of 
Mycobacterium tuberculosis resistant isolates in a cell culture model of murine 
macrophages. J. Antimicrob. Chemother. 66, 2277–2280. 
Rivers, E.C., and Mancera, R.L. (2008). New anti-tuberculosis drugs in clinical trials with novel 
mechanisms of action. Drug Discov Today 13, 1090–1098. 
Rodrigues, L., Machado, D., Couto, I., Amaral, L., and Viveiros, M. (2012). Contribution of 
efflux activity to isoniazid resistance in the Mycobacterium tuberculosis complex. Infect. 
Genet. Evol. 12, 695–700. 
Schurig-Briccio, L.A., Yano, T., Rubin, H., and Gennis, R.B. (2014). Characterization of the 
type 2 NADH:menaquinone oxidoreductases from Staphylococcus aureus and the 
bactericidal action of phenothiazines. Biochim. Biophys. Acta - Bioenerg. 1837, 954–963. 
Sherman, D.R., Mdluli, K., Hickey, M.J., Arain, T.M., Morris, S.L., Barry, C.E., and Stover, 
C.K. (1996). Compensatory ahpC gene expression in isoniazid-resistant Mycobacterium 
tuberculosis. Science 272, 1641–1643. 
Silva, P.E., Bigi, F., Santangelo, M.P., Romano, M.I., Martín, C., Cataldi, A., and Aínsa, J.A. 
(2001). Characterization of P55, a multidrug efflux pump in Mycobacterium bovis and 
Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 45, 800–804. 
Singh, B.N., Ellrodt, G., and Peter, C.T. (1978). Verapamil: a review of its pharmacological 
properties and therapeutic use. Drugs 15, 169–197. 
Van Soolingen, D., Hernandez-Pando, R., Orozco, H., Aguilar, D., Magis-Escurra, C., 
Amaral, L., Van Ingen, J., and Boeree, M.J. (2010). The antipsychotic thioridazine shows 
promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS 
One 5, 1–6. 
Springer, B., Lucke, K., Calligaris-Maibach, R., Ritter, C., and Böttger, E.C. (2009). 
Quantitative drug susceptibility testing of Mycobacterium tuberculosis by use of MGIT 960 
and EpiCenter instrumentation. J. Clin. Microbiol. 47, 1773–1780. 
Sturgill-Koszycki, S., Schaible, U.E., and Russell, D.G. (1996). Mycobacterium-containing 
phagosomes are accessible to early endosomes and reflect a transitional state in normal 
phagosome biogenesis. EMBO J. 15, 6960–6968. 
Supply, P., Allix, C., Lesjean, S., Cardoso-Oelemann, M., Rüsch-Gerdes, S., Willery, E., 
Savine, E., De Haas, P., Van Deutekom, H., Roring, S., et al. (2006). Proposal for 
standardization of optimized mycobacterial interspersed repetitive unit-variable-number 
tandem repeat typing of Mycobacterium tuberculosis. J. Clin. Microbiol. 44, 4498–4510. 
Thompson, C.R., Iyer, S.S., Melrose, N., VanOosten, R., Johnson, K., Pitson, S.M., Obeid, 
L.M., and Kusner, D.J. (2005). Sphingosine kinase 1 (SK1) is recruited to nascent 
phagosomes in human macrophages: inhibition of SK1 translocation by Mycobacterium 
tuberculosis. J. Immunol. 174, 3551–3561. 
Vandal, O.H., Pierini, L.M., Schnappinger, D., Nathan, C.F., and Ehrt, S. (2008). A 
membrane protein preserves intrabacterial pH in intraphagosomal Mycobacterium 
tuberculosis. Nat. Med. 14, 849–854. 
Chapter 4:   Ion channel blockers act as antimicrobial agents and enhancers of macrophage 
killing activity against drug resistant Mycobacterium tuberculosis 
237 
Velmurugan, K., Chen, B., Miller, J.L., Azogue, S., Gurses, S., Hsu, T., Glickman, M., 
Jacobs, W.R., Porcelli, S.A., and Briken, V. (2007). Mycobacterium tuberculosis nuoG Is 
a virulence gene that inhibits apoptosis of infected host cells. PLoS Pathog. 3, 0972–0980. 
Viveiros, M., Rodrigues, L., Martins, M., Couto, I., Spengler, G., Martins, A., and Amaral, L. 
(2010). Evaluation of Efflux Activity of Bacteria by a Semi-automated Fluorometric System. 
In Antibiotic Resistance Protocols, S.H. Gillespie, and T.D. McHugh, eds. (Totowa, NJ: 
Humana Press), pp. 159–172. 
Viveiros, M., Martins, M., Rodrigues, L., Machado, D., Couto, I., Ainsa, J., and Amaral, L. 
(2012). Inhibitors of mycobacterial efflux pumps as potential boosters for anti-tubercular 
drugs. Expert Rev. Anti. Infect. Ther. 10, 983–998. 
Warman, A.J., Rito, T.S., Fisher, N.E., Moss, D.M., Berry, N.G., O’Neill, P.M., Ward, S.A., 
and Biagini, G.A. (2013). Antitubercular pharmacodynamics of phenothiazines. J. 
Antimicrob. Chemother. 68, 869–880. 
Weinstein, E.A., Yano, T., Li, L.-S., Avarbock, D., Avarbock, A., Helm, D., McColm, A.A., 
Duncan, K., Lonsdale, J.T., and Rubin, H. (2005). Inhibitors of type II 
NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc. Natl. 
Acad. Sci. U. S. A. 102, 4548–4553. 
Welin, A., Raffetseder, J., Eklund, D., Stendahl, O., and Lerm, M. (2011). Importance of 
phagosomal functionality for growth restriction of Mycobacterium tuberculosis in primary 
human macrophages. J. Innate Immun. 3, 508–518. 
WHO (2008). Anti-tuberculosis drug resistance in the world : fourth global report. (Geneva, 
Switzerland: World Health Organization Press). 
WHO (2013a). Global Tuberculosis Report 2013 (Geneva, Switzerland: World Health 
Organization Press). 
WHO (2013b). The Use of Bedaquiline in the Treatment of Multidrug-Resistant Tuberculosis 
(Geneva, Switzerland: World Health Organization Press). 
Yano, T., Lin-Sheng, L., Weinstein, E., Teh, J.S., and Rubin, H. (2006). Steady-state kinetics 
and inhibitory action of antitubercular phenothiazines on Mycobacterium tuberculosis 
Type-II NADH-menaquinone oxidoreductase (NDH-2). J. Biol. Chem. 281, 11456–11463. 
  
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
238 
 
  
 
 
 
 
Chapter 5:   The outer membrane pore 
protein CpnT of Mycobacterium 
tuberculosis mediates susceptibility to nitric 
oxide and drugs 
  
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
240 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Olga Danilchanka, David Pires, Elsa Anes, and Michael Niederweis 
In this chapter, I contributed in the design and execution of all the 
macrophage/bacteria interaction experiments as well as to the analysis and 
discussion of the results and the writing of the manuscript. 
Chapter 5:   The outer membrane pore protein CpnT of Mycobacterium tuberculosis mediates 
susceptibility to nitric oxide and drugs 
241 
The outer membrane pore protein CpnT of 
Mycobacterium tuberculosis mediates susceptibility to 
nitric oxide and drugs 
 
Olga Danilchanka, David Pires, Elsa Anes, and Michael Niederweis 
 
 
5.1.   Abstract 
The cell envelope of Mycobacterium tuberculosis contains an unusual outer 
membrane of low permeability protecting the bacteria from toxic molecules. Yet, 
most proteins that functionalize this membrane are unknown. Recently, we 
identified CpnT as an outer membrane channel protein of M. tuberculosis that is 
required for efficient nutrient uptake and for survival in macrophages. In this 
study, we show that the loss of CpnT conferred high level resistance of M. bovis 
BCG to multiple drugs and nitric oxide. Thus, CpnT is not only utilized for 
nutrient uptake, but also constitutes the first outer membrane susceptibility 
factor in slow-growing mycobacteria. This dual function of CpnT is reflected in 
macrophage infection experiments: While loss of CpnT was detrimental for 
M. bovis BCG in human macrophages that enable bacterial replication, 
presumably due to inadequate nutrient uptake, it conferred a survival advantage 
in mouse macrophages that mount a strong bactericidal response. Expression 
of the pro-inflammatory genes IL-1β and iNOS in mouse macrophages was 
lower providing an additional mechanism for the increased survival of the cpnT 
mutant. Expression of mspA did not rescue the growth defect of the cpnT 
mutant even in growth-permissive human macrophages although full 
complementation of all in vitro phenotypes was observed. This indicated that 
the CpnT channel mediates sufficient nutrient influx, but is less accessible to 
toxic host immune factors than the MspA channel. Taken together, our results 
provide evidence that the CpnT channel constitutes an outer membrane 
gateway controlling the influx of nutrients and toxic molecules into 
M. tuberculosis.  
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5.2.   Introduction 
Almost 10 million new cases of tuberculosis (TB) are reported each year (WHO, 
2013a). Although current TB chemotherapy cures up to 95% of patients within 
six months (Koul et al., 2011), concerns about a global TB epidemic are 
growing due to an increasing prevalence of multiple drug-resistant (MDR) and 
extreme drug-resistant (XDR) strains of Mycobacterium tuberculosis (Udwadia, 
2012). Thus, development of new drugs that are active against drug-resistant 
M. tuberculosis strains and that can shorten duration of TB chemotherapy is 
highly desirable. However, the low permeability of M. tuberculosis towards the 
vast majority of small molecules, and the poorly understood transport processes 
across the mycobacterial cell envelope (Niederweis, 2008a), render most in 
vitro screening approaches ineffective and hamper the discovery of new TB 
drugs (Koul et al., 2011). Despite numerous genomic, proteomic and 
metabolomic studies of M. tuberculosis physiological processes such as 
transport across the mycobacterial cell envelope are poorly understood 
(Niederweis, 2008a). Although mycobacteria are classified as Gram-positive 
bacteria, their cell envelope consists of a complex macromolecule in which an 
outer membrane of low permeability is covalently linked to the peptidoglycan-
arabinogalactan copolymer (Hoffmann et al., 2008; Niederweis et al., 2010). 
Outer membrane integrity is required for protection of M. tuberculosis from toxic 
compounds (Brennan and Nikaido, 1995), and is essential for virulence and 
pathogenicity of M. tuberculosis (Barry, 2001). Additionally, nutrient molecules 
must be able to permeate the outer membrane to sustain M. tuberculosis 
viability and replication. Uptake of small, hydrophilic solutes across the outer 
membrane of Gram-negative bacteria is mediated by water-filled protein 
channels called porins (Zeth and Thein, 2010). Influx of solutes through pore 
proteins is driven by a concentration gradient and primarily depends on the size, 
charge, hydrophobicity, and shape of the solute (Nikaido and Rosenberg, 
1983). Many drugs and toxic solutes exploit the porin channels to enter bacterial 
cells (Pagès et al., 2008). It has been shown that channel-forming proteins exist 
in slow-growing mycobacteria such as M. tuberculosis, but their low channel 
activity prevented their identification (Kartmann et al., 1999; Lichtinger et al., 
1999).  
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MspA is the best characterized outer membrane channel protein of 
mycobacteria. However it is present only in fast-growing species such as M. 
smegmatis (Niederweis, 2008b). MspA is, to date, the only mycobacterial 
protein whose β-barrel structure is consistent with that of an integral outer 
membrane protein (Faller et al., 2004), and is widely used as an outer 
membrane marker protein in mycobacteria (Bansal-Mutalik and Nikaido, 2011; 
Feltcher et al., 2013; Rezwan et al., 2007). MspA is the major porin of 
M. smegmatis (Stahl et al., 2001), and mediates diffusion of small, hydrophilic 
solutes across the outer membrane both in M. smegmatis (Stephan et al., 2005) 
and upon heterologous overexpression in M. tuberculosis (Mailaender et al., 
2004). 
Recently, we identified CpnT as an outer membrane protein in M. tuberculosis 
(Danilchanka et al., 2014). CpnT consists of two domains: The oligomeric N-
terminal domain forms an outer membrane channel and is required for efficient 
glycerol uptake. The toxic C-terminal domain is cleaved, secreted and induces 
necrosis of eukaryotic cells by a currently unknown mechanism. Thus, CpnT 
promotes replication of M. tuberculosis in macrophages probably by increasing 
nutrient uptake, and escape from the macrophage by inducing a necrosis-like 
cell death through the secreted toxin (Danilchanka et al., 2014). The domain 
organization of CpnT and its function in secreting its own C-terminal domain 
resembles autotransporters in Gram-negative bacteria (Leyton et al., 2012). It 
was proposed that the N-terminal domain remains in the outer membrane as an 
open channel after cleavage and secretion of the C-terminal toxin. Such a 
functional role of the β-domain of autotransporters in nutrient uptake has not 
been observed in Gram-negative bacteria, most likely because their outer 
membranes contain up to 1,000-fold more porins as compared to M. 
tuberculosis (Mailaender et al., 2004). 
While the function of the CpnT pore domain in glycerol uptake has been 
established (Danilchanka et al., 2014), the involvement of this protein in other 
transport processes across the outer membrane of M. tuberculosis has not 
been examined yet. In this study, we showed that the CpnT channel is exploited 
by a multitude of chemically very different antibiotics and TB drugs, and also by 
toxic immune host factors such as NO to enter the mycobacterial cell. Thus, 
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CpnT constitutes the first outer membrane susceptibility factor of M. bovis BCG 
and M. tuberculosis. While CpnT is required for replication of both mycobacteria 
in permissive macrophages, the presence of CpnT is detrimental for M. bovis 
BCG in macrophages with a strong bactericidal response. This implies that 
cpnT expression and the channel activity must be well coordinated to fine-tune 
the outer membrane permeability to enable sufficient nutrient influx and to limit 
exposure to toxic compounds.  
 
5.3.   Materials and Methods 
5.3.1.   Chemicals and Enzymes 
Hygromycin B was purchased from Calbiochem. All other chemicals were 
purchased from Merck or Sigma at the highest purity available.  
 
5.3.2.   Bacterial strains, media and growth conditions 
M. bovis BCG strains (Strain Institute Pasteur) were grown in Middlebrook 7H9 
medium (Difco) supplemented with 0.2% glycerol, 0.02% Tyloxapol and 10% 
OADC (Remel) or on Middlebrook 7H10 plates supplemented with 0.5% 
glycerol and 10% OADC (Remel). Antibiotics were used when required at the 
following concentrations: hygromycin (50 μg/ml), kanamycin (30 μg/ml). M. 
bovis BCG strains and plasmids used in this work are described in (Danilchanka 
et al., 2014). Briefly, ML383 is a wild-type derivative of M. bovis BCG with L5 
integrated empty vector pML2008 containing hygromycin resistance marker, 
ML1012 is a transposon mutant of M. bovis BCG disrupted with insertion in 
cpnT, ML386 – ML1012 derivative containing pML2008, ML387 – ML1012 
derivative complemented with mspA, ML388 – ML1012 derivative 
complemented with cpnT, ML805 – ML1012 derivative complemented with 
cpnTNTD.  
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5.3.3.   Antibiotic susceptibility measurements 
The minimal inhibitory concentration (MIC) was determined using a microplate 
Alamar Blue assay (Franzblau et al., 1998) with modifications (Danilchanka et 
al., 2008a, 2008b). Final drug concentrations were: for isoniazid and 
ethambutol, 0.03125-1 µg/ml; for streptomycin and rifampicin, 0.04 - 1.28 µg/ml; 
for levofloxacin, ofloxacin and clarithromycin, 0.0625-2 µg/ml; for p-
aminosalicylic acid and moxifloxacin, 0.25-8 µg/ml; for ciprofloxacin and 
norfloxacin, 0.5-16 µg/ml; for chloramphenicol and cycloserine, 1 -32 µg/ml; for 
vancomycin, 2.5 - 80 µg/ml; for erythromycin A and tetracycline, 8 - 256 µg/ml; 
for ampicillin, 30 -960 µg/ml. The Alamar Blue assays were performed twice in 
triplicate. The nitrate reductase assay was performed to determine MICs of M. 
tuberculosis as previously described (Mojib et al., 2010).  
 
5.3.4.   Susceptibility to nitric oxide 
M. bovis BCG strains were grown in 7H9/OADC/0.01% Tyloxapol to an OD600 of 
2. Cultures were pelleted by centrifugation, washed and re-suspended in 1/10 of 
original volume. A 0.1-ml aliquots of suspensions were added to 0.9 ml of fresh 
media containing 0 mM, 5 mM, 25 mM and 100 mM sodium nitroferricyanide 
(III) dehydrate (SNP, Sigma). Each suspension was incubated at 37°C (200 
rpm) for 0, 1, 3 or 7 days. Serial dilutions of the cultures were plated on 
7H10/OADC/Hyg plates and incubated at 37 °C for 3 weeks, after which colony 
forming unites (CFU) were counted. The data was recalculated as the percent 
survival ([number of CFU exposed at day X/number of CFU unexposed at day 
X] x 100 %). Each strain was tested in triplicate; assay was repeated three 
independent times.  
 
5.3.5.   Macrophage infection experiments.  
The human acute monocytotic leukemia cell line THP-1 (ATCC TIB202) and the 
mouse macrophage cell line J774A.1 (ATTC TIB-67) were maintained as 
described previously (Jordao et al., 2008). Differentiation of THP-1 monocytes 
into macrophages was induced overnight with 50 nM phorbol 12-myristate 13-
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acetate (PMA). THP-1 cells were infected at a multiplicity of infection (MOI) of 5. 
In each experiment, three hours after infection, cells were washed three times 
with PBS to remove non-internalized bacteria. At different time points after 
infection (3 h, 1, 3, 5 and 7 days) cells were washed with PBS and lysed with 
1% Igepal (Sigma) solution in water. Serial dilutions were done in water and 
plated on Middlebrook 7H10/OADC plates. Colony forming units (CFU) were 
counted after two weeks of incubation at 37 °C. When required, macrophages 
were treated with murine IFN- (100 IU) overnight before infection. 
 
5.3.6.   Statistical analysis  
Data are presented as mean ± standard deviation; p values were calculated 
using the Student’s t test and a P value of <0.05 was considered to be 
significant.  
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5.4.   Results 
5.4.1.   Absence of CpnT confers high level drug resistance to M. bovis 
BCG.  
The permeability barrier of the outer membrane is a major drug resistance 
determinant in slow-growing mycobacteria (Danilchanka et al., 2008b). Since 
lack of porins in Gram-negative bacteria and M. smegmatis confers low level 
resistance to some small, hydrophilic drugs, in particular β-lactam antibiotics 
(Danilchanka et al., 2008a; Mojib et al., 2010; Nikaido, 2003; Stephan et al., 
2004), we hypothesized that channel proteins might be important for uptake of 
drugs through otherwise impermeable outer membrane of M. tuberculosis. Thus 
far, such proteins are unknown. However, the porin MspA of M. smegmatis 
increases drug susceptibility when expressed in slow-growing mycobacteria 
(Mailaender et al., 2004). As CpnT was shown to be essential for transport of 
glycerol in slow-growing mycobacteria (Danilchanka et al., 2014) we thought to 
test its role for drug resistance. To this end, we determined the drug 
susceptibility of M. bovis BCG cpnT::Tn using the microplate Alamar Blue 
assay. Resistance to small, hydrophilic antibiotics (Table 5.1) was drastically 
increased in the absence of cpnT by up to 32-fold. Resistance to the anti-
tuberculosis drugs ethambutol, isoniazid and p-aminosalicylic acid (PAS) was 
increased more than 4-fold. Expression of mspA or full-length cpnT fully 
restored the susceptibility of the cpnT::Tn mutant (Table 5.1) providing evidence 
that insertion of a pore protein in the outer membrane is sufficient to mediate 
susceptibility to these antibiotics, presumably by increasing drug uptake. 
Remarkably, minimal inhibitory concentrations (MICs) to large and hydrophobic 
antibiotics such as erythromycin and rifampicin were also increased in the 
cpnT::Tn mutant by at least 16-fold (Table 5.1). The lack of CpnT also made M. 
bovis BCG more resistant to large, hydrophilic antibiotics such as streptomycin 
and to several fluoroquinolones (Table 5.1). Importantly, expression of both 
mspA and cpnT restored the susceptibility of the cpnT::Tn strain to wt levels. 
These results indicate that the outer membrane protein CpnT is an essential 
drug susceptibility factor of M. bovis BCG. 
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Considering the important role of CpnT in drug susceptibility of M. bovis BCG 
we determined MICs of wt M. tuberculosis, the unmarked mutant of CpnT and 
of the mutant complemented with a full-length or an N-terminal pore domain of 
CpnT (Danilchanka et al., 2014) using a nitrate-reductase assay (Mojib et al., 
2010). We did not detect any significant difference in MICs of tested strains to a 
variety of drugs and antibiotics (Table 5.2). This result indicated that M. 
tuberculosis has additional outer membrane pore proteins that either do not 
exist, or are not expressed in M. bovis BCG.  
 
Table 5.1. Antibiotic resistance of the cpnT mutant of M. bovis BCG. 
 
Antibiotic 
MIC for M. bovis BCG (µg/ml) 
Resistance 
factora  
wt 
 
cpnT::Tn 
 
cpnT:Tn 
+mspA 
cpnT::Tn 
+cpnT 
A 
Ampicillin  30 960 60 60 32 
Tetracycline 31.25 >250 62.5 62.5 >8 
Chloramphenicol 4 64 8 8 16 
Ethambutol 0.125 >1 0.125 0.125 >8 
Isoniazid  0.25 >1 0.25 nd >4 
p-Amino-salicylic 
acid 
2 >8 2 2 >4 
cycloserine 4 8 4 4 2 
B 
Vancomycin  5 20 10 10 4 
Streptomycin 0.16 0.64 0.32 0.32 4 
C 
Clarithromycin 0.125 >2 0.5 0.25 >16 
Erythromycin A  16 >256 32 16 >16 
Rifampicin  0.008 >0.128 0.032 0.032 16 
D 
Ciprofloxacin 1 2 2 2 2 
Ofloxacin 0.25 0.5 0.25 0.25 2 
Levofloxacin 0.125 0.5 0.125 0.125 4 
Moxifloxacin 0.5 1 0.5 0.5 2 
Norfloxacin 1 4 2 2 4 
TB drugs and antibiotics were grouped into four classes: (A) small, hydrophilic 
antibiotics (molecular weight (MW): 102 - 444 g/mol), (B) large, hydrophilic (MW: 484 to 
1450 g/mol), (C) large, hydrophobic (MW: 612 - 823 g/mol) and, (D) fluoroquinolones 
(MW: 319 to 402 g/mol). The minimal inhibitory concentrations (MIC) were measured 
using the microplate Alamar Blue assay as described (Danilchanka et al., 2008b). (a) 
The resistance factor is defined as the ratio MICcpnT::Tn/MICwt. 
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Table 5.2. Antibiotic resistance of the cpnT mutant of M. tuberculosis. 
 
Antibiotic 
MIC for M. tuberculosis (µg/ml) 
wt 
 
ΔcpnT 
 
ΔcpnT 
+cpnTNTD 
ΔcpnT 
+cpnT 
Ampicillin  125 125 125 125 
Tetracycline 4 4 4 4 
Chloramphenicol 2 2 2 2 
Isoniazid  0.05 0.05 0.05 0.05 
Rifampicin  0.64 0.64 0.64 0.64 
Moxifloxacin 0.125 0.125 0.125 0.125 
Norfloxacin 2 2 2 2 
The minimal inhibitory concentrations (MIC) were measured using the nitrate reductase 
assay as previously described (Mojib et al., 2010). 
 
5.4.2.   CpnT is required for susceptibility of M. bovis BCG to nitric oxide.  
Next, we examined whether the CpnT channel plays a role in susceptibility of M. 
bovis BCG to other, physiologically more relevant toxic compounds. Nitric oxide 
(NO) plays a crucial role in control of M. tuberculosis infections in mice 
(MacMicking et al., 1997). Furthermore, previously it was shown that porins 
mediate susceptibility of M. smegmatis to NO and that aquaporin-1 is required 
for NO permeability in eukaryotic cells (Fabrino et al., 2009; Herrera et al., 
2006) suggesting that CpnT of M. bovis BCG might have a similar function. To 
this end, wt M. bovis BCG, the cpnT::Tn mutant, and the mutant complemented 
with either cpnT or mspA were exposed to the NO donor sodium 
nitroferricyanide (III) dehydrate (SNP), and serial dilutions were spotted on 
Middlebrook 7H10/OADC agar plates (Figure 5.1A). All strains were killed by 
SNP in a time-dependent manner (Figure 5.1B). A rapid decrease in viability of 
the wt and both complemented cpnT mutants was observed after 24 hours of 
exposure, with the majority of bacteria being killed after three days. By contrast, 
the cpnT::Tn mutant grew during the first 24 hours, and was approximately 100-
fold more resistant to killing by NO at later time points compared to the wt M. 
bovis BCG and the complemented mutants (Figure 5.1). Thus, CpnT might play 
an essential role in defense of slow-growing mycobacteria against toxic 
molecules produced by host immune cells. The observation that the 
susceptibility of the cpnT::Tn mutant to NO is restored by expression of mspA 
indicates that the channel function and/or outer membrane integration of CpnT 
and other pore proteins mediate NO susceptibility by increasing the permeability 
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of the outer membrane to this molecule. Furthermore, overexpression of mspA 
in the cpnT::Tn mutant resulted in almost complete clearance of the strain after 
24 hours of treatment (8.9±2.5% survival for the mspA expressing strain 
173±75% for the cpnT::Tn strain), thus suggesting that MspA-mediated uptake 
of toxic compounds reduced survival of the strain under adverse conditions.  
 
Figure 5.1. Absence of CpnT in M. bovis BCG renders high level resistance to nitric 
oxide. 
(A) Survival of wt M. bovis BCG and the cpnT::Tn mutant after 7 days of exposure to 
100 mM SNP. Serial dilutions were spotted on Middlebrook 7H10/OADC agar. (B) 
Survival of wt M. bovis BCG (●), cpnT::Tn (▼), cpnT::Tn complemented with mspA (■), 
or cpnT (▲) after exposure to 100 mM SNP for different times. The colony forming 
units of the original inoculum of each strain were set as 100% survival. The experiment 
was done in triplicate and repeated three times. Survival of the wt vs. mutant, or 
complemented strains was analyzed using Student’s t test. * p < 0.05 was deemed 
significant.  
 
 
5.4.3.   The channel-forming N-terminal domain of CpnT is required for 
growth and survival of M. bovis BCG in macrophages.  
Previously, we observed that both the channel and the toxin domain of CpnT 
contribute to the survival of M. tuberculosis in macrophages (Danilchanka et al., 
2014). This made it difficult to determine the individual roles of these CpnT 
domains during infection of host cells. M. bovis BCG does not permeabilize 
phagosomes and does not escape from phagosomes, in contrast to M. 
tuberculosis (Manzanillo et al., 2012; Simeone et al., 2012). Thus, the C-
terminal toxin domain of CpnT is capable of leaving the phagosome during M. 
tuberculosis infection to induce necrosis in cytosol, while it is likely trapped in 
phagosomes during M. bovis BCG infection where it is incapable to induce 
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necrosis. This assumption is supported by the virtual absence of cytotoxicity of 
M. bovis BCG or M. tuberculosis mutants that lack RD1 region, a primary 
virulence locus of M. tuberculosis that is also missing in M. bovis BCG (Hsu et 
al., 2003; McDonough and Kress, 1995). Hence, we sought to exploit this 
feature of M. bovis BCG to examine the role of the CpnT channel domain in the 
absence of confounding effects of the toxin domain. Here we show that the 
absence of cpnT drastically reduced intracellular growth of M. bovis BCG in the 
human monocytic cell line THP-1 (Figure 5.1). This is consistent with the results 
obtained for M. tuberculosis-infected THP-1 macrophages (Danilchanka et al., 
2014) and underlines the important role of CpnT for survival of slow-growing 
mycobacteria in macrophages. Growth of M. bovis BCG was fully restored by 
expression of cpnTNTD encoding the channel-forming N-terminal domain (NTD) 
of CpnT. This observation confirmed that the toxin domain is indeed 
dispensable for normal growth of M. bovis BCG in macrophages and that only 
the pore domain is needed for uptake of solutes and growth. By contrast, 
CpnTNTD is only capable to restore wt growth of M. tuberculosis in THP-1 
macrophages during the first 24 hours, while the toxic CpnTCTD is required for 
normal growth of M. tuberculosis at later time points (Danilchanka et al., 2014).  
Interestingly, expression of mspA did not rescue the growth defect of the 
cpnT::Tn mutant even in the growth-permissive THP-1 cells (Figure 5.2), 
although full complementation of all phenotypes was observed in vitro (Figure 
5.1; Table 5.1). These results indicate that the CpnT channel mediates sufficient 
nutrient influx, but provides a much better protection against toxic host immune 
factors than the wide open MspA channel (Faller et al., 2004). 
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Figure 5.2. Survival of M. bovis BCG in THP-1 cells. 
A. THP-1 cells were infected with wt M. bovis BCG (filled circles), cpnT::Tn (open 
circles), cpnT::Tn complemented with cpnTNTD (filled triangles), cpnT (open triangles) or 
mspA (squares) at an MOI of 5. The colony forming units of the original inoculum of 
each strain was set as 100% survival. (B)  Bar graph representing survival of M. bovis 
BCG in THP-1 cells 3 days post-infection. The colony forming units of the original 
inoculum of each strain was set as 100% survival. Survival of the wt vs. mutant, or 
complemented strains was analyzed using Student’s t test. * p < 0.05 was deemed 
significant.  
 
5.4.4.   The absence of CpnT protects M. bovis BCG from killing in 
macrophages and from the bactericidal response of stimulated 
macrophages.  
We showed that CpnT facilitates uptake of nutrients (Danilchanka et al., 2014), 
but also enables toxic molecules to enter the bacterial cell (Figure 5.1; Table 
5.1). Hence, we wondered which of these properties of CpnT would prevail in 
vivo when the uptake of nutrients for bacterial replication might be less 
important than protection from toxic compounds, such as NO, which utilize the 
CpnT channel to enter mycobacterial cells. To this end, we used J774 mouse 
macrophages in which M. bovis BCG does not replicate and is efficiently 
eliminated (Jordao et al., 2008). We hypothesized that the requirement for 
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uptake of nutrients through porins under these conditions is minimal, while 
resistance to toxic compounds produced by macrophages plays a crucial role in 
clearance of bacteria. As expected, the bacterial burden for all strains 
decreased during infection of J774 cells (Figure 5.3). However, the cpnT::Tn 
strain was more resistant to killing compared to the wt or complemented strains. 
Furthermore, stimulation of J774 with interferon-, a potent inducer of nitric 
oxide and other reactive nitrogen intermediates, reduced survival of wt M. bovis 
BCG, but did not affect the cpnT::Tn strain (Figure 5.3). These experiments 
suggest that the inertness of the cpnT::Tn mutant to the bactericidal response of 
macrophages upon interferon- stimulation is due to mutant’s high level of 
resistance to NO, a potent effector molecule of mouse macrophages 
(MacMicking et al., 1997), and possibly other toxic compounds produced by 
macrophages. 
 
 
Figure 5.3 Survival of M. bovis BCG in macrophages. 
A, B. J774 cells were infected with wt M. bovis BCG (●), cpnT::Tn (▼) (B), and the 
cpnT::Tn mutant complemented with cpnTNTD (⧫), or cpnT (▲) (C) at an MOI of 5. 
When required, J774 cells were treated with murine IFN-γ (100 IU) overnight before 
infection (open symbols). The colony forming units of the original inoculum of each 
strain was set as 100% survival. (B) Bar graph representing survival of M. bovis BCG in 
J774 cells 3 days post-infection.  When required, J774 cells were treated with murine 
IFN-γ (100 IU) overnight before infection (open bars). n.s.: non-stimulated J774 cells 
(filled bars). The colony forming units of the original inoculum of each strain was set as 
100% survival. ANOVA one parameter test was performed, with post hoc analysis 
using Holm-Sidak test. * p < 0.05 was deemed significant. 
 
 
Interference of Mycobacterium tuberculosis with the endocytic/ antigen presentation pathways 
on macrophages and dendritic cells 
254 
5.4.5.   The absence of CpnT reduces the pro-inflammatory response of 
macrophages infected with M. bovis BCG. 
In some cases porins are highly antigenic and are recognized by the host 
immune system (Kuusi et al., 1981; Tabaraie et al., 1994). Consequently, porins 
can induce inflammation in mice, activation of B cells and release of cytokines 
(Galdiero et al., 1993; Vordermeier et al., 1987). Thus, an alternative 
explanation for the increased resistance of the cpnT mutant to killing by 
macrophages might be a lower pro-inflammatory response of macrophages that 
could result in reduced bacterial killing (Mishra et al., 2010). To test this 
hypothesis we analyzed the expression of the pro-inflammatory interleukin 1β 
(IL-1β) gene and of the gene encoding the inducible isoform of nitric oxide 
synthase (iNOS) during infection of J774 mouse macrophages with M. bovis 
BCG. We focused on IL-1β and iNOS as key markers of M. tuberculosis 
immune responses due to their essential roles for pulmonary infection with this 
pathogen. Specifically, M. tuberculosis infection results in robust initial 
production of IL-1 in a mouse model of infection, that is followed by the 
induction of adaptive immune responses including expression of iNOS that 
produces nitric oxide, a molecule found to be essential not only for antibacterial 
control, but also for modulation of inflammatory immune responses through 
alteration of NLRP3 inflammasome (Mishra et al., 2013). We observed two- and 
five-fold lower iNOS and IL-1β mRNA levels, respectively, after infection of 
macrophages with the cpnT::Tn mutant compared to the wt strain (Figure 5.4). 
This difference was independent of the presence of interferon-. Expression of 
IL-1β and iNOS was partially restored in the cpnT mutant complemented by the 
full-length cpnT, and was fully complemented by cpnTNTD construct. Thus, lower 
levels of pro-inflammatory response of macrophages in response to infection 
with cpnT::Tn mutant is likely a contributing factor to its ability to survive better 
in macrophages with a strong bactericidal response. Taken together, these 
results suggest that the absence of CpnT confers a survival advantage in the 
presence of a strong bactericidal response of macrophages to mycobacterial 
infection, while the nutrient uptake function of CpnT appears to dominate in 
macrophages under conditions that enable bacterial replication. 
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Figure 5.4. Pro-inflammatory gene expression is reduced in the absence of CpnT. 
qRT-PCR quantification of iNOS (A) and IL-β (B) gene expression in J774 
macrophages 24 hours after infection with M. bovis BCG strains. Data is represented 
as the mean ± SD relative to uninfected cells (control). When required, J774 cells were 
treated with murine IFN- (100 IU) overnight before infection (open bars). N.S.: non-
stimulated J774 cells (filled bars). 
 
5.5.   Discussion 
5.5.1.   Role of CpnT in susceptibility of M. bovis BCG and M. tuberculosis 
to antibiotics and TB drugs 
The outer membrane permeability barrier is of utmost importance for survival of 
M. tuberculosis under harsh conditions in vivo (Barry, 2001; Brennan and 
Nikaido, 1995) and a key component of its intrinsic drug resistance (Jarlier and 
Nikaido, 1994). In this study we showed that the cpnT mutant of M. bovis BCG 
exhibited high level resistance to a wide variety of antibiotics and TB drugs. The 
resistance factors for most of these compounds were much higher than those 
previously observed for a single porin mutant of M. smegmatis (Stephan et al., 
2004), or for Gram-negative bacteria (Nikaido, 2003). In particular, the cpnT 
mutant of M. bovis BCG became more resistant to the TB drugs isoniazid and 
ethambutol, while their MIC’s were not affected by the deletion of the main porin 
gene mspA of M. smegmatis (Stephan et al., 2004). This difference might be 
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explained by the larger number of porins in the outer membrane of 
M. smegmatis compared to M. bovis BCG. While the number of porins is 
reduced from 2,400 to 800 by the deletion of mspA in M. smegmatis (Stephan 
et al., 2005), no open pores were detected by electron microscopy in 
M. bovis BCG and M. tuberculosis (Mailaender et al., 2004). Thus, the loss of 
CpnT probably has a much larger effect on permeability of M. bovis BCG 
compared with the loss of the porin MspA in M. smegmatis. The effect of a 
single porin deletion in Gram-negative bacteria on drug resistance is even less 
pronounced as they contain 100-1,000-fold more porins compared to 
M. smegmatis (Niederweis, 2003). 
Our results imply that uptake of small, hydrophilic anti-tuberculosis drugs 
ethambutol, isoniazid, and p-aminosalicylic acid is mediated by pore-forming 
proteins such as CpnT. Surprisingly, we also found that absence of CpnT in 
M. bovis BCG resulted in high-level resistance to large and hydrophobic drugs 
such as erythromycin and rifampicin. While we do not assume that these 
antibiotics diffuse directly through the CpnT pore, deletion of an outer 
membrane protein may indirectly reduce drug susceptibility. Such a mechanism 
has been revealed in M. smegmatis (Stephan et al., 2004). Deletion of the 
major porin MspA not only reduced the permeability of M. smegmatis for 
hydrophilic, but also hydrophobic compounds such as chenodeoxycholate and 
concomitantly increased resistance to large, hydrophobic antibiotics, in contrast 
to porin mutants of E. coli and other Gram-negative bacteria (Delcour, 2009). It 
has been proposed that integration of proteins interferes with lipid interactions in 
the outer membrane of mycobacteria and, hence, may increase permeability 
across the lipid bilayer inversely to its protein content (Stephan et al., 2004). 
Further experiments utilizing porins with closed channels that can integrate into 
the outer membrane, but are deficient for solute transport will enable to test this 
hypothesis.  
In contrast to M. bovis BCG the lack of CpnT did not increase drug resistance of 
M. tuberculosis. This may indicate that the lack of CpnT is compensated by 
another pore protein in M. tuberculosis that is not present or produced by M. 
bovis BCG. However, to our knowledge, such proteins have not been described 
yet, but their presence is suggested by previous biochemical characterization of 
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channel-forming proteins of slow-growing mycobacteria (Kartmann et al., 1999; 
Lichtinger et al., 1999). Since the genomes of M. bovis BCG and M. 
tuberculosis are almost identical except for the so-called regions of difference 
(RD) that were deleted during attenuation of M. bovis BCG (Brosch et al., 2001, 
2002), the apparent compensation of the lack of CpnT by M. tuberculosis might 
also result from a different regulation of gene expression in both mycobacterial 
species (48). The different susceptibility profiles of wt M. bovis BCG and M. 
tuberculosis (Table 5.1; Table 5.2) may reflect different pore-mediated outer 
membrane permeability in both organisms, probably in addition to other factors 
such as altered gene expression and metabolism (Lofthouse et al., 2013; Pan et 
al., 2012).  
To our knowledge, CpnT has not been previously associated with drug-resistant 
tuberculosis. However, resistance in approximately 5-30% of clinical isolates 
(dependent on antibiotic) cannot be explained by mutations in any known genes 
associated with resistance to a particular drug  (Louw et al., 2009) suggesting 
that other undefined mechanisms are involved. As deletion of cpnT in M. bovis 
BCG leads to multidrug-resistant phenotype in vitro, we propose that some of 
M. tuberculosis clinical isolates might also have mutations in this gene and 
other, so far unknown porin genes. Indeed, cpnT was recently identified as a 
gene with a strong, consistent association with drug resistance in a study that 
looked at 161 M. tuberculosis isolates from China with different drug resistance 
profiles (Zhang et al., 2013a). 
 
5.5.2.   Role of CpnT in resistance to nitric oxide and other toxic 
compounds in macrophages 
This study provides evidence that outer membrane proteins of M. tuberculosis 
have a major influence on the resistance to toxic compounds utilized in vivo to 
kill bacteria: The absence of CpnT renders M. bovis BCG 100-fold more 
resistant to nitric oxide compared to the wt strain. This is consistent with 
previous observations that the MspA porin of M. smegmatis mediates 
susceptibility to nitric oxide in mycobacteria (Fabrino et al., 2009; Purdy et al., 
2009), but, to our knowledge, porins of Gram-negative bacteria were never 
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implicated in this process. This is likely due to the very large number of various 
channel-forming proteins in the outer membrane of these bacteria (Kessel et al., 
1988). Thus, porin mutants in Gram-negative bacteria still have a relatively 
large number of channels remaining in the outer membrane which often 
prevents detection of phenotypes in susceptibility and/or transport experiments.  
Interestingly, expression of mspA did not rescue the growth defect of the 
cpnT::Tn mutant even in growth-permissive THP-1 cells (Figure 5.2), while full 
complementation of all phenotypes was observed in vitro (Table 5.1, Figure 
5.1). These results indicate that the CpnT channel mediates sufficient nutrient 
influx in M. bovis BCG, but provides a much better protection against toxic 
solutes in vivo than the wide open and potentially unregulated MspA channel 
(Faller et al., 2004). Although MspA provides an efficient uptake pathway for 
nutrients, the apparently unregulated uptake of toxic compounds by MspA leads 
to reduction of M. bovis BCG survival in macrophages. These observations 
suggest that in order to survive and grow in macrophages a tight balance 
between nutrient acquisition and minimization of the influx of toxic compounds 
is essential, and disturbance of this equilibrium in either direction might be 
detrimental during infection. These results also indicated that increasing the 
efficiency of channel protein-mediated outer membrane permeability may 
indeed be an attractive approach for developing new TB drugs with an 
alternative mechanism of action as proposed earlier (Niederweis et al., 2010). 
 
5.5.3.   CpnT constitutes a gateway protein in M. bovis BCG and M. 
tuberculosis 
The important role of CpnT in susceptibility to drugs and NO implies that it 
constitutes a gateway protein in the outer membrane of M. bovis BCG. This is 
consistent with the observation that other outer membrane channel proteins 
control entry of small, hydrophilic solutes including antibiotics into cells of Gram-
negative bacteria and mycobacteria (Danilchanka et al., 2008a; Pagès et al., 
2008). Not surprisingly, porin mutations often cause drug resistance of clinical 
isolates of Gram-negative bacterial pathogens. However, it needs to be noted 
that CpnT does not belong to the group of  classical porins as found in Gram-
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negative bacteria, whose physiological function is only to mediate influx of 
small, hydrophilic solutes through their water-filled channels across the outer 
membrane (Nikaido, 2003). The primary function of CpnT in M. tuberculosis 
appears to be the secretion of a novel necrosis-inducing toxin located on the C-
terminal domain of the protein by utilizing its N-terminal domain in an 
autotransporter-like mechanism (Danilchanka et al., 2014). Although details of 
this secretion process are unknown, it is clear that the channel-forming activity 
of the N-terminal domain of CpnT is the sole molecular determinant mediating 
drug susceptibility and nutrient transport in M. bovis BCG. It is interesting that 
the C-terminal domain does not seem to interfere with the channel activity 
indicating that perhaps the vast majority of CpnT proteins secrete the toxin and 
only the N-terminal domain remains in the outer membrane of M. tuberculosis. 
However, since full-length CpnT is also detectable in the outer membrane of 
M. tuberculosis, an alternative explanation for the fact that all resistance 
phenotypes of the cpnT mutant of M. bovis BCG are complemented by the 
CpnT N-terminal domain alone might be that the toxin domain does not interfere 
with transport through the CpnT channel. In this regard, it would be interesting 
to determine the ratio of full-length versus cleaved CpnT in M. bovis BCG and 
M. tuberculosis under different conditions, in addition to in vitro bilayer channel 
activity studies with a full-length CpnT protein. 
 
5.5.4.   The channel activity of CpnT is a double-edged sword for 
M. bovis BCG in macrophages 
The macrophage experiments with M. bovis BCG revealed dual functions of 
CpnT. (i) In macrophages that prevent intracellular mycobacterial replication, 
absence of CpnT confers a survival advantage. The 100-fold increased 
resistance of the cpnT mutant to nitric oxide might play a key role in this regard, 
although regulatory effects, as evidenced by reduced iNOS and IL-1β levels, 
probably contribute to the increased resistance of the cpnT mutant to killing in 
J774 macrophages. (ii) Under in vivo conditions that enable bacterial 
replication, such as in human THP-1 macrophages, the presence of CpnT is 
beneficial, probably because of increased nutrient uptake. However, the M. 
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tuberculosis cpnT mutant did not exhibit a virulence defect during mouse 
infection (Danilchanka et al., 2014) in agreement with the classification of cpnT 
as a non-essential gene in transposon site hybridization experiments (Sassetti 
and Rubin, 2003), and previous observations that glycerol utilization is not 
required for virulence of M. tuberculosis in mice (Pethe et al., 2010). The lack of 
a virulence defect for the M. tuberculosis cpnT mutant could be caused by the 
presence of an alternative outer membrane pore protein that is expressed in M. 
tuberculosis, but not in M. bovis BCG as indicated by the absence of drug 
resistance phenotypes of the M. tuberculosis mutant in this study. Identification 
of such additional channel proteins will be important to delineate drug and 
nutrient uptake pathways in the notoriously impermeable cells of M. 
tuberculosis.  
 
5.6.   Conclusions 
CpnT has multiple functions in nutrient uptake across the outer membrane and 
susceptibility to toxic solutes due to the activity of its N-terminal domain. The 
identification of this pore protein represents the first step in understanding outer 
membrane permeability of M. tuberculosis. Knowledge of the structure and the 
biophysical properties of the CpnT N-terminal channel domain might help to 
improve drug uptake and, thereby, to overcome the outer membrane 
permeability barrier, a major hurdle in TB drug development.  
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In this thesis I proposed to address the problem of how Mycobacterium 
tuberculosis manipulates the immune effectors of the endocytic and antigen 
presentation pathways of macrophages and dendritic cells. These are complex 
pathways comprehending a vast array of intervening molecules. This thesis only 
focused on a small, yet significant portion of these pathways, with a particular 
emphasis on the role of cathepsins and the phagolysosomal environment 
influencing their activity. Our choice for these molecules was originated from the 
realization that little attention was given to these enzymes in the context of 
bacterial infection when compared to cancer and other fields of biomedical 
research in spite of being implicated on several aspects of innate immunity and 
initiation of adaptive immunity. The network of processes in which cathepsins 
are implicated is also vast, being able to directly act on pathogens or indirectly 
being involved in the processing, maturation and activation of other immune 
effectors that in their turn will act on the pathogen. For these reasons, this 
thesis initially focused on cathepsins. 
Our first approach was to understand how cathepsins are subject to regulation 
induced by MTB infection and how does it influence the outcome of infection. 
Our results have shown that cathepsin regulation is tied to the infecting bacteria 
and also to the type of cells being infected. Macrophages displayed a complex 
regulation with different cathepsins being up-regulated or down-regulated in 
response to infection. Contrariwise, infection of DCs induced the up-regulation 
of the majority of cathepsins. These differences might reflect the different roles 
proposed for these cells and contrasting adaptations to those roles by the 
pathogens. As mentioned in this thesis, while MTB benefits from a reduced 
initial immune response to increase its burden to the host (depressed local 
immunity from MTB-infected macrophages) it might also benefit from the 
translocation of DCs to the lymph nodes and induction of signals resulting in the 
recruitment of fresh cells to the infection locus. Control of the local immune 
response is also crucial to avoid inflammatory lesions and the cellular response 
mediated by macrophages and T cells plays a relevant role in it. We also tested 
the effects of stimulating macrophages and DCs with IFN-γ or TNF-α, 
respectively. We did this to simulate the different cellular conditions that MTB 
might encounter upon infection. Overall, when comparing the phenotypes 
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induced by the M. smegmatis and MTB, our results indicated a common pattern 
in cathepsin expression. MTB induces the down-regulation of the majority 
cathepsins or represses their up-regulation. In macrophages, we discovered an 
endogenous intermediate in this regulatory process for cathepsin S, the micro 
RNA miR-106b-5p. The up-regulation of this miRNA correlated with the down-
regulation of cathepsin S observable 24h upon infection with MTB and we could 
prove the interaction between these two molecules. The result of cathepsin 
regulation was the increase of MTB intracellular survival as we showed in our 
inhibition and silencing experiments. Interestingly the down-regulation of 
cathepsins B, S and L also lead to an increase of the surface expression of 
HLA-DR, part of the HLA class II family. 
Cathepsins are subject to different forms of regulation and the vacuolar 
environment where they reside will influence their activity. We proposed that we 
could influence this environment using pharmacologic molecules already 
approved for other medical conditions. The common feature found on these 
molecules was their ability to inhibit ion channel transport activity leading to 
improved antibiotic treatment when used in combination with first line anti-TB 
drugs. From these initial evidences we hypothesized that this improved 
treatment was not only due to the inhibition of drug efflux systems of MTB but 
also to an increase in macrophage mediated killing mechanisms. Our evidences 
support the hypothesis that this improvement was due to a general vesicular 
acidification in host macrophages that not only is known to be a bactericidal 
response in its own, but as I have reported in this thesis, also induces an 
increase in cathepsin B activity. 
Finally, we focused our attention on the bacteria. In spite of all these 
mechanism of MTB killing and the improvements we were able to achieve 
through silencing or chemical inhibition of cathepsins and usage of ion channel 
blockers to enhance pH-dependent cathepsin activity, the fact is: some of the 
bacteria are able to survive. We concentrated on the membrane of MTB due to 
its characteristic and distinguishing features but also because it is the primordial 
barrier against foreign aggression. Indeed, we saw that restriction of membrane 
transport caused by the knock-out of the outer-membrane channel CpnT in 
mycobacteria is a relevant mechanism to enhance their survival when facing the 
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bactericidal actions of antibiotics or macrophage intracellular release of 
oxidative species. Furthermore, the lower induction of macrophage pro-
inflammatory genes by the CpnT mutant indicated that restriction of outer-
membrane transport or restriction of this surface channel complex might also 
help to avoid triggering innate recognition by the macrophage. 
Overall, with this thesis I propose that cathepsins are main effectors and 
mediators of the innate and adaptive response against MTB and because of 
their relevance MTB evolved to restrict their activity using the host own 
mechanisms to increase its intracellular survival. I propose that since the host 
own mechanisms are being targeted by MTB, we should focus to implement 
strategies to counter-modulate those mechanisms in favor of the host and 
combine them with current antibiotic therapy in order to improve the chances of 
success. I propose two methods for that; (1) the usage of miRNAs or their 
inhibitors to restore the bactericidal response against MTB; (2) modulation of 
the phagosome and phago-lysosomal environment using ion channel inhibitors 
to generate a degradative milieu and an increased proteolytic activity. Lastly, I 
propose that although membrane transport in MTB is reduced, it still provides a 
pathway for antibiotics and host bactericidal molecules and by understanding 
this pathway we may develop drugs that can exploit it to enter the bacilli. 
